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Abstract 
With the ever-increasing prevalence of poorly soluble compounds in drug 
development pipelines, the identification of compounds with poor ‘developability’ 
owing to sub-optimal absorption properties has led to formulation and delivery 
challenges in drug development. There is a consequent need to develop both novel 
formulations that overcome the solubility limitations of poorly water soluble drugs 
(PWSD), along with a range of predictive in vitro and in silico biopharmaceutics based 
tools for guiding formulation design and forecasting in vivo performance. This thesis 
aims to assess both novel bioenabling formulations and new in vitro and in silico tools 
to predict their in vivo performance in pigs as a means to improve efficiency in 
formulation development.  
This thesis has, firstly, demonstrated the ability of two novel bioenabling approaches 
to improve oral bioavailability of fenofibrate in fasted pigs. Secondly, the utility of in 
vitro and in silico tools to predict in vivo performance in fasted pigs has been 
investigated. Thirdly, the ability of the pig to act as a model of human bioavailability, 
as well as its suitability to act as an in vivo screening tool for bioenabling approaches 
for PWSD has been described. Finally, limitations of the pig model for assessment of 
food effect using current approaches have been identified, and suggestions for future 
characterisation have been made. Overall, the utility of the pig in assessing 
bioenabling approaches has been demonstrated.  Concomitantly, the predictive 
ability of in vitro and in silico biopharmaceutical tools has been demonstrated. Thus, 
the pre-clinical pig model has proven useful in the assessment of both bioenabling 
formulations and the predictive capacity of biorelevant biopharmaceutical tools.   
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Chapter 1 : Introduction 
This chapter contains material partially published/submitted to the following 
publications: 
Partially published: 
Lipid Based Formulations 
In Encyclopaedia of Controlled Drug Delivery, Second Edition, In Press 
Joseph P. O’Shea, Caitriona M. O’Driscoll, Brendan T. Griffin 
And  
The pig as a pre-clinical model for predicting oral bioavailability and in vivo 
performance of pharmaceutical oral dosage forms - a PEARRL review 
Laura J. Henze, Niklas J. Koehl, Joseph P. O’Shea, Edmund Kostewicz, René Holm, 
Brendan T. Griffin 
Journal of Pharmacy and Pharmacology, 2018, In Press, doi: 10.1111/jphp.12912 
And 
Food for thought: Formulating away the food effect - a PEARRL review 
Joseph P. O’Shea, René Holm, Caitriona M. O’Driscoll, Brendan T. Griffin 
Journal of Pharmacy and Pharmacology, Under Review 
 
 
  
 
 
2 
 
Strategies to improve ‘developability’ in drug product R&D 
A significant focus for drug development scientists over the last number of decades 
has been the ‘developability’ of new chemical entities and current drug candidates. 
In that time there has been a significant shift towards discovery of candidate drugs 
that display less than optimal drug like properties, particularly with regard to 
solubility and/or lipophilicity (Butler and Dressman, 2010). This trend has variously 
been ascribed to the biology of the drug target, the methods of drug screening and 
discovery and nature of combinatorial chemistry utilised in drug development 
(Bergström et al., 2016). The advent of modern drug discovery techniques, such as 
combinatorial chemistry and high throughput screening, has led to a distinct trend 
towards lead drug candidates with optimized pharmacodynamic properties, but poor 
‘developability’ owing to sub-optimal absorption properties. Developability, in this 
context, is widely used to describe just how ‘drug like’ a molecule is, with regard to 
its physicochemical and biopharmaceutical characteristics, with a particular 
emphasis on the absorption, distribution, metabolism, excretion and toxicology 
(ADMET) process (Saxena et al., 2009). The identification of such limitations in drug 
molecules has led to increased candidate attrition in development pipelines.  
The need to establish a framework to diagnose these biopharmaceutical limitations 
of new drug candidates led to the establishment of numerous classification systems, 
most notably the biopharmaceutical classification system (BCS), which classified 
compounds based on their solubility and permeability (Amidon et al., 1995), the 
biopharmaceutical drug disposition classification system (BDDCS) (Wu and Benet, 
2005), the rule of five (Ro5) (Lipinski et al., 1997) and the developability classification 
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system (DCS) (Butler and Dressman, 2010). However, despite major advancements 
in understanding the key factors influencing absorption there is actually evidence 
that the number of drugs in development pipelines displaying these limitations has 
increased and it is estimated that anywhere from 40%-70% of current drug 
candidates display poor solubility, such that their absorption is compromised 
(Bergström et al., 2016). These molecules display solubility or dissolution rate limited 
bioavailability, where complete dissolution would take longer than the transit time 
past the absorptive region of the gastrointestinal tract (GIT), or require a larger 
volume of fluid than that which is present in the GIT (Butler and Dressman, 2010). 
These factors contribute towards limiting oral bioavailability, and the formulation 
and delivery of these poorly water soluble drugs (PWSD) poses a major challenge to 
their successful development into new medicines, where delays in development or 
even failure to gain approval can occur. Increasing lipophilicity associated with these 
poorly soluble drugs also leads to increased susceptibility to food mediated 
alterations in bioavailability, particularly an increased likelihood of a positive food 
effect (Custodio et al., 2008, Raman and Polli, 2016). Such food effects are considered 
as limiting factors in drug development, where there are clinical and commercial 
preferences for drug/ formulation combinations which are resistant to food 
mediated changes in bioavailability. Consequently, a significant body of research has 
focused on formulating these compounds to overcome food effects (Lentz, 2008, 
Schmidt and Dalhoff, 2002). An alternative approach is the use of label claims that a 
medicine should be taken in a specific prandial state, though this approach can result 
in low levels of adherence in certain patient populations, limiting clinical utility (Todd 
et al., 2012, Singh and Malhotra, 2004, Kang and Ratain, 2010, Thombre et al., 2011). 
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Successful delivery of these challenging compounds often relies on the use of novel 
bioenabling formulations, designed to enhance their in vivo solubility and/or 
dissolution. In this regard, novel formulation approaches, such as nanoformulations, 
solid dispersions and lipid based formulations are increasingly being used in drug 
development pipelines, however, there are still gaps in the knowledge of formulation 
of PWSD and technologies to increase exposure (Kwong, 2015, Lennernas et al., 
2014). A key reluctance in the industry appears a perceived risk associated with the 
early stage selection of bioenabling formulations – reflecting a lack of guidance on 
how to select an appropriate bioenabling formulation. As a result, working in 
restricted drug development timelines, pharmaceutical development scientists have 
been known to formulate drugs using conventional formulation approaches in pre-
clinical testing, yielding sup-optimal bioavailability and wasted resources. Developing 
an understanding of the key biopharmaceutical properties and how they affect the 
ADMET process can help to drive efficiencies in the formulation screening process, 
which can otherwise be a predominantly iterative process that may still result in 
failure to achieve adequate exposure (Kwong, 2015, Bergstrom et al., 2014). 
Introducing more clinically relevant screening methods, especially in the context of 
quality by design (QbD), could make development more cost-effective while 
maintaining quality (Lennernas et al., 2014). Development of predictive 
biopharmaceutical tools and the validation of existing approaches with respect to 
their performance in predicting the in vivo outcomes is central to this process. This is 
one of the assortment of limitations which has led to declining productivity in 
pharmaceutical research and development (R&D) productivity over the last six 
decades.  
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Declining productivity in Pharmaceutical drug product development 
Over the last few decades, despite huge advances in therapeutic target discovery, 
the number of new medicines approved for clinical use has decreased consistently. 
For example, the number of new medicines approved per $1 billion invested in R&D 
has decreased by 50% every nine years since the 1950s, reflecting the high attrition 
rates encountered in translating drug molecules to medicines (Scannell et al., 2012). 
Numerous industry reports have indicated there is a clear need to develop new 
technologies to improve the developability of emerging drug candidates and to 
unlock key bottle-necks stifling innovation in pharmaceutical development 
(Arrowsmith, 2011). With upwards of 90% of drug candidates failing to ever gain 
approval, and with approximately 30-40% phase III clinical trials failing, there is 
significant financial and time costs associated with failures in drug development 
pipelines (Hay et al., 2014). Consideration must be given to the impact of these high 
failure rates on the cost of drug development and how best to incentivise continued 
focus on breakthrough medicines (Calcoen et al., 2015). Poor biopharmaceutic and 
pharmacokinetic (PK) properties are among the direct causes of this attrition, and 
such drug candidates can consequently take more time and resources to develop, 
and may make efficacy failures more likely (Kostewicz et al., 2014b, Hann and Keseru, 
2012).  
In order to overcome these challenges, a major focus of R&D in pharmaceutical 
industry is reduction of costs and development cycle time-frames. Through utilising 
earlier proof of concept studies and focusing on the ‘R&D sweet-spot’ prior to phase 
II clinical trials a ‘quick win, fast fail’ can be achieved, improving phase II success rates 
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(Paul et al., 2010). Attrition is the single biggest determinant of R&D efficiency, and 
reducing attrition, particularly at stage II and stage III, will have profound effects on 
the cost of developing new medicines (Paul et al., 2010). To achieve this, a major goal 
is to shift compound and formulation attrition earlier in the development process, 
with key “go/no-go” decisions occurring even prior to the clinical stage (Paul et al., 
2010, Kwong, 2015).  
Any strategy to streamline formulation development to meet the accelerated time-
lines, therefore, needs to tackle both R&D inefficiencies and reduce R&D costs and 
delays, through improving the predictivity of early screening and avoiding 
unnecessary testing.  Considering the limitations of current R&D approaches outlined 
above, and recognizing that most new drugs are poorly soluble, the drive to 
accelerate the development and approval of break-through therapy drugs urgently 
requires an accelerated development paradigm, consisting of three key elements:  
1. Deign of innovative, bioenabling formulations for poorly soluble drugs, with 
choice guided through knowledge harnessed in formulation screening 
2. Generation of predictive in vitro and in silico tools capable of rapidly and 
accurately screening formulations and predicting their ability to deliver drug 
in vivo 
3. Improving the predictive capacity of pre-clinical in vivo testing by prudent 
choice of animal model and understanding of the key biopharmaceutical 
properties of model choice 
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The current thesis focuses on these key questions, through the pre-clinical in vitro, in 
vivo and in silico assessment of two novel bioenabling formulations and the 
absorption enhancing capacity of co-administration of PWSD with food in the pig 
model, with a specific focus on eliminating the food effect. The dual aim is to assess 
the capability of these bioenabling approaches to enhance the bioavailability of 
PWSD, while also examining the predictive capacity of the range of biorelevant in 
vitro, in silico and pre-clinical in vivo screening methods implemented in formulation 
assessment. The formulation and assessment approaches utilised are further 
described in the introduction below. 
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Bioenabling formulation approaches 
At a high level, there are two strategies to deal with poor solubility and/or dissolution 
in drug development (Lohani et al., 2014); 
1. Lead modification; ensuring good biopharmaceutical properties are 
incorporated into the molecule during the drug design  
2. Formulation development; mitigating the problem through prudent selection 
of drug form, excipient and production methods 
With the ever-increasing prevalence of lipophilic, poorly soluble compounds in drug 
development pipelines and the limited ability of lead modification to enhance 
molecule developability, the successful delivery of these challenging compounds will 
often rely on the use of novel bioenabling formulations, designed to enhance their in 
vivo solubility and/or dissolution (Hauss, 2007, Williams et al., 2013b, Butler and 
Dressman, 2010). Dissolution is considered the rate-determining step for absorption 
of poorly soluble and highly permeable (BCS class II) compounds and bioenabling 
formulations are frequently investigated for their potential to improve oral 
bioavailability of these molecules through increases either in the rate of absorption 
or in overall extent of bioavailability (Buckley et al., 2013). While changes in drug 
products generally have less influence over permeability, which tends to be an innate 
characteristic of a compound, there are cases where excipients have an impact on in 
vivo permeability, though these are rare (Butler and Dressman, 2010). The primary 
focus, however, has been on the development of bioenabling formulations, which 
enhance the solubility and/or dissolution of poorly soluble drugs and generate 
supersaturation, a metastable state where drug concentrations exceed the 
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equilibrium solubility in the medium, facilitating absorption. This is both due to these 
molecules being the most commonly observed class in drug development pipelines, 
and the fact that these molecules are the most amenable to formulation approaches 
designed to overcome their biopharmaceutical limitations. This has provided a focus 
for the development of bioenabling formulations, ultimately with the aim of ensuring 
BCS class II compounds will behave more like BCS class I compounds in vivo through 
enhancing dissolution and generating supersaturation. To exploit supersaturation as 
a strategy to improve intestinal absorption of poorly water‐soluble drugs, the 
supersaturated state needs to be both generated and maintained. Guzmán et al. 
(2007) described this concept by using the term ‘spring and parachute approach’, as 
illustrated in figure 1-1. The ability of these formulations to generate supersaturation 
has been described as the ‘spring’ that enhances absorption and bioavailability 
(Brewster et al., 2008, Guzman et al., 2007). Generation of a ‘spring’ relies on 
reduction in the energy required for dissolving drug, for example by forming an 
amorphous drug form, or by presenting the drug in a pre-solubilised form, bypassing 
the need for dissolution altogether. Supersaturated solutions contain drugs at higher 
concentrations than their saturation solubility, and acts a driver of intestinal flux, 
facilitating absorption. However, supersaturated states tend to be inherently 
thermodynamically unstable and a potential risk of such strategies is the possibility 
of drug precipitation. Precipitation generally results in the formation of the 
energetically favourable crystalline form of a drug, which will have poor dissolution 
properties. Formation of such a crystalline form following formulation delivery will 
negate the favourable dissolution performance associated with formulating drugs in 
this manner. For this reason, bioenabling drug delivery systems often also include a 
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‘parachute’ which aims to stabilise and prolong the supersaturated state, be 
generating a metastable condition (Guzman et al., 2007). Such parachutes may 
include the use of precipitation inhibitors, or by utilising solubilising species such as 
lipids and surfactants to enhance solubility and reduce the maximum supersaturation 
ratio, maintaining the supersaturated state (Williams et al., 2013a, Xu and Dai, 2013). 
 
Figure 1-1 Schematic drug concentration–time proﬁles illustrating the spring and parachute approach of 
supersaturating drug delivery systems. Proﬁle 1: dissolution of the most stable crystalline phase; proﬁle 2: 
dissolution of a higher energy ‘‘spring’’ form of the drug in absence of precipitation inhibitors; proﬁle 3: 
dissolution of a higher energy ‘spring’ form of the drug in presence of precipitation inhibitors that act as a 
‘‘parachute.’’ Ceq represents the equilibrium solubility. Adapted from (Brouwers et al., 2009) 
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With this in mind, there has been much research in a wide range of formulation 
approaches designed to improve drug solubility and/or dissolution and potentially 
generate supersaturation. These approaches include those listed below and 
summarised in figure 1-2 (Williams et al., 2013b); 
1. Salt formation 
2. Optimising crystal habit/ using optimal polymorphs 
3. Addition of co-solvents and/or surfactants 
4. Complexation with cyclodextrins 
5. Particle size reduction – including micronisation and nanonisation 
6. Lipid based formulations 
7. Amorphous solid dispersions 
We have divided these approaches, very broadly, into two contrasting but 
complementary groupings, namely dissolution enhancing techniques and solubilising 
approaches. In practical terms, solubilising techniques will also lead to increases in 
dissolution rate, while it can also be difficult to definitively and exclusively classify 
these approaches to one group or the other. This is exemplified by the fact that 
nanonisation of particles straddles both classifications, where reduction in particle 
size to the nano-scale is expected to increase dissolution rate, but also has been 
shown  to result in the formation of imperfections in crystals, leading to a 
corresponding increase in the kinetic solubility of dissolving particles (Shah et al., 
2016, Chen et al., 2017).  
 
 
12 
 
 
Figure 1-2 Approaches to formulation design for poorly water soluble drugs (PWSD) 
One of the primary aims of the current thesis was the development and assessment 
of novel bioenabling formulations in the pre-clinical pig model. Two different 
formulation platforms were assessed during this thesis  
 Lipid based formulations 
 Mesoporous silica based solid dispersions 
A brief introduction to these formulation platforms is provided here. 
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Lipid based formulations 
One approach to bioenabling formulation development is the use of lipid-based 
formulations (LBF), where drug is co-formulated with exogenous lipids to enhance 
solubility and dissolution. LBF confer numerous biopharmaceutical advantages for 
delivering poorly soluble API, which are summarized in table 1-1 and discussed here 
Table 1-1 Biopharmaceutical effects of oral lipid based formulations, adapted from (Constantinides and Wasan, 
2007) and (Benet, 2013). 
BCS class 
% 
Marketed 
drugs 
% New 
molecular 
entities 
Biopharmaceutical 
effects of Lipid Based 
Formulations 
Potential of 
Lipid based 
formulations 
Class I 
High Solubility 
High permeability 
40% 18% Gut wall efflux↓ +/- 
Class II 
Low Solubility 
High permeability 
33% 54% 
Solubilisation ↑ 
Permeability ↑ 
Efflux ↓ 
Lymphatic transport↑ 
+++ 
Class III 
High Solubility 
Low permeability 
21% 22% 
Permeability ↑ 
Enzymatic degradation↓ 
Efflux↓ 
+ 
Class IV 
Low Solubility 
Low permeability 
6% 6% 
Solubilisation ↑ 
Permeability ↑ 
Efflux ↓ 
Lymphatic transport↑ 
+++ 
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LBF have long been investigated for their role in enhancing the absorption of PWSD. 
LBF include many different types of drug delivery systems, but particular interest has 
been shown in self-emulsifying drug delivery systems (SEDDS). SEDDS are 
combinations of digestible oils with surfactants, which spontaneously emulsify to 
form a stable emulsion on dispersion in the GIT and are of particular interest in the 
wider literature owing to the numerous commercially available examples, with 
Neoral® being the most well documented success story. Neoral® is a SEDDS 
formulation of cyclosporine which improved the oral bioavailability of this poorly 
soluble immunosuppressant. Additionally, the SEDDS formulation was less sensitive 
to food effects and reduced inter-individual variability (Mueller et al., 1994). Given 
the commercial success of such approaches, a SEDDS formulation approach was 
identified as a promising platform for assessment in this thesis. 
Mechanisms of lipid mediated improvements in bioavailability 
The original rationale for the investigation of LBF to improve absorption of PWSD was 
the observation that numerous drugs showed favourable increases in oral 
bioavailability when co-administered with food. Clinical reliance on co-
administration with food, however, is inherently variable and unpredictable owing to 
variability in food ingestion and meal composition (Williams et al., 2013b). Focus 
instead shifted to identification of the physiological and biopharmaceutical 
properties underpinning this effect. Understanding these mechanisms has allowed 
co-administration of PWSD with formulated lipids, mostly derived from food oils, 
providing a predictable and reproducible route to the advantages of lipid co-
administration. The primary methods by which LBF enhance absorption are 
described in this section and summarized in figure 1-3.  
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Figure 1-3 Schematic representation of the critical steps in oral drug absorption and the possible influences of 
lipid-based formulations. Solubility/ dissolution effects in left panel. Permeability/absorption effects in right panel. 
Adapted from (O'Driscoll and Griffin, 2008). 
Increased drug solubilization and dissolution in the GIT 
The ability to pre-solubilize drug in LBF, allowing delivery of a lipidic solution offers a 
clear advantage for drugs which display dissolution-rate limited bioavailability. 
Maintenance of solubilisation on formulation dispersion bypasses the drug 
dissolution step that is required when drug is administered in a crystalline solid-state 
(Mu et al., 2013).  Additionally, the lipidic excipients – namely lipids and lipophilic 
surfactants – and co-solvents can also improve drug solubilization within the GIT 
(O'Driscoll and Griffin, 2008).  
Increased intestinal permeability, reduced first pass metabolism and intestinal efflux 
Lipids, surfactants and co-solvents, the principal components of LBF, have all been 
shown to impact intestinal permeability. In particular, the permeability enhancing 
effects of various bile salts, exogenous surfactants and end-stage lipid digestion 
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products are well known (Goole et al., 2010). These include increasing transcellular 
flux by promoting membrane solubilization and increasing membrane fluidity, 
inhibiting efflux transporters and intestinal enzyme activity and altering tight junction 
(TJ) integrity (figure 1-4). Promotion of lymphatic uptake will also result in avoidance 
of first pass metabolism (FPM). 
Promotion of intestinal lipid absorption and lymphatic uptake 
It is noteworthy that dietary lipids share many of the physicochemical properties that 
predispose PWSD to poor absorption, yet these dietary components are well 
absorbed. This occurs as a result of a highly efficient lipid absorption process (Gajjar 
et al., 2007). Dietary lipids stimulate the release of biliary salts and lipids, while also 
promoting secretion of lipase enzymes. These enzymes ultimately digest triglycerides 
to monoglycerides and fatty acids, which are solubilized in bile salt mixed micelles, 
from which absorption can occur. Once in the enterocyte, lipids enter the systemic 
circulation either via the portal blood or the intestinal lymphatic system (figure 1-4).  
Drug absorption from LBF can be described as ‘piggy backing’ on the lipid absorption 
pathway. Co-administration of formulation lipids is intended to stimulate the same 
physiological response as dietary lipids and studies have shown that LBF can indeed 
generate at least a ‘semi-prandial’ response by stimulating gallbladder contraction 
and slowing gastrointestinal transit (Kossena et al., 2007, Christiansen et al., 2016). 
Targeting of lymphatic uptake using LBF is somewhat more specific than attempting 
to exploit the lipid absorption pathway and is a function of both formulation design 
and the physicochemical properties of the drug. Inclusion of long chain lipids in a 
formulation is more likely to promote intestinal lymphatic absorption of highly 
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lipophilic drugs, via stimulation of triglyceride rich lipoproteins synthesis in intestinal 
cells. Specific drug characteristics favouring lymphatic absorption include high 
lipophilicity (e.g. log P > 5, solubility >50mg/g in triolein) (Lawless et al., 2015). 
Figure 1-4 provides a useful summary of the mechanisms of transport from LBF into 
systemic circulation, highlighting these bioenabling mechanisms. Table 1-1 
meanwhile provides a summary of the expected benefits of LBF for each class of BCS 
compounds. 
 
Figure 1-4 Schematic diagram of the mechanisms of intestinal drug transport from lipid-based formulations via 
the portal and mesenteric lymphatic routes. The main effects shown include: (A) increased membrane fluidity 
facilitating transcellular absorption, (B) opening of TJ to allow paracellular transport, (C) inhibition of P-gp and/or 
CYP450 to increase intracellular concentration and residence time, and (D) stimulation of lipoprotein/chylomicron 
production. ABL, aqueous boundary layer; D, drug; D−, ionized drug; FA MG, fatty acid monoglyceride; LCFA, long 
chain fatty acid; ME, microemulsion; SEDDS, self-emulsifying drug delivery systems; TG, triglyceride; TJ, tight 
junction, adapted from (O’Driscoll, 2002). 
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Summary 
LBF have proved successful in enhancing the bioavailability of PWSD, with numerous 
commercial examples. The propensity for formulation lipids to enhance dissolution 
and solubilization in the GIT, stimulate physiological absorption pathways and 
facilitate permeation means that LBF are ideally tailored to overcome poor 
absorption characteristics of PWSD, and particularly with regard to eliminating food 
mediated changes in bioavailability. While current in vitro tools used in the 
assessment of LBF suitability and prediction of performance give insights into the 
likely fate of a formulation, direct in vitro- in vivo correlation (IVIVC) remains elusive. 
In particular, the complex relationship between solubilization, supersaturation and 
precipitation on formulation dispersion and digestion and the overall effect in vivo 
remains a significant area of interest. Establishing more biorelevant in vitro tests, the 
refinement of PBPK models and the increasing volume of preclinical in vivo data is 
aiding our understanding of the critical quality attributes (CQA) of LBF. 
Thus, development of a novel LBF and its preclinical characterisation are among the 
aims of the current thesis. Given the significant interest in the ability of LBF to 
overcome food effect bioavailability, a particular emphasis is placed on eliminating 
food effect with a novel lipidic dispersion. The ability of in vitro and in silico tools to 
forecast pre-clinical in vivo performance in pigs is also assessed. These aspects of 
formulation development are further discussed in the proceeding sections of this 
introduction. 
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Mesoporous silica 
Amorphous solid dispersions 
In recent years, the use of amorphous materials, and amorphous solid dispersions 
(ASD) in particular, has gained considerable traction for solubility and dissolution 
enhancement of poorly water soluble drugs (Vo et al., 2013, Newman et al., 2015, 
Vasconcelos et al., 2007). Amorphous materials differ from crystalline compounds 
due to the lack of long-range order, leading to higher free energy. As a result, 
amorphous materials can display an increase in apparent solubility, even up to 
several orders of magnitude over the corresponding crystalline form, leading to 
generation of supersaturated state upon dissolution, providing an initial ‘spring’ to 
drive bioavailability (Guzman et al., 2007). However, one drawback of amorphous 
materials is the higher free energy associated with this metastable state can lead to 
recrystallization upon storage, or indeed that the supersaturation generated after 
dissolution can be transient and lead to precipitation of drug in a crystalline form, 
negating the solubility advantage achieved by formulating drug in this manner. 
Consequently, it is often necessary to stabilise formulations containing glassy, 
amorphous materials. While the traditional approach to stabilise amorphous 
materials is through their dispersion within inert polymer carriers, forming 
amorphous solid dispersions, mesoporous silica carriers are gaining increasing 
interest as alternative carriers to stabilise such formulations (Newman et al., 2015, 
Vo et al., 2013). 
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Mesoporous silica drug delivery systems 
Mesoporous silica is a form of silicon dioxide, which possesses pores in the range of 
2-50nm and it is possible to control the pore size and architecture during the 
manufacturing process (Maleki et al., 2017). The porous structure leads to vast 
increases in surface area (700-1000m2/g), relative to non-porous material, facilitating 
drug loading onto the silica surface. In particular, ordered mesoporous silicas, which 
possess uniform pore size, shape and volume, have proven beneficial in drug delivery 
and in enhancing the dissolution of PWSD (Van Speybroeck et al., 2009, Kiekens et 
al., 2012). The characteristics of the mesoporous silica material itself plays a crucial 
role in determining the drug loading and release characteristics of the formulation. 
In particular the pore size, volume and geometry, level of drug loading, surface 
functionalisation and overall particle surface area play major roles in controlling 
release characteristics (McCarthy et al., 2016). By controlling pore size and volume 
as well as the surface chemistry, the formulation can be tailored for each drug 
molecule with regard to its physicochemical characteristics. The optimised 
preparation can maximise drug loading and facilitate long-term stability via inhibition 
of recrystallization within the limited pore space (Salonen et al., 2008, Maleki et al., 
2017).  Mesoporous silica formulations possess a number of advantages in improving 
dissolution of poorly soluble drugs, which have been the focus of significant research 
over the last two decades, culminating in the first human study in 2016. This study 
demonstrated an improvement in fenofibrate bioavailability, indicating the promise 
of mesoporous silica formulations in drug delivery (Bukara et al., 2016b). Some of 
these properties are briefly discussed here.  
 
 
21 
 
Factors affecting drug loading, release and stability 
Adsorption of drug onto a mesoporous silica carrier has a number of advantages for 
enhancing drug dissolution. The ordered mesoporous structure and high porosity of 
silica allows high drug loads to be adsorbed (Vialpando et al., 2011, Singh et al., 2011). 
Drug molecules adsorb to the silica surface in a noncovalent manner, principally 
through electrostatic interaction, hydrogen bonding or van der Waal’s forces, which 
are easily broken on exposure of the formulation to an aqueous environment, 
enabling release of drug in its molecular form and facilitating absorption. The drug 
can exist in an amorphous or molecularly dispersed state on the silica surface, thus 
displaying higher apparent solubility and dissolution rate compared to the crystalline 
substance (Hancock and Zografi, 1997). Although amorphous materials can display 
thermal instability, adsorption onto the mesoporous silica has proven effective in 
stabilising amorphous systems, and the long-term stability of these formulations has 
been repeatedly demonstrated (McCarthy et al., 2016, Van Speybroeck et al., 2009). 
Adsorption to the silica surface generates a physical stabilisation effect, due to a 
decrease in the free energy of the drug/silica system, reducing the tendency to 
crystallise (Morris et al., 2001). Secondly, size-confinement of molecularly dispersed 
amorphous materials can also lead to stabilisation of the system. Drug molecules in 
the mesopores are constrained to such an extent that they cannot reach a critical 
nucleation size, therefore preventing crystal formation and growth (Alcoutlabi and 
McKenna, 2005). The critical pore size at which crystal growth is prevented is 
generally observed to be approximately ten to fifteen times the molecular size 
(Maleki et al., 2017, Sliwinska-Bartkowiak et al., 2001, Rengarajan et al., 2008). Along 
with controlling pore size and volume, it is also possible to functionalise the silica 
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surface with differing functional groups, such as amino groups or alkyl chains of 
varying lengths, in order to alter drug loading and/or release (Balas et al., 2006, 
Doadrio et al., 2006). 
Supersaturation and precipitation in mesoporous silica formulations 
The presence of adsorbed drug in a stabilised amorphous or molecularly dispersed 
state on the surface of mesoporous silica is useful in enhancing the 
solubility/dissolution behaviour of PWSD, and can be used to enhance drug 
bioavailability (Bukara et al., 2016b, Van Speybroeck et al., 2011).  The favourable 
dissolution and solubility behaviour associated with these formulations can be used 
to generate supersaturation, where the concentration of solute within the solution 
is above the thermodynamic equilibrium solubility, favouring absorption, providing 
the ‘spring’ for the supersaturated state. A drawback of using mesoporous silica 
materials for stabilisation of amorphous systems is that the more conventional 
polymeric matrices may also have inhibitory effect on precipitation, even after drug 
release from the polymeric carrier (Laine et al., 2016). To counteract this problem, 
an increasing body of research has focused on the co-formulation of mesoporous 
silica formulations with polymeric precipitation inhibitors (Laine et al., 2016, 
Dressman et al., 2016, Van Speybroeck et al., 2010b). 
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Polymeric precipitation inhibitors 
One method to create a ‘parachute’ is the inclusion of a polymeric precipitation 
inhibitor (PPI) as a functional excipient to slow the rate of precipitation (Van 
Speybroeck et al., 2010b, Warren et al., 2010, Laine et al., 2016). The use of PPIs has 
previously been established in the development of conventional solid dispersion 
formulations, as well as in other formulation approaches including LBF (Yamashita et 
al., 2003, Gao et al., 2003). PPIs aim to maintain drug in a metastable supersaturated 
state over a period of time that is sufficient to allow absorption (Warren et al., 2010). 
In general PPIs are effective only at delaying the rate of precipitation, and do not alter 
the equilibrium solubility. PPIs are thought to slow precipitation by both preventing 
nucleation, which is a pre-requisite to crystal formation precipitation, and prohibiting 
crystal growth on nuclei which have already been formed. A wide range of potential 
mechanisms have been identified, which can be broadly classified into two distinct 
categories; (1) altering solution bulk properties, such as surface tension and 
diffusivity, preventing nucleus formation and (2) adsorption to crystal interface, 
growth terraces and imperfections, principally through hydrogen bonding and 
hydrophobic interactions, preventing crystal growth through steric hinderance 
(Machefer et al., 2008, Gao et al., 2009, DiNunzio et al., 2008, Ilevbare et al., 2012, 
Xu and Dai, 2013). A wide range of polymeric precipitation inhibitors exist, including 
polyvinylpyrrolidine (PVP), hydroxypropyl methylcellulose (HPMC), hydroxypropyl 
methylcellulose acetate succinate (HPMCAS) and copovidone (PVPVA) (Dressman et 
al., 2016). A point to consider is the lack of a ‘one size fits all’ approach to choosing a 
PPI. While “there are likely to be common functional attributes of ‘good’ PPIs” 
(Warren et al., 2010), effective screening remains essential and choice of an 
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appropriate PPI is crucial. This is exemplified by the studies by Van Speybroeck et al. 
(2010) and Dressman et al. (2016). These studies had contrasting findings on the 
relative performance of the cellulosic derivatives, HPMC and HPMCAS, on 
precipitation indicating there is still a ways to go fully elucidating the mechanistic 
understanding of PPI performance, and polymer performance may well be 
compound specific (Bevernage et al., 2011, Dressman et al., 2016, Van Speybroeck 
et al., 2010b). 
Summary 
Mesoporous silicas have demonstrated excellent properties for the enhancement of 
drug dissolution and oral bioavailability of a variety of poorly water-soluble BCS II 
compounds and while a commercial preparation has yet to be realised, a first, human 
proof of concept study has recently demonstrated the realistic prospect of such a 
formulation (Bukara et al., 2016b). The ability of stabilised amorphous drug loaded 
onto mesoporous silica to generate a supersaturation and improve oral 
bioavailability has been repeatedly demonstrated, and the use of precipitation 
inhibitors to stabilise such systems has also been addressed. However, there remains 
gaps in the knowledge regarding the in vitro and in vivo performance of such 
formulations (McCarthy et al., 2016). One of the aims of the current thesis is the in 
vitro and in vivo assessment of such a formulation to determine its ability to 
overcome dissolution/ solubility limitations of a model PWSD, while also attempting 
to link in vitro and in vivo performance. 
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Food effects on bioavailability and formulating away the ‘food effect’ 
The concomitant administration of oral dosage forms with food can have a significant 
impact on drug pharmacokinetics and bioavailability relative to the fasted state. With 
oral drug delivery continuing to be the method of choice for drug administration, 
understanding the effects food has on the biopharmaceutical aspects of drug delivery 
is key to the drug development process as well as the effective and rational use of 
medicines in the clinical setting (Fleisher et al., 1999, Abuhelwa et al., 2017). As 
previously mentioned, the original rationale for designing LBF was the observation of 
increased oral bioavailability for many drugs when they were taken with food.  While 
there are clinical and commercial preferences to formulate drug products to 
overcome food effects, co-administration with food, as a bioenabling approach, has 
been utilised clinically through the provision of ‘label claims’ with regard to food 
intake for many drugs, where patients are instructed to take these medications in a 
specific prandial state, quite often with the aim of enhancing bioavailability. In this 
regard, co-administration with food can be considered a bioenabling technique in its 
own right. The use of this approach is widespread, with research carried out by this 
group suggesting that approximately 40% (67 of 157 products identified; 42.68%) of 
medicines licensed by the EMA and FDA since January 1st, 2010 display a significant 
food effect or have been licensed with a label restriction with regard to dosing with 
or without food (O'Shea et al., 2018). The effects of food on drug bioavailability and 
the mechanisms which underpin them are described briefly here.  
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What is a food-effect? 
In its simplest terms, food effects on drug absorption are observed when the rate 
and/or extent of drug bioavailability is altered when a drug or drug product is 
administered in fed state, compared to the fasted state. The clinical effects and 
significance of food effects on absorption are generally assessed with regard to the 
rate and extent of bioavailability – as measured by peak plasma concentrations 
(Cmax), time to peak plasma concentration (Tmax) and the total extent of bioavailability 
(area under the curve; AUC) (Fleisher et al., 1999). Welling classified food drug 
interactions into five categories causing (Welling, 1989); 
 Reduced extent of bioavailability  
 Delayed rate of absorption 
 Increased extent of bioavailability  
 Accelerated rate of absorption 
 No effect 
With regard to clinical significance, the most crucial aspect of food effect is generally 
considered to be the extent of bioavailability change, and the terms ‘positive food 
effect’ and ‘negative food effect’ have been coined to describe either an increase or 
decrease in the overall extent of bioavailability, respectively (Fleisher et al., 1999). 
FDA guidance defines that a food-effect is established if the 90% confidence intervals 
for the ratio of population geometric means, based on log-transformed data, for 
either AUC0→∞ or Cmax fall outside the 80-125% bioequivalence limits relative to the 
reference, i.e. the same formulation administered in the fasted stated (FDA, 2002). 
The fed state represents dosing post ingestion of a high fat, FDA standard breakfast, 
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containing 800 – 1000 kcal with approximately 50% of total calories coming from fat, 
to maximise potential for demonstrating a food effect (FDA, 2002).  
Figure 1-5 illustrates the key steps in drug absorption and bioavailability and indicates 
how food influences these processes. 
 
Figure 1-5 Schematic diagram of critical steps in drug absorption and influence of food and food components; 
FPM: first pass metabolism 
Mechanisms underlying the food effect 
Drug absorption via the oral route is a function of the interplay of various complex 
biopharmaceutical processes, namely (i) drug molecular and physicochemical 
properties, (ii) formulation characteristics, (iii) the physiological changes of the 
gastrointestinal tract induced in the fed state and (iv) the physical chemical changes 
in the composition of the gastrointestinal fluid (Fleisher et al., 1999). The 
Biopharmaceutical Classification System (BCS) and Biopharmaceutical Drug 
Disposition Classification system (BDDCS) provide a useful predictor of potential food 
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effects based on drug physicochemical properties, as summarised in figure 1-6 (Wu 
and Benet, 2005, Amidon et al., 1995). The anticipated effects are predicted by the 
most likely limiting factor for bioavailability, namely solubility or dissolution for 
BCS/BDDCS class II compounds, permeability for class III compounds, or a 
combination thereof for BCS class IV compounds. An overall delay in Tmax and reduced 
Cmax for highly bioavailable compounds can be associated with a delayed gastric 
emptying (Custodio et al., 2008). While this tool does not capture all the potential 
effects of food, it is the most widely utilised simple tool to predict food effect 
behaviour, and is estimated to be accurate in approximately 70% of cases (Benet, 
2013). 
 
Figure 1-6 Predicted effect of high fat meals by BCS/BDDCS class. Adapted from Custodio et al. (2008) 
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Drug absorption is inherently variable, owing to both inter- and intra-individual 
variability in the physiology of the GIT. When considering the gut physiology 
McConnell et al. have stated that there is ‘no such thing as an average 
person’(McConnell et al., 2008), and despite regulatory guidance, equally there is no 
such thing as a standard meal (FDA, 2002). The purpose of FDA guidance is to provide 
a standard for bioavailability and bioequivalence studies, where the likelihood of 
observing a food effect is maximised. However, this is not always reflective of the fed 
state for patients, which adds further to the variability and complexity of absorption 
and drug product performance.  
In the fed state the physicochemical composition of the gastrointestinal fluid, 
including its volume, pH, osmolality, surface tension, hydrodynamics and overall 
composition change (Abuhelwa et al., 2017, Clarysse et al., 2009b, Abuhelwa et al., 
2016a). Modulation of other physiological functions, such as gastrointestinal transit, 
enzymatic and intestinal transporter activity and endo- and exocrine secretions also 
occur in the fed state (Won et al., 2012, Custodio et al., 2008, Abuhelwa et al., 2016b, 
Varum et al., 2013). There are a number of additional factors that may influence 
absorption from oral dosage forms in the fed state, with the most pertinent aspects 
summarised in figure 1-7. 
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Figure 1-7 Summary of human physiological changes in the fed state (adapted from (Varum et al., 2013)) 
Mechanisms of food effect 
As has been mentioned above, food has a complex and significant effect on the 
physiology of the gastrointestinal tract and the physicochemical properties of 
gastrointestinal fluid, which in turn can have a significant effect on drug absorption. 
These effects are dependent on both the physicochemical properties of the drug, 
principally solubility, pKa and LogP/logD, and formulation characteristics, including 
release and disintegration of solid dosage forms (Mullertz, 2010, Gu et al., 2007, 
Singh, 2005). For the purposes of this introduction, the focus will predominantly be 
on immediate release and bioenabling formulations, the mechanisms by which food 
causes these changes in bioavailability are discussed here and summarised in table 
1-2.  
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Positive food effects 
The principal cause of positive food effects is the increase in dissolution and 
solubilisation of PWSD in the fed state. The release of bile salts and the presence of 
exogenous solubilising species, such as ingested lipids and their digestion products 
serve to enhance solubilising capacity of gastrointestinal fluid (Augustijns et al., 2014, 
Stappaerts et al., 2014, Geboers et al., 2016, Clarysse et al., 2011, Clarysse et al., 
2009a, Di Maio and Carrier, 2011). For drugs which are dissolution rate, rather than 
solubility limited, the increased gastric residence time also can improve 
bioavailability, while the increase in gastric pH may result in improved solubility and 
dissolution of weak acids. In practical terms, it is difficult to isolate the impact of any 
one of these factors, which work synergistically to increase solubility and dissolution 
of PWSD. 
The inhibition of intestinal transporters can play a role in enhancing bioavailability of 
certain drugs. Wu and Benet have demonstrated that for BCS class II compounds 
efflux transporters predominate, and that for these compounds transporter 
inhibition is likely to improve bioavailability (Elgart et al., 2013, Wu and Benet, 2005, 
Custodio et al., 2008, Benet et al., 2004). 
Reduction in first pass metabolism in the fed state can also lead to increases in 
bioavailability and this can occur through numerous mechanisms including altered 
blood flow, increased lymphatic uptake and reduced enteric metabolism. Food intake 
is associated with an increase in splanchnic blood flow by as much as 60% depending 
on the volume and nature of the meal. This allows drug to bypass the liver, while the 
increase in hepatic blood flow may also reduce the first pass effect for drugs which 
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display low to moderate clearance (Melander and McLean, 1983, Marasanapalle et 
al., 2011, Liedholm et al., 1990).  Co-administering lipophilic drugs with food allows 
efficient absorption of these molecules with dietary lipids, via lipid absorption 
pathways, while particularly lipophilic drugs (logP>5) can also show significant 
lymphatic uptake (Di Maio and Carrier, 2011, Charman and Stella, 1986, Lawless et 
al., 2015). This can increase the systemic absorption by both increasing the fraction 
escaping the gastrointestinal lumen and reducing the first pass effect.  
The inhibitory effect of food on meal components on CYP3A4 is also a significant 
contributor to the reduction of enteric drug metabolism and increased bioavailability 
in the fed state. Inhibition of CYP3A metabolism by grapefruit juice has been widely 
associated with increases in bioavailability and subsequent increases in adverse 
events for a wide range of pharmacologically diverse compounds (Custodio et al., 
2008, Gibbs and Hosea, 2003). While other fruit juices and other food components, 
including teas and alcoholic beverages, as well as high fat meals generally have been 
implicated in reduced enzymatic activity, though the clinical implications of such 
interactions have not yet been extensively characterised (Won et al., 2012).  
Negative food effects 
Negative food effects encompass both reduced and delayed drug absorption. With 
regard to delayed absorption in the fed state, this often occurs for immediate release 
preparations without a corresponding reduction in overall bioavailability. The main 
mechanism by which this occurs is delayed gastric transit in the fed state. This 
manifests itself as a prolonged Tmax, which may or may not be accompanied by a 
reduction in Cmax or a significant lag time. For medicines which are chronically dosed 
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and where overall exposure, rather than peak plasma levels, mediate 
pharmacodynamic action, this is unlikely to result in clinically meaningful effects 
(Schmidt and Dalhoff, 2002). 
Decreased absorption in the fed state results in a reduction in AUC, along with a 
reduction in Cmax, and can lead to sub-therapeutic plasma levels and loss of efficacy. 
The most common causes of reduced bioavailability in the fed state are direct 
physicochemical interactions between drugs, or drug products, and food. One 
potential cause of this effect is the reduced diffusivity of drug in the viscous 
postprandial upper GIT. The increased viscosity can result in either inhibition of 
disintegration of a dosage form, preventing drug release, or hindering diffusion of 
drug to the absorptive membranes of the GIT (Radwan et al., 2014, Yildiz et al., 2015, 
Kelly et al., 2003, Cole et al., 2004). This can be problematic for poorly permeable 
drugs, particularly those with narrow absorption windows, as by the time viscosity 
has reduced in the distal gut, the absorption window has been traversed and 
absorption will be reduced (Radwan et al., 2012, Radwan et al., 2013, Radwan et al., 
2017). This effect is amplified by viscous meals or those high in dietary fibre (Radwan 
et al., 2012, Rodin and Johnson, 1988). A second direct mechanism by which food 
can hinder drug absorption is by binding of drug with food components (Gertz et al., 
1995, Schmidt and Dalhoff, 2002). This is prevalent in the case of polyvalent cations, 
which are abundant in dairy products (Leyden, 1985, Neuvonen et al., 1991, Schmidt 
and Dalhoff, 2002, Wallace and Amsden, 2002, Polk, 1989). 
Physiological factors can also play a role in negative food effects, especially in the 
case of drugs displaying instability and possibly acid lability in the GIT. Prolonged 
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gastric residence can result in increased degradation of these molecules, though in 
the case of acid labile drugs the effect may be somewhat mitigated by the increase 
in gastric pH (Jones et al., 2006). Food can also result in alterations in absorption 
through altering both passive permeability and active transport. The presence of 
increased lipids and bile salts in the fed state can result in a decreased free fraction 
of drug, causing a reduction in permeability (Holmstock et al., 2013, Sugano et al., 
2010, Kataoka et al., 2012, Singh, 2005, Stappaerts et al., 2014). While for poorly 
soluble drugs, this is generally more than compensated for by increases in solubility, 
highly soluble and poorly permeable compounds may display reduced absorption in 
this case.  
The inhibition of uptake transporters may also result in negative food effects. For 
poorly permeable drugs, the inhibition of these transporters may result in a reduction 
in absorption, as these compounds are often reliant on the action of uptake 
transporters. The general inhibition of intestinal transporters observed in the fed 
state is therefore likely to reduce the bioavailability of BCS class III compounds. Care 
is needed, however, when applying this rule of thumb, as class III compounds may be 
candidates for both uptake and efflux transporters and the relative inhibition of 
either uptake or efflux transporters, or the extent to which a specific molecule will 
be a substrate for each particular class can determine the overall effect of 
bioavailability (Custodio et al., 2008).  
The events described here are summarised and examples of drugs affected by the 
various mechanisms are provided in table 1-2. 
  
 
 
35 
 
Table 1-2 Summary of physiological mechanisms and biopharmaceutical aspects underpinning the food effect 
Physiological mechanism Biopharmaceutical aspects Effect on Drug exposure Example(s) 
Increased pH in stomach Solubility and dissolution of 
ionisable compounds can be altered 
 
Increases AUC and Cmax for weak acids 
Decreases AUC and Cmax for weak bases 
Cefuroxime 
Dipyridamole, 
indinavir 
Increased concentration of 
solubilising species e.g. bile 
salts, lipid digestion products 
Solubilisation of poorly water 
soluble drugs increases 
 
 
Increases AUC and Cmax Fenofibrate  
Alectinib 
Danazol 
Increased splanchnic blood flow 
 
Saturation of liver enzymes and 
avoidance of FPM 
Increases AUC and Cmax Propranolol; Tacrine; 
Dronedarone 
Inhibition of gastrointestinal 
Cytochrome P450 – e.g. with 
Grapefruit juice 
 
Fraction of drug escaping gut 
metabolism increases 
Increases AUC and Cmax Felodipine; 
Ciclosporin; 
Atorvastatin 
Inhibition of intestinal 
absorptive and efflux 
transporters 
Fraction of drug subject to either 
absorptive or efflux transport is 
reduced 
Increases AUC and Cmax for drugs 
subject to efflux 
Decreases AUC and Cmax for drugs 
which require uptake transporters 
 
Ganciclovir 
 
Fexofenadine 
Talinolol 
Delayed gastric emptying Presence of food in stomach delays 
transit of drug to small intestine 
 
Increases Tmax, can decrease Cmax, may 
cause Tlag 
Widespread NSAIDs 
Paracetamol 
 
Increase in viscosity of intestinal 
fluid 
Reduction in water diffusivity, 
increase in luminal viscosity, slower 
water penetration of dosage form, 
increased disintegration time 
Increases Tmax, may reduce Cmax and F, 
may cause Tlag 
Chlorothiazide, 
Metformin 
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Summary 
Despite the increased awareness of the negative clinical impact of food effects on 
bioavailability and the strict regulatory guidance regarding the appropriate testing of 
new medicinal products in the fed and fasted states there appears to be an ever-
increasing challenge of food mediated alterations in drug bioavailability, likely 
reflecting the increasing prevalence of PWSD in drug development pipelines. While 
there has been increasing understanding and development of improved drug delivery 
technologies, there remains an overall lack of appreciation of the scale of the food 
effect challenge, as evidenced by the fact that over 40% of new medicines display 
significant food effects or possess a label claim in respect of dosing with regard to 
food intake.  This has had a knock-on effect in the clinic, where the success or 
commercial advantage of compounds can be affected, particularly with antipsychotic 
and oncological preparations. 
Formulating compounds to overcome food effect remains largely empirically driven, 
with only sporadic case studies for individual compounds published. While the 
presence or absence of food effects is unlikely to be a key driving factor in early 
formulation development, it can be a critical factor when entering the clinic. In the 
absence of large databanks of formulation design studies in easily obtainable 
literature, greater use of mechanistic and in silico approaches will be central to 
enhancing our ability to discriminate between formulations likely to overcome food-
mediated alterations in drug bioavailability. Thus, the development of a novel 
formulation to overcome food effect, along with its preclinical in vitro, in vivo and in 
silico assessment are among the primary aims of this thesis. 
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Pre-clinical formulation screening 
With the increasing need to develop novel formulation technologies to overcome the 
problems observed with increasing lipophilicity of development pipelines, there is 
consequently a greater need for efficiency in formulation development, and in 
particular in formulation assessment. Assessment of these novel drug/ formulation 
combinations involves a range of screening methods and in vitro techniques, before 
ultimately being assessed in vivo. Traditionally this development process has been 
largely empirically driven, resulting in an inefficient, iterative, ‘trial and error’ based 
approach involving screening of range of bioenabling formulations, before eventually 
selecting the most appropriate candidate formulation for clinical trials. However, this 
process is both inefficient as multiple formulation technologies are often developed 
and assessed in parallel and presents ethical implications as parallel development 
can lead to excessive pre-clinical bioavailability screening (Lennernas et al., 2014, 
Kuentz et al., 2016).  
Overcoming this limiting factor involves greater use of predictive biopharmaceutical 
tools to model the interplay of various drug, formulation and physiological 
properties, with the ultimate goal of forecasting the ability of formulation 
technologies to improve oral bioavailability (Kawabata et al., 2011, Pandey et al., 
2014).  This will involve moving away from empirically driven development programs, 
toward a Quality by Design (QbD) approach, utilizing an improved biopharmaceutical 
toolkit based upon a sound scientific understanding of in vivo behaviour. Enhanced 
predictive capacity earlier in the drug development process can greatly reduce early 
risk, improve developability assessment of candidate drugs and potentially even 
 
 
38 
 
result in reduction of animal studies (Lennernas et al., 2014). The implementation of 
these enhanced biopharmaceutical tools will involve an integrated approach with a 
combination of physicochemical measurements, in vitro tests, in vivo studies and in 
silico models. By enhancing the mechanistic understanding of biopharmaceutical and 
absorptive processes efficient screening will remove bottlenecks in drug 
development improving overall efficiency (Kostewicz et al., 2014b). There is a need 
to assess and validate the predictive capacity of current methods of formulation 
assessment, and also design and implement optimized, novel laboratory assessments 
and in silico models that will better predict the biopharmaceutical performance 
where current approaches are found wanting (Flanagan et al., 2016).  
The predictive capacity of new tools depends on their ability to simulate the dynamic 
gastrointestinal environment, particularly with regard to gastrointestinal transit, in 
vivo dissolution and/or precipitation and intestinal absorptive flux, incorporating the 
effects of the solubility- permeability interplay (Kostewicz et al., 2014b, Selen et al., 
2014). To this end, there has been significant focus in the last number of decades and 
designing and validating improved biorelevant, biopharmaceutical tools for 
formulation assessment and prediction of in vivo performance. These approaches 
include the introduction and refinement of in vitro permeability models, 
development of biorelevant dissolution media and in silico PBPK models for 
integration of in vitro data and prediction of GI drug absorption. A brief overview of 
the in vitro, in silico and in vivo approaches implemented and assessed is provided 
below. 
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In vitro screening 
The primary method of lab-based evaluation of oral solid dosage forms is by means 
of drug release testing, predominantly by means of in vitro dissolution testing, but 
also encompassing other methods such as disintegration and lipolysis. The link 
between drug release testing and in vivo performance has been recognized for well 
over 100 years. While traditional pharmacopoeial setups have proved useful in the 
quality control (QC) lab, both the apparatus and the media used in these compendial 
systems are far from optimized for dosage form development and predictive 
evaluation (Kostewicz et al., 2014b). This has led to significant development of these 
approaches over the past three decades, which is briefly summarised here. 
Choice of media 
One of the most crucial factors in biorelevant solubility and dissolution testing is the 
choice of dissolution medium when attempting to simulate the conditions of the 
intestinal lumen. While traditional compendial media have proven useful for QC 
purposes, they lack the biorelevance desired for the design of predictive 
biopharmaceutical dissolution tool. An alternative approach would be to use human 
and/or pre-clinical animal gastrointestinal aspirates for solubility and dissolution 
assessment. While such studies have been carried out, the obvious practical 
difficulties and ethical implications of using this approach on a routine basis has 
meant alternative approaches have been developed (Diakidou et al., 2009, Fagerberg 
et al., 2015, Augustijns et al., 2014). In order to be more predictive of in vivo 
performance and representative of the conditions in the intestinal lumen, the 
importance of using synthetic, simulated biorelevant media was first proposed in 
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1998 (Dressman et al., 1998). These media aim to provide an easily obtained and 
reproducible method of mimicking the physicochemical properties of human 
gastrointestinal fluid. Considerable efforts have been made in the interim to both 
characterize the luminal contents of the upper GI tract (Vertzoni et al., 2008, Kalantzi 
et al., 2006, Koziolek et al., 2013, Schneider et al., 2016, Clarysse et al., 2009b) and 
to design improved media have been proposed (Vertzoni et al., 2005, Vertzoni et al., 
2010, Vertzoni et al., 2004, Jantratid et al., 2008, Fuchs et al., 2015, Markopoulos et 
al., 2015). This has provided pharmaceutical scientists with a wide array of different 
media, representative of different prandial conditions in both the stomach, small 
intestine and colon, along with ‘snapshot’ media, which are reflective of specific post-
prandial timepoints in each region. Other specialist simulated media, such as that 
suitable for use in permeability assays, in lipolysis experiments or media with a 
modified viscosity for assessing disintegration or diffusion related effects have also 
been developed (Wuyts et al., 2015a, Wuyts et al., 2015b, Markopoulos et al., 2014, 
Klein et al., 2004, Cvijic et al., 2014, Williams et al., 2012, Zangenberg et al., 2001). 
While the choice of media will ultimately depend on the particular aspect of the 
biopharmaceutical drug delivery process under investigation, Markopoulos et al. 
(2015) have recently suggested a hierarchical approach to choose dissolution media 
based on level of biorelevance required (figure 1-8). While for drugs which display 
high solubility and a low dose; solubility ratio (BCS class I and III compounds) a simple 
aqueous buffer system (Level I biorelevant media) may be sufficient to assess pH 
related effects. For poorly soluble and lipophilic drugs more complex media is 
recommended which includes bile salts and products of digestion (Level II biorelevant 
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media). The authors of this work suggest that Level III biorelevant media, which also 
includes dietary proteins, enzymes and simulates the increased viscosity of luminal 
contents in the fed state is not routinely used but may be necessary for drug or 
formulation specific considerations. Such examples include lipolysis testing for lipid 
based formulations, assessment of the impact of increased viscosity on modified 
release dosage forms or the effect of degradation on peptide based therapies 
(Markopoulos et al., 2015). While the availability of these media is a significant 
benefit for development scientists, limitations and drawbacks remain. Specifically, 
these media represent a snapshot of the luminal conditions in the upper intestine 
and cannot replicate the rapid and dynamic changes in the conditions along the 
intestine. The inter- and intra-individual variability in GI composition can be 
considerable, questioning the reliability of using a single medium. While, in general, 
the approaches involving biorelevant media represent an improvement over 
traditional compendial media in terms of predicting in vivo performance, there 
remains a of lack systematic validation of this approach. 
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Figure 1-8 An overview of the four levels of biorelevant media recommended for the simulation of the luminal 
environment during development of oral formulations (Markopoulos et al., 2015) 
 
Choice of apparatus 
A second key factor to consider is the type of apparatus chosen. The USP type I 
(basket) and II (paddle) apparatus remain the most popular equipment for 
dissolution testing in drug development, partly due to familiarity and availability of 
the equipment, but also due to how robust they have proven at providing useful 
insights into dosage form performance. In particular, they have proven useful in 
quality control when used under sink conditions to demonstrate complete release of 
hydrophilic molecules (Kostewicz et al., 2014b). However, their use has also extended 
from the QC process to that of drug development, particularly when coupled with 
biorelevant media at physiological volumes. The paddle apparatus has been 
frequently used for BCS class II drugs in IR dosage forms in conjunction with 
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biorelevant media to predict in vivo performance and identify formulation and food 
effects. The use of type III (reciprocating cylinder) compendial apparatus in 
development has been largely restricted to modified release dosage forms, with 
relatively few published examples (Fotaki and Vertzoni, 2010, Klein et al., 2013). Type 
IV (flow through cell) is increasing in popularity in drug development, and in IVIVC 
generation, particularly for controlled release formulations (McCarthy et al., 2017, 
Sunesen et al., 2005, Jantratid et al., 2009).  
The vast majority of dissolution tests continue to be carried out in conventional, USP 
I and II compendial apparatus, with a single static medium, at a constant pH, volume 
and which may or may not include an absorption sink. These conditions do not 
adequately mimic the in vivo situation, where gastrointestinal motility exposes the 
formulation to a complex, rapidly evolving luminal environment (Kostewicz et al., 
2014b). In order to better reflect the in vivo environment, more biorelevant 
dissolution methods which mimic the dynamic gastrointestinal environment have 
been developed. 
The simplest such method is the two-compartment transfer model first designed by 
Kostewicz et al. (Kostewicz et al., 2004). This experimental set-up consists of two USP 
type II vessels side by side and simulates transfer from the stomach to the intestine 
by first placing a drug solution in a simulated gastric fluid compartment which is 
transferred into the simulated intestinal compartment at a constant rate, reflective 
of gastric emptying rate, via a peristaltic pump. Such a set-up is useful in both 
modelling the impact of gastric emptying and can be used in the assessment of 
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supersaturation and precipitation. While the type IV apparatus can facilitate media 
changing in an “open” setup, such set-ups are not commonly used (Fotaki, 2011). 
Even with the development of such transfer models, the limitations of a static 
dissolution vessels in any of the compendial apparatus for simulating the dynamic in 
vivo processes of gastric emptying, absorption, changes in pH and fluid composition 
and volume and intestinal transit are well reported. This has led to the development 
of “GI tract in lab” systems, which are more complex systems incorporating 
numerous compartments and various levels of control on processes such as gastric 
emptying. Having originated from research in the nutritional sector, there are several 
examples of these apparatus being used to assess formulation performance and the 
impact of food on bioavailability. Systems such as the TIM-1 and TIM-2 systems 
(Brouwers et al., 2011, Lyng et al., 2016) and the dynamic gastric model (DGM) 
(Thuenemann et al., 2015, Mason et al., 2016, Chessa et al., 2014) are dynamic multi-
compartmental simulators intended to mimic the main mechanical and chemical 
functions of the gastrointestinal tract, as well as the effect of the presence or absence 
of absorption sinks. There has been relative success with these apparatus, however, 
their scant availability, prohibitive cost and lack of systematic validation has limited 
their widespread use in industry. While such methods hold some promise for 
improved in vivo predictions, evaluation and validation remain anecdotal. More 
widespread utilisation of these methods has also likely been limited due to the 
relative success of integrating simple solubility and dissolution measurements with 
in vivo pharmacokinetic data through the use of PBPK models, which is further 
discussed below.  
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Permeability and absorption 
While dissolution assessment can provide a useful prediction of dissolution 
performance in vivo, one of the major challenges with biorelevant dissolution 
methods can be the absence of an absorption sink. A significant drawback of 
conventional dissolution methods is the inability to mimic the in vivo absorption of 
drug in the static in vitro environment in a satisfactory manner. As dissolved or 
solubilised drug remains present in dissolution apparatus, this can create an 
inhibitory effect on dissolution or even stimulate precipitation. This is particularly 
likely for poorly soluble, lipophilic compounds where rapid absorption is likely in vivo 
and may be compensatory for poor dissolution (Butler and Dressman, 2010). Simply 
ignoring absorption during dissolution assessment may compromise the 
biorelevance and predictive capacity of the test (Takano et al., 2012). Traditional 
approaches to overcome this have focused on the utility of synthetic surfactants to 
generate sink conditions, or simply through predicting drug flux and fraction 
absorbed, based on combining measured concentrations with drug permeability 
(Kostewicz et al., 2014b). The use of alternative dissolution media, where these 
compounds will not demonstrate poor solubility and therefore sink conditions will be 
maintained, such as those traditionally used for quality control, risks the loss of 
biorelevance. For this reason, a number of approaches have been investigated in 
combination with traditional dissolution methodology to mimic the absorptive in vivo 
process.  
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Alternative methods have been developed, where an absorption step is taken into 
account, either in the form of a biphasic dissolution set-up, where the absorptive sink 
is provided by the use of a non-miscible organic solvent layer (Shi et al., 2010, 
Pestieau and Evrard, 2017), or the combined use of a dissolution/permeation (D/P) 
apparatus (Kataoka et al., 2012, Buch et al., 2009, Miyaji et al., 2016). Such D/P 
apparatus may use either cellular based absorption assays, most often a Caco-2 
monolayer, or indeed may use tissue-based techniques, such as in situ perfusion 
studies of intestinal segments, most likely rat intestine, or using Ussing chamber 
mounted tissue. These systems have also been adapted for use with biorelevant 
media (Markopoulos et al., 2014, Wuyts et al., 2015a, Wuyts et al., 2015b, Stappaerts 
et al., 2014). By coupling the dissolution and permeation process, the complex 
interplay of dissolution and permeation can be more accurately assessed.  These 
systems vary significantly in set-up, operation and biorelevance, and while 
integrating absorption into in vitro dissolution assessment is critical for accurate 
prediction of performance of certain bioenabling formulations, the benefit of some 
of these approaches remains unclear and their validation, too, is often anecdotal. 
With the proliferation of in vitro tools to predict in vivo performance, there is now a 
wide array of tools of varying levels of complexity available to forecast formulation 
behaviour. However, there remains significant gaps in our ability to model all the 
physiological determinants of absorption. For this reason, there has been significant 
development of in silico models which combine data from these newly developed, 
biorelevant screening tools with physiological measurements to model and predict 
in vivo performance, as described here. 
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In silico methods 
Prediction of human pharmacokinetics generally relies on interpretation and 
extrapolation from in vitro and preclinical in vivo data (Suenderhauf and Parrott, 
2013). There has been significant development in computational approaches to 
predict human pharmacokinetics, ranging from classical computational absorption 
simulation based on compartmental PK through to more complex physiologically 
based pharmacokinetic (PBPK) models, which can integrate data from both these 
sources to give an estimate of human PK (Dressman et al., 2011). Despite the 
improvements in the biorelevance of in vitro screening over the last 25 years, routine 
dissolution screening as currently implemented cannot accurately model all the 
dynamic in vivo processes involved in drug absorption and meaningful IVIVC for 
immediate release, bioenabling formulations remains elusive. Gastrointestinal 
transit, permeability measurement, dynamic changes in pH, luminal physicochemical 
properties and first pass extraction, among other variables, are factors which can 
influence drug and formulation performance but are not measured in commonly 
used in vitro tests. These factors play a crucial role in determining the rate and extent 
of bioavailability from immediate release formulations, and the inability to routinely 
calculate these variables in vitro limits the capacity to generate direct IVIVC.  
As an alternative approach to the increasing complexity of in vitro techniques or the 
proliferation of in vivo studies, integration of in vitro analysis with in vivo 
pharmacokinetic data, through the use physiologically based pharmacokinetic (PBPK) 
models, not only allows estimation of the overall rate and extent of bioavailability, 
but also enables prediction of the overall disposition and elimination process, 
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allowing prediction of a simulated drug plasma profile (Shono et al., 2009, Flanagan 
et al., 2016, Dressman et al., 2011, Shono et al., 2010). 
PBPK models are mathematical models that integrate drug physicochemical and in 
vitro data with in vivo physiological data to simulate pharmacokinetic profiles and 
systemic tissue exposures, allowing their prediction from preclinical in vitro and in 
vivo data (Jones et al., 2015). The distinguishing feature of PBPK models, relative to 
empirical computational models, is the application of prior physiological knowledge 
in the mechanistic mapping of model compartments and in the processes that 
determine absorption (Suenderhauf and Parrott, 2013, Kostewicz et al., 2014a). This 
physiological knowledge, incorporating parameters such as gastrointestinal transit, 
pH and luminal volume, is combined with physiochemical measurements, for 
example, dissociation constants and partition coefficients, and in vitro 
measurements, such as solubility and dissolution rates and enzymatic degradation 
kinetics, into the PBPK model to provide a simulated PK profile (Dressman et al., 
2011, Suenderhauf and Parrott, 2013). PBPK models allow predictions of drug 
disposition based on a series of mass-balance equations, which incorporate 
physiological, physiochemical and in vitro data within an in silico model. They offer a 
significant advantage in enabling integration of all collected data into a single model 
so that the relative importance of each can be assessed and CQAs identified 
(Hansmann et al., 2016). Numerous commercial PBPK software systems are available, 
most notably Simcyp®, GastroPlus® and PK-Sim®, while there is also widespread use 
of user-built models, built using packages such as MATLAB, Berkeley Madonna, MoBi, 
STELLA or acslX® (Kostewicz et al., 2014a). While the structure and functionality of 
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these programmes can vary greatly, a common feature is the mathematical 
modelling of all relevant processes to the GI absorption of drugs, including 
disintegration, solubility and dissolution, precipitation, uptake and efflux, first pass 
metabolism and gastrointestinal transit to predict the rate and extent of drug 
absorption, while also providing a mechanistic understanding of interplay of these 
various factors. Such a tool is particularly useful, not only for linking in vitro and in 
vivo data, but also allowing a virtual, mechanistic exploration of the critical factors 
and parameter values affecting absorption, potentially identifying quantitative 
relationships between drug and formulation factors and in vivo outcomes (Kostewicz 
et al., 2014a, Hansmann et al., 2016).  
Numerous PBPK models have been successfully utilised to identify the key issues in 
the drug development. To date these models have been particularly successful with 
regard to late stage formulation bridging, assessing the potential for drug-drug 
interactions, examining effects in special populations, such as those displaying 
enzymatic polymorphism and in disease states, such as hepatic impairment and 
achlorhydria (Wagner et al., 2012, Kesisoglou, 2014, Jones et al., 2015).  
The successful prediction of plasma profiles relies on the ability of in vitro models to 
accurately simulate true in vivo values. As the drug development process proceeds, 
more accurate and biorelevant data is generated, particularly in the late preclinical 
and early clinical stages. Continual refinement of PBPK models with this data will 
result in a more predictive model, capable of accurately modelling in vivo 
performance and identifying CQAs. Appropriate use of these models and 
interpretation of results from these simulated studies has the potential to reduce 
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both the time and cost of drug development (Lave et al., 2007). Recent studies have 
demonstrated a reasonable reliability of PBPK models to simulate post-absorptive 
events. However, true prospective “bottom up” prediction of complete oral 
pharmacokinetic profiles for a drug/ formulation remains a pipedream (Hansmann et 
al., 2016). Currently, the most practical use of PBPK models involves “middle out” 
approaches, with a ‘learn and confirm’ paradigm adapted, through using observed in 
vivo data to refine and optimise existing PBPK models (Kostewicz et al., 2014a).  
The future development of improved PBPK models relies on the continuing 
development of biorelevant in vitro screening methods and increased ability to link 
these bench-top tests to clinical performance, while also continually validating these 
approaches. Measurement and prediction of permeability related parameters is of 
particular interest (Hansmann et al., 2016). To date, the lack of systematic validation 
limits the widespread implementation PBPK models. While regulatory agencies are 
increasingly receptive of in silico modelled data as part of submission dossiers, with 
FDA recently publishing guidelines for submission of PBPK derived data, there 
remains significant scope for increased acceptance of validated PBPK data (FDA, 
2016). There is a strong need for better understanding of 
pharmaceutics/biopharmaceutics factors to improve predictions of GI drug 
absorption using these in silico tools (Poulin et al., 2011). Continuous improvement 
of the predictive capacity of these models will further enhance the regulatory 
acceptance (Jones et al., 2015). 
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Pre-clinical animal studies 
While the use of biorelevant in vitro and in silico approaches for formulation 
assessment, with regard to predicting bioavailability and disposition, have become 
increasingly refined, there remains a significant knowledge gap on the interplay of 
the various biopharmaceutical properties, namely drug physicochemical 
characteristics, formulation properties and gastrointestinal physiology, on in vivo 
drug absorption and pre-clinical in vivo assessment remains the mainstay of 
diagnosing biopharmaceutical performance (Grignard et al., 2016). Despite obvious 
and well publicized differences in both physiology and in drug/formulation 
performance between species, pre-clinical animal models are still widely regarded as 
the most accurate predictor of bioavailability in humans.  
The conventional drug product development process involves initial in vitro screening 
followed preclinical testing before proceeding to clinical evaluation in humans. There 
are two key stages where improvements can be made with regard to our 
understanding of the biopharmaceutical prediction of drug and formulation 
performance. Firstly, the link between the in vitro testing and the preclinical in vivo 
performance, there is a need for an improved biorelevance of in vitro screening 
techniques such that they become more predictive of pre-clinical performance, 
either through direct IVIVC or in conjunction with PBPK modelling, and in vivo testing 
becomes truly confirmatory rather than investigatory. Secondly, there is a need to 
validate the reliability of preclinical models to predict performance in humans so that 
clinical studies become confirmatory of preclinical investigations. Improving both of 
these aspects of preclinical development involves the selection of both the 
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appropriate in vitro and in silico screening tools, along with prudent selection of a 
pre-clinical species for in vivo assessment 
There remain considerable gaps in our knowledge regarding the appropriate animal 
models for the assessment of oral bioavailability in humans and often animal studies 
yield species specific differences and pose the question of which animal species is 
most representative for humans (Lennernas et al., 2014, Henze et al., 2018b, Sjogren 
et al., 2014). These pre-clinical studies often involve a range of species, most 
commonly rats, dogs and non-human primates. While these models have proven 
useful in drug development, there remains significant drawbacks to each. Such 
limitations can include differences in anatomy and physiology of the GI tract and 
difficulty in study setup, such as designing a dosage regimen, amount of water or 
food, the type of meal, chewing patterns and route of administration, where these 
factors do not mimic the intended use of the dosage form in humans. In particular, 
the relatively small size of rats means that the potential for dosing intact dosage 
forms is limited while there is significant deviation the physiology of the GIT, 
particularly with regard to the secretion of bile (Sjogren et al., 2014, Davies and 
Morris, 1993). Dogs are the most widely utilised large animal model for prediction of 
human bioavailability, however, differences in gastrointestinal anatomy and 
physiology, principally their relatively short small intestine, high gastric pH and 
differences in intestinal and hepatic metabolism patterns limits their utility in certain 
instances (de Zwart, 1999, Dressman, 1986). Non-human primates are widely 
regarded as the most representative organisms when it comes to predicting 
bioavailability in humans, however divergences still remain in metabolic pathways, 
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while prohibitive cost and ethical implications prevent their more widespread use 
(Hatton et al., 2015, Sjogren et al., 2014). Thus, while there is a well-established 
history of using these pre-clinical models, there is also significant limitations of these 
animal models, with regard to their ability to predict human in vivo performance 
(Sjogren et al., 2014, Hatton et al., 2015, Musther et al., 2014). Nevertheless, 
pharmaceutical development relies on these studies, since animals represent 
complete organisms necessary to replicate the complex interplay of drug dissolution, 
permeation and metabolism. Recognising the limitations of a “one size fits all” 
approach in the context of animal modelling, and the absence of one ideal species 
that mimics closely human GI physiology and function, the most reliable approach 
appears to be the utilisation of numerous different animal models to model the 
various aspects of human pharmacokinetics (Hatton et al., 2015).  
In order to streamline pre-clinical development and reduce repeated testing in 
various animal models it is necessary to get a better understanding which particular 
animal model is suitable for a specific drug candidate and how predictive of humans 
it will be (Henze et al., 2018b). While there has been extensive discussion in the 
literature on the use of dog and non-human primate models to predict oral 
bioavailability in humans, in relation to the pig models there are significant gaps in 
our understanding.  
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The pig in pre-clinical drug development 
The pig presents numerous advantages in the assessment of pre-clinical 
formulations, particularly with regard to the anatomical and physiological similarities 
in the gastrointestinal tract of pigs and humans and can be considered a translational 
model (Hatton et al., 2015, Swindle and Smith, 1998, Puccinelli et al., 2011, 
Suenderhauf and Parrott, 2013, Sjogren et al., 2014). In this regard, the use of the pig 
model in pre-clinical assessment has expanded significantly in recent years (Colleton 
et al., 2016). Pigs have, therefore, become increasingly popular as an alternative 
species in drug development (Forster et al., 2010, Helke and Swindle, 2013, Bode et 
al., 2010, Ganderup et al., 2012). However, the potential use of pigs as an in vivo 
model for drug formulation research and development remains relatively unclear 
and requires further exploration. This is also complicated by the fact that there are 
several breeds of domestic and minipigs used in research studies, including the 
domestic landrace pig and the Göttingen and Yucatan minipigs, which may have 
considerably different characteristics and traits, but which are most often classified 
and summarised together (Henze et al., 2018b, Sjogren et al., 2014). To understand 
in which circumstances pigs should be considered, a clear understanding of the 
conditions in the GI tract is essential.  
Henze et al. (2018b) have recently summarised the use of the pig model in preclinical 
studies, reviewing similarities and differences between porcine and human 
gastrointestinal structure, function and physiology as part of the work. While there 
are many similarities in the gastrointestinal structure and physiology between pigs 
and humans, there are also significant differences. Similarities are particularly 
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evident with regard to the gastrointestinal pH profile and intestinal morphology and 
relative length of gastrointestinal sections. However, significant variations exist 
particularly with regard to gastrointestinal transit and metabolising enzymes (Henze 
et al., 2018b). These similarities are differences in porcine and human 
gastrointestinal are described in greater detail below. 
Gastrointestinal anatomy 
The internal physiology of humans and pigs is quite similar to that of humans, with 
the presence of similar thoracic and abdominal organs. With regard to the GIT, most 
obvious similarities between pig and human is that both are monogastric omnivores, 
with glandular stomachs where acid secretion occurs as a function of exogenous and 
endogenous stimuli, such as food intake and gastric volume, while bile secretion is 
also stimulated by food intake (Sjogren et al., 2014, Hatton et al., 2015). While the 
overall size of the pig GIT is larger than that of humans, with a greater stomach 
capacity (pigs; 8L: humans; 1-1.6L) and intestinal length (pigs; 24cm/kg: humans; 
14cm/kg), the internal diameter, at 2.5 – 3.5cm,  and the relative length of the major 
intestinal structures, namely the stomach, small intestine and large intestine, are 
quite similar (Henze et al., 2018b, Merchant et al., 2011, Suenderhauf and Parrott, 
2013, Kararli, 1995, Hatton et al., 2015).  
With a significantly longer small intestine, the smooth luminal surface area available 
for absorption in pigs is significantly greater than that in humans, and this large 
surface area is thought to facilitate high levels of absorption (Hatton et al., 2015). 
However, DeSesso and Williams have suggested that their total surface area is more 
comparable when taking into account the increased surface area generated by the 
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plicae, villi and micro-villi of the apical brush border (DeSesso and Williams, 2008) A 
notable anatomical difference between pigs and humans is the structure of the large 
intestine, where the pig cecum, ascending and transverse colon and the proximal 
portion of the descending colon are arranged in a series coils, known as the spiral 
colon, which may be relevant for colonic targeted drug delivery (Henze et al., 2018b). 
Gastrontesinal fluid pH, volume and characterisation 
The gastric pH in fasted pigs and humans is broadly similar, though pig gastric pH is 
somewhat variable (1.2–4.0) relative to humans (1.0 – 3.5), with an indication of 
regional pH variation within the porcine stomach (Hossain et al., 1990, Oberle and 
Das, 1994, Sjogren et al., 2014). An overview of the pH along the length of the GI tract 
of both humans and Landrace pigs is presented in Table 1-3, and this demonstrates 
a similar increase in the pH along the length of the small intestine, and slight 
reduction in the colon in both species. Similar trends were noted in the pH profiles in 
both the fasted and fed states in both pigs and humans. The effect of food in 
buffering the gastric pH, while also resulting in a slight reduction in small intestinal 
pH through a gastric emptying effect, is seen in both species. This is one distinct 
advantage of the porcine model compared to the canine model and is particularly 
important with regard to predicting the in vivo performance of weakly acidic and 
basic compounds (Sjogren et al., 2014, Henze et al., 2018b). 
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Table 1-3 Comparison of pH in the gastrointestinal tract of humans ( and landrace pigs (adapted from (Henze et 
al., 2018b) 
 Human Landrace Pig 
Segment Fasted pH (a, b) Fed pH (a, b) Fasted pH (b, c) Fed pH(d) 
Stomach 1.0-3.5 3.0-6.0 1.2-4.0 4.4 
Duodenum 6.0-7.0 5.0-5.5 6.7 6.1-6.5 
Jejnum 6.0-7.7 5.0-6.5 6.8 6.3-6.6 
Ileum 6.5-8.0 6.5-8.0 6.9 6.5-6.7 
Colon 5.5-8.0 6.0-7.5 6.1-6.6 6.5-6.6 
A (Abuhelwa et al., 2016a) 
B  (Kararli, 1995) 
C (Hossain et al., 1990) 
D (Merchant et al., 2011) 
While pH profiles are quite similar, Merchant et al. have compared to the 
gastrointestinal fluid volumes of pigs and humans. Compared to pigs (∼1545g, 20 
g/kg body weight, or 0.65 g/cm gut length) lower fluid volumes are reported in the 
human gut (∼517 g, 8.2 g/kg body weight, or 0.58 g/cm gut length) (Merchant et al., 
2011, Hatton et al., 2015). Most of this fluid volume observed in humans is actually 
in the bound state, as indicated by the much smaller amounts of free water (54 ± 41 
mL in small intestine and 11 ± 26 mL in colon), which is mostly present in fluid pockets 
along the length of the intestine (Schiller et al., 2005). Conversely, it has been 
suggested from post-mortem studies that fluid present in pigs is more ‘free-flowing’, 
and that this may enhance the suitability of pigs in assessing the bioavailability of 
dissolution rate limited drugs (Merchant et al., 2011, Hatton et al., 2015). 
Merchant et al. have also compared the buffer capacity, osmolality and surface 
tension of gastrointestinal aspirates between pigs and humans. Buffer capacity of 
human duodenal aspirates was similar in pigs and humans, though ileal and jejunal 
aspirates from pigs had appreciably higher buffer capacity than those of humans. 
While gastric osmolality was higher in humans than pigs, this is greatly influenced by 
the composition of an administered meal, and that observed in the small intestine is 
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similar in both species. Surface tension, meanwhile, was significantly lower in human 
aspirates compared to those of pigs (Merchant et al., 2015). 
An area where data remains relatively sparse is in the bile salt concentrations in both 
fasted and fed state gastrointestinal fluid in pigs (Henze et al., 2018b). Significant 
work has contributed to the profiling of bile salts in other porcine physiological fluids, 
as well as bile flow rates, however, gastrointestinal concentrations have not been 
quantified (Bergman et al., 2009, Juste et al., 1983, Alvaro et al., 1986, Scanff et al., 
1997). This measure is of critical importance in assessing the solubilising capacity of 
porcine gastrointestinal fluid for PWSD (Holm et al., 2013b). 
Gastrointestinal transit 
Pigs appear to demonstrate slow and variable gastric emptying, and this is an 
important species difference to human with high potential implications for the in vivo 
investigations of bioenabling formulations, while also having particular implications 
for investigating food effects in the pig model (Davis et al., 2001, Oberle and Das, 
1994, Patterson et al., 2008, Hossain et al., 1990). In fact, Henze et al. have recently 
failed to demonstrate any significant variation in gastric emptying in fed or fasted 
minipigs, even where a prokinetic (metoclopramide) agent was administered (Henze 
et al., 2018a). This is a finding which has also been demonstrated elsewhere 
previously, and this may be a factor in designing fasting regimens for fasted state 
bioavailability studies in pigs (Suenderhauf et al., 2014, Christiansen et al., 2015).  
The gastric emptying rate in pigs is considered to be longer and more variable than 
in humans, where a recently assessed meta-mean of 1.37 hours in the fasted state, 
which increases in the fed state as a function of caloric content and meal volume, has 
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been reported (Abuhelwa et al., 2016b). The values reported for gastric emptying 
rate in pigs vary significantly, with many potential sources of such variation including 
the distinctive bimodal and incomplete gastric emptying, the presence of a unique 
muscular out-pouching which can lead to food retention or, indeed, methodological 
differences in how gastric emptying is assessed (Hatton et al., 2015, Henze et al., 
2018b). Values ranging from 1.1-2.2 hours for liquids and pellets and 1.5 – 6 hours 
for tablets, to 6 to 24 hours have been reported for gastric emptying rate in pigs 
(Oberle and Das, 1994, Davis et al., 2001). These inconsistent and variable values 
have been the focus of renewed attention recently, with Christiansen et al. and 
Suenderhauf and co-workers investigating the effects of various dietary regimens 
and pharmacological interventions on gastric emptying in an attempt to improve the 
predictive capacity of porcine models of oral absorption, with a particular focus on 
mini-pigs (Suenderhauf and Parrott, 2013, Suenderhauf et al., 2014, Christiansen et 
al., 2015). One of the aims of the current thesis is to focus on further characterisation 
of gastric emptying in Landrace pigs, with a particular emphasis on the effects of 
dietary regimens on gastric emptying. 
 Intestinal transit times, in contrast to gastric transit times, are more comparable to 
that in humans, while also appearing to be relatively consistent at 3–4 hours in pig 
compared to 2–4 hours in humans (Davis et al., 2001, Gardner et al., 1996, 
Suenderhauf et al., 2014). In summary, the gastric emptying rate appears to be 
significantly longer and more variable in pigs relative to humans, while the small 
intestinal transit time appears both more conserved and reflective of that in humans. 
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Intestinal metabolism and transporters   
Another area where there is uncertainty with regard to the predictive capacity of the 
porcine model is with regard to intestinal permeability, enzymatic metabolism, both 
intestinal and hepatic, and intestinal uptake and efflux transporters. With regard to 
permeability, intestinal enzymes and transporters, the principal drawback is a lack of 
data and clarity, where homology has not been widely characterised and mechanistic 
studies are required to determine comparability. While Westerhout et al. have used 
ex vivo intestinal tissue to compare porcine and human Papp, and demonstrated its 
superiority to Caco-2 cultures, the number of such studies is low and needs further 
validation (Westerhout et al., 2014). Vaessen et al. have recently investigated 
expression levels of transporters and enzymes along the pig intestinal tract, 
demonstrating relative comparability, indicating further promise. However, 
expression levels of specific transporters, most notably breast cancer resistance 
protein (BCRP), multidrug resistance proteins (MRP) 1 and 3 and organic anion 
transporter protein (OATP) 4A1 differ significantly between the species, indicating 
there may be limitations in drugs subject to significant levels of intestinal efflux in the 
pig model (Vaessen et al., 2017).  
Hepatic enzyme homology is also an area of concern when choosing the pig as a 
potential animal model. While CYP 1A1, 1A2, 2B, 2E1 and 3A (3A4 in particular) 
display good homology between pigs and humans, this is not the case with other CYP 
families (Puccinelli et al., 2011, Anzenbacherova et al., 2005). In particular there 
appears to be less comparability of CYP 2C and 2D families (Helke and Swindle, 2013, 
Puccinelli et al., 2011, Anzenbacher et al., 1998, Thörn et al., 2011). Further 
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investigations in vitro, ex vivo and in vivo for the characterization of the intestinal 
permeability, metabolism (especially that mediated by CYP2C and CYP2D enzymes) 
and transporters are required for optimum application of the pig as a preclinical 
model (Sjogren et al., 2014). 
Summary 
Overall, while the pig model displays relative similarities to the GI conditions of 
humans anatomical and physiological perspective, there are also significant 
limitations to its utility to predict human bioavailability of oral dosage forms. While 
some of this variability is due to inherent differences between porcine and human 
physiology, it is also at least partially due to remaining gaps in our knowledge 
regarding the pig model, particularly regarding gastric emptying and fasting protocols 
to ensure a true ‘fasted’ state, the food effect and the effects of metabolic enzymes. 
There is an overall need to harness knowledge from a wider range of drug molecules 
to assess the utility of the pig model’s predictive capacity. There is also an 
opportunity to improve the link between in vitro screening and in vivo testing in 
preclinical animals through developing a deeper mechanistic understanding of the 
pig model.  
To this end, the current thesis focuses on further characterisation of the pig model 
in pre-clinical formulation assessment. Particular emphasis is placed on the ability of 
the pig to screen bioenabling formulation performance, to act as a model of food 
effect and how representative the pig model is of human bioavailability. The effect 
of various fasting protocols to ensure complete fasting is assessed. The ability of 
biorelevant in vitro and in silico tools to forecast pre-clinical in vivo performance in 
pigs is also evaluated.  
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Summary 
Methods of characterizing drug and formulation performance have evolved 
substantially since they were first introduced as quality control tools. As a greater 
understanding of the biopharmaceutical aspects of oral drug delivery has been 
gained, the biorelevance of the screening tools has consequently increased 
significantly, as has the ability to predict in vivo performance. There remains a 
dichotomy in pre-clinical evaluation, where there is a desire for a screening tool 
which is “as simple as possible, but as complex as necessary” to predict in vivo 
performance. In practice it will not be possible to capture all the aspects of drug 
absorption in one simple to use, routine in vitro test method, rather a suite of tools 
is required. This toolkit is likely to be diverse and with varying levels of complexity, 
sometimes focusing on a single aspect of the in vivo environment likely to be critical 
to a specific drug product, such as lipolysis of LBF, and on other occasions needing to 
be capable of mimicking multiple aspects of importance to in vivo performance, such 
as the use of GI tract in lab apparatus. These tests will also provide crucial inputs for 
PBPK modelling, allowing both prediction of in vivo pharmacokinetics and 
mechanistic investigation of the critical factors affecting in vivo performance. To 
improve the biorelevance and predictive capacity of these approaches there needs 
to be an increase in attempts of systematic validation of these approaches. This 
involves both the assessment of the predictive capacity of these in vitro tools of in 
vivo performance, through generating IVIVC either directly or through in silico 
modelling, while also increasing the number of in vivo data at our disposal to allow 
validation of these tools. The attempts to address these issues are among the primary 
aims of the current thesis. 
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Model compounds 
In order to assess the utility of the approaches described above, a range of model 
compounds is required. Two PWSD were used in this thesis and are described here.  
Fenofibrate 
 
Figure 1-9 Chemical structure of fenofibrate 
Fenoﬁbrate (figure 1-9) is an orally active ﬁbric acid derivative used in the treatment 
of hypercholesterolemia (Miller and Spence, 1998). As a neutral molecule with a high 
dose: solubility ratio, fenoﬁbrate is a model poorly soluble drug and is often used as 
a test sub-stance to evaluate novel bioenhancing strategies. Pharmacokinetic 
evaluation of fenofibrate is based on quantifying its major active metabolite, 
fenofibric acid, which it is rapidly and completely converted to by gut wall esterases 
(Miller and Spence, 1998). Fenoﬁbrate has been shown to be amenable to re-
formulation in dissolution enhancing preparations, with subsequent improvements 
in bioavailability allowing dose reduction and food-independent dosing of these 
novel formulations (Ling et al., 2013). Such formulations include micronised, 
nanosized and lipid-based formulations, demonstrating that approaches to enhance 
solubility and dissolution of fenoﬁbrate can improve its bioavailability, both in 
preclinical studies and in clinical use (Guichard et al., 2000, Sauron et al., 2006, Fei et 
al., 2013). The Lipantil Micro® formulation, a micronised product, displays food 
 
 
64 
 
dependent bioavailability, and therefore requires administration with food. A re-
formulated product, Lipantil® Supra was developed using NanoCrystal® technology, 
to overcome this limitation and allows food independent administration and dose 
reduction (Sauron et al., 2006, Guichard et al., 2000, Junghanns and Muller, 2008). 
Celecoxib 
 
Figure 1-10 Chemical structure of celecoxib 
Celecoxib (figure 1-10) is a non-steroidal anti-inflammatory drug (NSAID) which 
exerts its pharmacological action by selective inhibition of the cyclooxygenase-2 
(COX-2) isozyme. It is widely used in the treatment of osteo- and rheumatoid arthritis 
and ankylosing spondylitis (Shi and Klotz, 2008, Davies et al., 2000). Celecoxib is 
highly lipophilic and very poorly water soluble, with an approximate aqueous 
solubility of 1μg/ml, but demonstrates good permeability and is classed as a BCS class 
II compound with dissolution/solubility limited oral absorption (Guzman et al., 2007, 
Paulson et al., 2001, Laine et al., 2016). As a result, the marketed Celebrex™ 
formulation was designed to maximise dissolution, with particle size identified as a 
critical quality attribute (CQA) during the regulatory process. The commercial 
preparation has a D90 of below 25μm and the addition of sodium lauryl sulphate as a 
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wetting agent, with the function of improving dissolution of the API in vivo (Laine et 
al., 2016, FDA, 1998). As a BCS class II compound, a significant positive food effect is 
anticipated for celecoxib. However, while a significant increase in Cmax (1.9 fold 
increase) is observed in the fed state, mediated by increases in post-prandial 
solubilisation, there is only a modest increase in overall bioavailability (approximately 
1.1 to 1.3 fold), allowing Celebrex™ to be dosed independent of prandial state 
(Paulson et al., 2001, Pfizer Inc., 2000, Lyng et al., 2016).  
Celecoxib bioavailability has previously been shown to be highly variable, with a 
coefficient of variation (CoV) in AUC shown to vary between 40-78% in fasted 
humans. Differences in metabolism mediated by enzymatic polymorphism have been 
shown to have a significant effect on celecoxib pharmacokinetics and exposure. 
CYP2C9 is the primary enzyme involved in celecoxib metabolism (Paulson et al., 1999, 
Gong et al., 2012) and genetic variation in this enzyme reduces clearance and can 
more than double celecoxib exposure, with drug label warnings expressing caution 
in use of celecoxib in patients known to be poor 2C9 metabolisers owing to the risk 
of observing abnormally high plasma levels of celecoxib (Kirchheiner et al., 2003, 
Tang et al., 2001, Pfizer Inc., 2000). In such cases, using celecoxib at half the 
recommended lowest dose is advised. 
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Thesis objectives 
In light of the factors described here, the specific objectives of this thesis are, 
therefore, to assess novel bioenabling formulations and new in vitro and in silico tools 
to predict their in vivo performance in pigs as a means to improve efficiency in 
formulation development. The current thesis aims to shed new insights on the 
processes involved in drug product development. Specifically, we have assessed the 
utility of the pig as a pre-clinical animal model with regard to the assessment of 
bioenabling approaches, using dissolution enhancing formulations and by 
concomitantly administering dosage forms with food. By utilising the current 
approach, the principle aims of the current thesis were; 
1. To assess the ability of novel bioenabling formulations for the enhancement 
of oral bioavailability of poorly water soluble drugs, with a specific focus on 
eliminating food-effects 
2. To investigate the utility of the pig to act as a model species for the 
assessment of these bioenabling formulations 
3. To assess the ability of biorelevant screening approaches, in conjunction with 
in silico approaches of varying levels of complexity to predict in vivo 
performance 
4. To investigate the pig as a potential model for food effect bioavailability as an 
alternative bioenabling approach, particularly with regard to the physiological 
conditions in the pig in the fasted and fed state. 
The approaches involved in assessing these aims are described in detail in the 
proceeding chapters, and an overall, general discussion of the findings and how they 
relate to the wider literature is also provided. 
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Abstract   
Objectives: Mesoporous silicas (SLC) have demonstrated considerable potential to 
improve bioavailability of poorly soluble drugs by facilitating rapid dissolution and 
generating supersaturation. The addition of certain polymers can further enhance 
the dissolution of these formulations by preventing drug precipitation. This study 
uses fenoﬁbrate as a model drug to investigate the performance of an SLC-based 
formulation, delivered with hydroxypropyl methylcellulose acetate succinate 
(HPMCAS) as a precipitation inhibitor, in pigs. The ability of biorelevant dissolution 
testing to predict the in vivo performance was also assessed.  
Key ﬁndings: Fenoﬁbrate-loaded mesoporous silica (FF-SLC), together with HPMCAS, 
displayed signiﬁcant improvements in biorelevant dissolution tests relative to a 
reference formulation consisting of a physical mixture of crystalline fenoﬁbrate with 
HPMCAS. In vivo assessment in fasted pigs demonstrated bioavailabilities of 86.69 ± 
35.37% with combination of FF-SLC and HPMCAS in capsule form and 75.47 ± 14.58% 
as a suspension, compared to 19.92 ± 9.89% with the reference formulation. A 
positive correlation was identiﬁed between bioavailability and dissolution efﬁciency. 
Conclusions: The substantial improvements in bioavailability of fenoﬁbrate from the 
SLC-based formulations conﬁrm the ability of this formulation strategy to overcome 
the dissolution and solubility limitations, further raising the prospects of a future 
commercially available SLC-based formulation. 
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Introduction 
The poor aqueous solubility and resulting slow and/or incomplete in vivo dissolution 
of poorly soluble drugs often limits their bioavailability after oral administration. 
Adsorption onto mesoporous silica has demonstrated considerable potential in 
enhancing the oral bioavailability of poorly soluble drugs (Van Speybroeck et al., 
2011, Vialpando et al., 2011). These bioenabling formulations improve absorption of 
such drugs through the generation of supersaturation, a metastable state in which 
dissolved drug concentration exceeds the equilibrium solubility in the medium 
(Brouwers et al., 2009, McCarthy et al., 2016).  
Adsorption of drug onto a mesoporous silica carrier has a number of advantages for 
enhancing drug dissolution. The ordered mesoporous structure and high porosity of 
silica allows high drug loads to be adsorbed (Vialpando et al., 2011). Drug molecules 
adsorb to the silica surface in a noncovalent manner, principally through electrostatic 
interaction, hydrogen bonding or van der Waal’s forces, which are easily broken on 
exposure of the formulation to an aqueous environment, enabling release of drug in 
its molecular form and facilitating absorption. The drug can exist in an amorphous or 
molecularly dispersed state on the silica surface, thus displaying higher apparent 
solubility and dissolution rate compared to the crystalline substance (Hancock and 
Zografi, 1997). Although amorphous materials can display thermal instability, 
adsorption onto the mesoporous silica has proven effective in stabilising amorphous 
systems, and the long-term stability of these formulations has been repeatedly 
demonstrated (McCarthy et al., 2016, Van Speybroeck et al., 2009). By controlling 
pore size and volume as well as the surface chemistry, the formulation can be tailored 
 
 
70 
 
for each drug molecule with regard to its physicochemical characteristics. The 
optimised preparation can maximise drug loading and facilitate long-term stability 
via inhibition of recrystallization within the limited pore space (Salonen et al., 2008). 
The favourable dissolution and solubility behaviour associated with these 
formulations and their ability to generate supersaturation has been described as the 
‘spring’ that enhances absorption and bioavailability (Brewster et al., 2008). 
However, a potential risk of such strategies is the possibility of precipitation from the 
supersaturated solution that is formed during drug release. For this reason, 
bioenabling drug delivery systems often also include a ‘parachute’ which aims to 
stabilise and prolong the supersaturated state (Guzman et al., 2007). One method to 
create a ‘parachute’ is the inclusion of a polymeric precipitation inhibitor as a 
functional excipient to slow the rate of precipitation (Van Speybroeck et al., 2010b, 
Warren et al., 2010, Laine et al., 2016). The mechanism by which these excipients 
prevent crystallisation is by interacting with drug molecules and thus precluding 
nucleation, which is a pre-requisite to precipitation. Examples of polymeric 
precipitation inhibitors include polyvinylpyrrolidine (PVP), hydroxypropyl 
methylcellulose (HPMC), hydroxypropyl-methyl cellulose acetate succinate 
(HPMCAS) and copovidone (PVPVA) (Dressman et al., 2016). 
Fenoﬁbrate is an orally active ﬁbric acid derivative used in the treatment of 
hypercholesterolemia (Miller and Spence, 1998). As a neutral molecule with a high 
dose: solubility ratio, fenoﬁbrate is a model poorly soluble drug and is often used as 
a test substance to evaluate novel bioenhancing strategies. Fenoﬁbrate has been 
shown to be amenable to re-formulation in dissolution enhancing preparations, with 
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subsequent improvements in bioavailability allowing dose reduction and food-
independent dosing of these novel formulations (Ling et al., 2013). Such formulations 
include micronised, nanosized and lipid-based formulations, demonstrating that 
approaches to enhance solubility and dissolution of fenoﬁbrate can improve its 
bioavailability, both in preclinical studies and in clinical use (Guichard et al., 2000, 
Sauron et al., 2006, Fei et al., 2013). The ability of mesoporous silicas to enhance the 
solubility and absorption of poorly soluble drugs, such as fenoﬁbrate, has been 
demonstrated through numerous studies in different animal models (Mellaerts et al., 
2008, Van Speybroeck et al., 2010a, Kiekens et al., 2012, Bukara et al., 2016a). While 
these formulations have shown promise in pre-clinical studies, the development of a 
commercial preparation has yet to be realised and further characterisation of 
formulation behaviour in vivo is warranted (McCarthy et al., 2016). 
Pigs are growing increasingly important as a preclinical species to assess 
biopharmaceutical aspects of drug delivery as well as forecasting absorption in 
humans. The comparable physiology in the GIT, particularly the comparable 
intestinal anatomy, physiology and transit, makes pigs a useful translational model in 
preclinical studies (Sjogren et al., 2014). 
In a previous investigation, a combination of fenoﬁbrate-loaded mesoporous silica 
with HPMCAS added in a 4:1 ratio demonstrated excellent improvement in the 
dissolution of fenoﬁbrate in a simulated intestinal environment (Dressman et al., 
2016). The current study expands on this previous in vitro work and aims to explore 
the use of mesoporous silica with a precipitation inhibitor in a porcine model. To our 
knowledge, this is the ﬁrst time that the absolute bioavailability has been determined 
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for a mesoporous silica-based formulation delivered with a precipitation inhibitor in 
a large animal model. The absorption of fenoﬁbrate from the optimised silica 
formulation administered in both capsule and suspension forms was compared to 
that of a simple fenoﬁbrate/HPMCAS mixture. Hence, in the current study, we have 
attempted to expand on the existing body of knowledge regarding the combined use 
of mesoporous silica with precipitation inhibitors in vivo. 
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Materials and methods 
Chemicals and materials 
Fenoﬁbrate was purchased as crystalline drug from D.K. Pharmachem Pvt. Ltd., 
Mumbai, India. Porous silica powder (Parteck® SLC 500) was kindly donated by Merck 
KGaA, Darmstadt, Germany. HPMCAS-HF was purchased from Shin-Etsu, Tokyo, 
Japan. FaSSIF Powder (formerly known as SIF Powder) was kindly donated by 
Biorelevant.com (London, UK). Mannitol (Parteck® M 200) was purchased from 
Merck KGaA, Darmstadt, Germany. HPMC Capsules (Size 00) were obtained from 
Capsugel, Morristown, NJ, USA. Fenoﬁbric acid and sulindac were purchased from 
Sigma-Aldrich Ireland Ltd., Wicklow, Ireland. All other chemicals were of analytical 
grade. 
Preparation of prototype formulations 
Preparation of fenofibrate loaded Parteck® SLC 
Fenoﬁbrate silica formulations were prepared by the solvent impregnation method 
according to a previously published method (Dressman et al., 2016). Brieﬂy, a 
measured amount of fenoﬁbrate was dissolved in acetone and added dropwise to 
the silica powder to ensure even spreading of the drug solution on the silica while 
avoiding excessive wetting and aggregation (Alcalá and Real, 2006). The organic 
solvent was simultaneously evaporated under continuous stirring. The addition and 
evaporation process was repeated until the loading was complete, i.e. 29% w/w. In 
order to remove residual solvent from the pores, the fenoﬁbrate loaded silica was 
subjected to overnight drying at 50°C. 
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Preparation of formulations 
For further evaluation, the fenoﬁbrate-loaded silica (FF-SLC) was blended with 
HPMCAS (12.5% w/w), mannitol (30% w/w) and NaHCO3 (7.5% w/w) using a Turbula 
mixer. Samples of the resultant mixture (corresponding to 67mg of fenoﬁbrate) were 
ﬁlled into size 00 HPMC capsules. Mannitol and NaHCO3 were included to ensure 
rapid disintegration of the capsule shell and to avoid clumping during drug release. 
The capsule formulation will be subsequently referred to as the FF-SLC: HPMCAS (4:1) 
capsule. Dissolution studies were also performed with this powder blend, by 
emptying the capsule contents directly into the dissolution medium. This formulation 
will be subsequently referred to as the FF-SLC: HPMCAS (4:1) powder. A suspension 
formulation of the fenoﬁbrate-loaded silica was additionally prepared, by preparing 
a mixture of four parts fenoﬁbrate-loaded (29% w/w) silica with one part HPMCAS 
and dispersing the mixture in distilled water to attain a ﬁnal volume of 25ml. This 
formulation is subsequently referred to as the FF-SLC: HPMCAS (4:1) suspension. 
Samples of the physical mixture of pure crystalline fenoﬁbrate (80% w/w) and 
HPMCAS (20% w/w) corresponding to 67mg fenoﬁbrate per sample were ﬁlled into 
size 00 HPMC capsules and designated as the reference formulation. The 
compositions of the formulations evaluated in the dissolution and in vivo studies are 
summarised in table 2-1. 
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Table 2-1 Composition of dosage forms 
Formulation 
Components 
Formulation composition (%) 
  
FF-SLC: 
HPMCAS 
(4:1) Capsule 
FF-SLC: 
HPMCAS (4:1) 
Suspension 
FF-SLC: 
HPMCAS 
(4:1) Powder 
Reference 
formulation 
Fenofibrate 
Loaded on 
silica at 29% 
Loaded on 
silica at 29% 
Loaded on 
silica at 29%  
80% as pure 
drug 
Parteck® SLC 
500 
(Mesoporous 
silica) 
50% 80% 80% - 
HPMCAS 12.50% 20% 20% 20% 
Parteck® M 200 
(Mannitol) 
30% - - - 
Sodium 
Bicarbonate 
7.50% - - - 
Final dosage 
form 
HPMC 
Capsule 
(Vcaps Plus, 
Capsugel) 
Reconstituted 
in 25ml water 
Powder 
HPMC 
Capsule 
(Vcaps Plus, 
Capsugel)  
 
In vitro dissolution using biorelevant media 
Considering the solubility data for pure fenoﬁbrate in various biorelevant media and 
previous characterisation studies, a medium representing upper GI conditions in the 
fasted state was chosen for the in vitro dissolution studies (Dressman et al., 2016, 
Juenemann et al., 2011). FaSSIF was prepared by dissolving the appropriate amount 
of FaSSIF Powder in a phosphate buffer with a pH of 6.5, as described by the 
manufacturer (Biorelevant.com, Croydon, UK) The dissolution studies were carried 
out using a USP Apparatus II (AT7 Smart by Sotax, Allschwill, Switzerland) in 500ml of 
biorelevant medium at 37 ± 0.5°C at 75rpm. Formulations (each corresponding to 
67mg of fenoﬁbrate) were added to the pre-warmed dissolution medium. The 
concentration of released drug in the dissolution medium was evaluated at 5, 10, 15, 
20, 25, 30, 45, 60, 75, 90, 105 and 120 min. Samples were automatically removed and 
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ﬁltered using a CP7-35 piston pump (Sotax, Allschwill, Switzerland) and GF/D 2.7-lm 
ﬁlter (Whatman, Kent, UK). Measurements were carried out using a UV–vis 
spectrophotometer (Specord 200 Plus by Analytic Jena, Jena, Germany) at k = 290nm 
in a continuous ﬂow through the cuvette (2mm, QS SUPRASIL®; Hellma Analytics, 
Müllheim, Germany). Each test was performed in triplicate, and results were 
expressed as mean values together with the standard deviation (SD). 
Oral bioavailability in pigs 
All experimental procedures were approved and performed in accordance with 
licences issued by the Department of Health, Ireland (project licence B100/2877) as 
directed by the Cruelty to Animals Act Ireland and EU Statutory Instruments. Local 
ethical approval was granted by University College Cork Animal Experimentation 
Ethics Committee (AEEC). Oral bioavailability studies were conducted as previously 
described (Griffin et al., 2014, O’Shea et al., 2015). Brieﬂy, six male Landrace pigs 
(12.5–16kg, mean 14.5kg) were studied. On day 1, an indwelling intravenous (i.v.) 
catheter was inserted into the jugular vein, under general anaesthesia. During the 
study, pigs were fed approximately 175g of standard weanling pig pellet feed twice 
daily. The final feed was given 24 hours prior to dosing. As part of the study design 
any remaining food was to be removed 16 hours before dosing, however no food 
remained at this point in any of the study legs. On day 3, following an overnight fast 
of 16 hours, pigs were administered either FF-SLC: HPMCAS (4:1) capsule, FF-SLC: 
HPMCAS (4:1) suspension or reference formulation capsule, as part of a partially 
randomised three-way crossover study design. To facilitate handling during oral 
dosing, an intramuscular dose of ketamine (5mg/kg) and xylazine (1mg/kg) was 
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administered, serving as a mild relaxant. Capsule formulations were administered 
with the aid of a dosing gun, after which the pigs received ≈50mL of tap water via 
syringe. The suspension was reconstituted by mixing the appropriate quantity of 
formulation blend in 25mL of tap water in a dosing syringe, which was then 
administered to the pigs. A further 25mL of tap water was used to ensure that the 
whole dose was administered. A washout period of 6 days was observed between 
each of the three study legs. After dosing, pigs were returned to their pens and blood 
samples (4mL) were collected at time zero (pre-dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 
4, 5, 6, 8, 10, 12 and 24 hr post dosing. Water was available ad libitum throughout 
the study period, and the animals were fed 8hr post-dose. All blood samples were 
collected in heparinised tubes (Sarstedt, Germany) and immediately centrifuged at 
3220g for 5min at 4°C (Eppendorf 5810r swinging bucket rotor centrifuge, Eppendorf 
AG, Hamburg, Germany). Plasma was collected and stored at -80°C until analysis by 
HPLC. 
Quantitative analysis of fenofibric acid 
The pharmacokinetic evaluation of fenoﬁbrate was based on the quantiﬁcation of 
fenoﬁbric acid, the major active metabolite of fenoﬁbrate, using a validated HPLC-UV 
method, as previously described (Griffin et al., 2014). Brieﬂy, 0.5mL plasma was 
spiked with 20μL of a sulindac 100μg/mL solution in methanol as an internal 
standard. Proteins were precipitated through addition of 0.5mL of 25% NaCl solution 
and 1mL of 1% H3PO4 in methanol with thorough mixing. Samples were centrifuged 
at 11,500g for 9 min (Hermle z233 M-2 ﬁxed angle rotor centrifuge; HERMLE 
Labortechnik GmbH, Wehingen, Germany). The clear supernatants were injected 
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onto a Synergi Fusion C18 reversed phase column (250 x 4.6mm, 4μm) (Phenomenex 
Inc., Macclesﬁeld, UK) using an Agilent 1200 series HPLC system (Agilent 
Technologies, Santa Clara, CA, USA). The mobile phase consisted of 80% methanol: 
20% water (adjusted to pH 2.5) at a ﬂow rate of 1mL/min, resulting in elution of 
fenoﬁbric acid and fenoﬁbrate at 6.5 and 10.5min, respectively. UV detection was 
performed at 286nm. The analysis showed linearity over the range of 50–2000ng/mL 
with an LOQ of 80ng/mL and extraction recoveries were ≥95%. 
Pharmacokinetic data analysis 
The AUC for fenoﬁbric acid after oral administration was calculated using Prism (ver. 
5; GraphPad Software Inc., La Jolla, CA, USA). The peak plasma concentrations (Cmax) 
and the time for their occurrence (Tmax) were noted directly from the individual 
plasma concentration vs time proﬁles. The absolute bioavailability (Fa) was calculated 
according to equation 2-1 below: 












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Dose
Dose
AUC
AUC
Fa ..
..
.             (2-1) 
The i.v. pharmacokinetic measurements were obtained from a study conducted 
under similar conditions, which has previously been reported (O’Shea et al., 2015). 
The intravenous pharmacokinetic parameters were ﬁtted to a two-compartment 
model using the PKPlus™ module in Gastroplus™ (ver. 8.6; Simulations Plus Inc., 
Lancaster, CA, USA) and are summarised in table 2-2. All pharmacokinetic parameters 
are reported as mean ± SD, with the exception of Tmax which is reported as median 
(range). 
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Statistical analyses 
One-way ANOVA was used to determine the statistical signiﬁcance of calculated in 
vivo bioavailability and Cmax. Tukey’s post hoc test was used to identify pairwise 
statistical signiﬁcance. The Kruskal–Wallis rank test, with Dunn’s multiple 
comparison using rank sums, was used to determine the signiﬁcance of differences 
in Tmax. All statistical analyses were performed using GraphPad™ Prism version 5, 
utilising the P < 0.05 signiﬁcance level. 
In vitro- in vivo relationships 
The dissolution efﬁciency for each formulation was calculated from in vitro 
dissolution data to facilitate comparison of in vitro and in vivo data. Dissolution 
efﬁciency was calculated according to equation 2-2 below, as derived by Khan (Khan, 
1975); 
                             𝐷𝑖𝑠𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝐷. 𝐸. ) =  
∫ 𝑦.𝑑𝑡
𝑡
0
𝑦100.𝑡
. 100%                       (2-2) 
where y is the percentage dissolved drug product at time t, and y100 is the area of the 
rectangle described by 100% dissolution at t. Percent bioavailability and dissolution 
efﬁciency were correlated linearly. In vitro dissolution efﬁciency was considered the 
explanatory (x) variable, while in vivo bioavailability was considered the response (y) 
variable. Correlation was quantiﬁed by calculating Pearson’s correlation coefﬁcient 
(r) using equation 2-3 below; 
𝑟 =  
∑ (𝑥𝑖−?̅? )(𝑦𝑖−?̅?)
𝑛
𝑖=1
√∑ (𝑥𝑖−?̅? )2
𝑛
𝑖=1 .√∑ (𝑦𝑖−?̅?)
2𝑛
𝑖=1
                                          (2-3) 
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Results 
Dissolution studies 
The reference formulation, ﬁlled into a capsule shell, the FF-SLC: HPMCAS powder, 
the FF-SLC: HPMCAS (4:1) capsule and the FF-SLC: HPMCAS (4:1) suspension were all 
subjected to dissolution studies. The FF-SLC: HPMCAS (4:1) suspension was prepared 
by simple reconstitution immediately before evaluation, as was the case in the in vivo 
studies. The reference formulation was compared to the fenoﬁbrate-loaded silica 
formulations to determine the inﬂuence of the mesoporous silica on the release 
characteristics. The FF-SLC: HPMCAS formulation was also studied without the 
capsule (by emptying the capsule directly into the dissolution medium) to determine 
whether the capsule shell had any inﬂuence on the release kinetics. Results of the 
dissolution studies are shown in figure 2-1.  
 
 
81 
 
 
Figure 2-1 Release of fenofibrate from FF-SLC HPMCAS (4:1) capsules, FF-SLC HPMCAS (4:1) suspension, FF-SLC: 
HPMCAS (4:1) powder and reference formulation (each unit corresponding to 67mg fenofibrate) in fasted state 
simulated intestinal fluid (FaSSIF) (mean ± SD, n = 3). 
 
Dissolution of fenoﬁbrate from the reference formulation in FaSSIF was poor, with 
less than 5% of the total drug released over a period of two hours. This formulation 
was also unable to generate any supersaturation. These results were in good 
agreement with previously reported solubility data of pure fenoﬁbrate in biorelevant 
media (Juenemann et al., 2011). The results reﬂect the poorly soluble, non-ionisable 
and lipophilic characteristics of fenoﬁbrate, which consequently has very low 
solubility in media representing the fasted state (e.g. FaSSGF and FaSSIF) (Dressman 
et al., 2016). During previous investigations, dissolution of the pure drug in FaSSGF 
and FaSSIF-V2 had revealed that less than 1% of the dose of fenoﬁbrate dissolved 
within 2hr and that even the marketed product TriCor® (which contains nanosized 
fenoﬁbrate 145 mg) released less than 2% during a two-hour experiment (Dressman 
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et al., 2016). The slightly higher % release observed with the reference formulation 
compared to the earlier results can be attributed to (1) the lower dose applied and 
(2) the presence of the HPMCAS in the formulation. All formulations containing 
mesoporous silica achieved far better dissolution of fenoﬁbrate compared to the 
reference formulation. Dissolution proﬁles for both FF-SLC: HPMCAS (4:1) powder 
and FF-SLC: HPMCAS (4:1) capsule reached drug concentrations corresponding to 
around 65% release. The slight delay for drug release from FF-SLC: HPMCAS (4:1) 
capsule formulation in comparison with the FF-SLC: HPMCAS (4:1) powder was 
attributed to the time required for disintegration of capsule shell. Further, the FF-
SLC: HPMCAS (4:1) capsule and FF-SLC: HPMCAS (4:1) powder formulations were 
effective at keeping fenoﬁbrate in solution. The dissolution proﬁle of the FF-SLC: 
HPMCAS (4:1) suspension in FaSSIF differed from those of the FF-SLC: HPMCAS (4:1) 
powder and the FF-SLC: HPMCAS (4:1) capsule formulation, showing slightly faster 
initial drug release but a lower maximum % release of fenoﬁbrate, that is 52 ± 0.42%. 
Moreover, the suspension formulation was less able to maintain fenoﬁbrate at a 
supersaturated concentration in the dissolution medium, with the concentration 
declining to only 13% remaining in solution after 2 hours. Despite the excellent 
improvement in the dissolution characteristics achieved with the silica formulations, 
100% release of fenoﬁbrate was not achieved under fasted state conditions by any 
of the formulations. 
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Oral bioavailability in pigs 
The oral bioavailability of the reference formulation, FF-SLC: HPMCAS (4:1) capsule 
and FF-SLC: HPMCAS (4:1) suspension formulations was determined using a pig 
model. Figure 2-2 displays the plasma concentration–time proﬁle following oral 
administration of 67mg of fenoﬁbrate as each of these formulations to fasted pigs. 
Absolute bioavailability was calculated utilising i.v. pharmacokinetic data from a 
similar, previously reported study (Griffin et al., 2014, O’Shea et al., 2015). The key 
pharmacokinetic parameters are summarised in Table 2-2. 
 
 
Figure 2-2 Plasma concentration of fenofibric acid vs time profiles after oral administration of 67mg fasted pigs 
(mean ± SE, n = 6), (■) indicates FF‐SLC : HPMCAS (4:1) capsule, (♦) indicates the reference capsule and (▲) 
indicates silica FF‐SLC : HPMCAS (4:1) suspension. 
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Table 2-2 Summary of pharmacokinetic parameters after i.v. administration of 25mg of fenofibrate to fasted pigs 
(mean ± SD, n = 4) and after oral administration of 67mg of fenofibrate to fasted pigs (mean ± SD, n = 6) 
*Intravenous data reproduced from O’Shea et al. (O’Shea et al., 2015) 
** Median (range) 
Intravenous 
pharmacokinetic 
Parameters* 
Oral pharmacokinetic parameters 
Vc (L/kg) 0.345 ± 
0.02504 
 FF-SLC: 
HPMCAS 
(4:1) 
capsule 
FF-SLC: 
HPMCAS 
(4:1) 
suspension 
FF: 
HPMCAS 
(4:1) 
reference 
capsule 
Kel (hr-1) 0.221 ± 
0.064428 
Cmax (ng/mL) 3294 ± 
1614 
3512 ± 863 890 ± 433 
Kel (hr-1) 0.099 ± 
0.038687 
Tmax** (hours) 4.5 (2.5-6) 4.5 (2.5-10) 10 (8-12) 
Kel (hr-1) 0.35125 ± 
0.241289 
Bioavailability 
(%) 
86.69 ± 
35.37 
75.47 ± 
14.58 
19.92 ± 9.89 
AUC0→24hrs 
(ng.h/ml) 
18382 ± 
4591 
AUC0→24hrs 
(ng.h/ml) 
42705 ± 
17422 
37178 ± 
7184 
9815 ± 4871 
 
Absorption from the reference formulation was slow and incomplete with an overall 
bioavailability of 19.92 ± 9.89% and a maximal plasma concentration of 890 ± 
433ng/mL occurring at a median Tmax of 10hr. Absorption from both mesoporous 
silica formulations showed a marked improvement in bioavailability compared to the 
reference formulation. A signiﬁcant increase in overall absorption was evident (P = 
0.0003) for both the FF-SLC: HPMCAS (4:1) capsule and FF-SLC: HPMCAS (4:1) 
suspension formulations, with bioavailabilities of 86.69 ± 35.37% and 75.47 ± 14.58%, 
respectively. Signiﬁcant increases were also demonstrated for peak plasma 
concentrations, as represented by Cmax (P = 0.0013) and rate of absorption, as 
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demonstrated by a reduction in Tmax (P = 0.0066), respectively. Post hoc analysis 
revealed no signiﬁcant differences in rate or extent of bioavailability between both 
the FF-SLC: HPMCAS (4:1) capsule and FF-SLC: HPMCAS (4:1) suspension 
formulations. A summary of these analyses is represented graphically in figure 2-3. 
 
Figure 2-3 Summary pharmacokinetics of fenofibrate from FF-SLC: HPMCAS (4:1) capsules, FF-SLC: HPMCAS (4:1) 
suspension and the reference formulation. (a) Displays Cmax (mean ± SD, n = 6), (b) displays Tmax (median, range, 
n = 6) and (c) displays bioavailability, (mean ± SD, n = 6). Statistical significance represented in comparison with 
the reference formulation. Pairwise comparison of capsule and FF-SLC: HPMCAS (4:1) suspension formulations 
was nonsignificant in all cases. 
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In vitro- in vivo relationship 
In the current study, single-point correlations for the fenoﬁbrate-loaded silica 
formulations and the reference formulation using the mean data values obtained 
from pharmacokinetic and in vitro dissolution data were evaluated. The dissolution 
efﬁciency (DE), calculated as described in the method section, was correlated with 
the absolute bioavailability. Figure 2-4 shows that a high level of correlation exists 
between DE (%) and Fa (%) values for the silica formulations (Pearson’s correlation 
coefﬁcient; r = 0.98). This implies that increases in in vitro dissolution of fenoﬁbrate 
from silica formulations are translated into enhancement of in vivo dissolution and 
therefore oral bioavailability. However, for quantitative predictions of absorbed 
fraction in vivo, further data generation and/or application of physiologically based 
pharmacokinetic modelling would be necessary. 
 
Figure 2-4 Correlation of bioavailability (mean ± SD, n = 6) and dissolution efficiency (mean ± SD, n = 3); 
Pearson′s correlation coefficient; r = 0.98. 
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Discussion 
Dissolution studies 
In a previous investigation, the potential of mesoporous silica in combination with 
polymeric precipitation inhibitors to improve the in vitro release of fenoﬁbrate was 
evaluated in biorelevant dissolution tests (Dressman et al., 2016). It was observed 
that this formulation strategy not only substantially improved the dissolution proﬁle 
of fenoﬁbrate under fasted state conditions but also helped to sustain 
supersaturated concentrations of fenoﬁbrate, compared to either pure drug or the 
marketed product (TriCor®145 mg) (Dressman et al., 2016). The current study was 
carried out to determine whether this extraordinary enhancement in fenoﬁbrate 
release observed with the optimised silica formulation could be translated into 
improved in vivo performance. The inﬂuence of dosage form on the release proﬁle 
was assessed by in vitro dissolution before carrying out in vivo studies. Compared to 
classical quality control media, biorelevant media resemble the fasted state intestinal 
conditions more accurately and, hence, can provide better possibility to predict the 
drug release in upper GI tract (Jantratid et al., 2008). Therefore, in this study, 
biorelevant media resembling the fasted state in the intestine (FaSSIF) were used to 
obtain a better understanding of how the different dosage forms of optimised blend 
of mesoporous silica would release fenoﬁbrate. Similar to the previous study, all 
mesoporous silica formulations showed far higher release proﬁles than the 
drug/HPMCAS mixture in FaSSIF, suggesting that there would be a substantial 
improvement in the bioavailability. The FF-SLC: HPMCAS (4:1) suspension showed a 
very rapid drug release in FaSSIF, displaying a pronounced ‘spring effect’. However, 
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the maximum % release achieved was lower than for the powder and capsule 
formulations, and the maintenance of supersaturation was poorer, leading to a 
limited ‘parachute effect’. This is most likely due to high levels of supersaturation 
being transiently generated in preparing the suspension formulation, where the dose 
is suspended in a 25ml volume of water immediately before the addition to the 
500ml dissolution vessels. Such high levels of supersaturation in the suspension 
increase the risk of precipitation. In the case of the capsule, gradual disintegration in 
the larger (500ml) volume is less likely to result in such high levels of supersaturation 
and the risk of precipitation is lower. Dissolution proﬁles of both the powder and 
capsule versions of the FF-SLC: HPMCAS (4:1) formulation reached their highest 
levels after the ﬁrst few sampling time points. Apart from a slightly later onset of drug 
release from the capsule, both formulations showed comparable dissolution proﬁles. 
It was concluded that the release of fenoﬁbrate from the optimised blend of 
mesoporous silica in small intestine would not be negatively inﬂuenced by ﬁlling the 
powder blend into a capsule shell. Both solid formulations successfully maintained 
supersaturation of released fenoﬁbrate up to 2hr during release studies, indicating 
strong potential to act as both a ‘spring’ and a ‘parachute’. Generation and 
maintenance of supersaturation is expected to boost the absorption and hence the 
bioavailability of poorly soluble drugs (Brouwers et al., 2009). Therefore, based on 
results of dissolution tests in biorelevant media, one would predict that the capsule 
formulation has better potential to improve the bioavailability of fenoﬁbrate than 
the suspension or reference formulations. 
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In vivo studies 
This bioavailability enhancing potential was subsequently assessed in a 
pharmacokinetic study in fasted pigs. Fenoﬁbrate absorption and bioavailability has 
been well characterised and is typical of a BCS class II compound, with conventional 
formulations of fenoﬁbrate displaying low and variable bioavailability in the fasted 
state due to low solubility and resultant slow dissolution (Miller and Spence, 1998). 
Fenoﬁbrate bioavailability increases signiﬁcantly with increased solubilisation and/or 
dissolution, as demonstrated by the considerable increases in absorption when 
delivered either in the fed state or in dissolution enhancing formulations (Sauron et 
al., 2006). In the current study, a blend of crystalline fenoﬁbrate with HPMCAS 
displayed slow (Tmax 8–12 hr) and incomplete absorption (Fa = 19.92 ± 9.89%) which 
is in line with both previous and current in vitro dissolution studies. The poor 
absorption of this reference formulation was predicted well by the poor dissolution 
performance demonstrated in vitro in both this and previous studies (DE = 2.13 ± 
0.19%) (Dressman et al., 2016). Both the rate and extent of bioavailability were 
signiﬁcantly increased by delivery of the fenoﬁbrate-loaded silica formulated with 
HPMCAS. The supersaturation observed in vitro appears to have been replicated in 
vivo with almost complete absorption from both the FF-SLC: HPMCAS (4:1) capsule 
(Fa = 86.69 ± 35.37%) and FF-SLC: HPMCAS (4:1) suspension formulation (Fa =75.47 
± 14.58%). These results compare favourably to other formulations previously 
assessed in fasted pigs including a commercial nanosized preparation (Lipantil 
Supra®; 71.08 ± 25.78%), a commercial micronised capsule (Lipantil® Micro; 66.1 ± 
3.5%) and novel lipid based formulation (lipidic dispersion; 60.3 ± 8.2%) (McCarthy 
et al., 2017, O’Shea et al., 2015). Rapid dissolution also appears to have occurred, 
 
 
90 
 
with Tmax reduced to a median of 4.5 hr for both the FF-SLC: HPMCAS (4:1) capsule 
and FF-SLC: HPMCAS (4:1) suspension formulations, respectively. This improved in 
vivo dissolution was anticipated based on the enhanced dissolution performance 
demonstrated in vitro in dissolution studies of the FF-SLC: HPMCAS (4:1) capsule (DE 
= 45.41 ± 2.37%) and FF-SLC: HPMCAS (4:1) suspension formulations (DE = 29.18 ± 
0.80%) in FaSSIF. As the reference formulation and the two silica-based formulations 
both contained HPMCAS in the same quantity, it can be additionally concluded that 
the drug dissolution and enhanced drug absorption can be mainly attributed to use 
of mesoporous silica. 
Conclusions 
The combination of fenoﬁbrate-loaded silica with HPMCAS as a polymeric 
precipitation inhibitor (FF-SLC: HPMCAS (4:1) capsule and FF-SLC: HPMCAS (4:1) 
suspension formulations) achieved substantial improvements in bioavailability in 
fasted pigs compared to a mixture of crystalline fenoﬁbrate with HPMCAS. 
Biorelevant in vitro dissolution data provided a useful indicator of formulation 
performance in vivo, with enhanced dissolution and supersaturation in vitro 
transferring into improvements in bioavailability in the in vivo studies. The results 
conﬁrm the ability of this formulation strategy to improve biopharmaceutical 
performance of fenoﬁbrate in higher animal models, and further raises the prospects 
of a commercial silica-based formulation in the near future. 
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bioavailability of fenofibrate: in vitro, in vivo and in silico 
assessments 
Joseph P. O’Shea1, Waleed Faisal2, Therese Ruane-O’Hora3, Ken J. Devine1, 
Edmund S. Kostewicz4, Caitriona M. O’Driscoll1, Brendan T. Griffin1 
 
1Pharmacodelivery Group, School of Pharmacy, University College Cork, Cork, 
Ireland 
2Faculty of Pharmacy, Minia University, Egypt 
3Department of Physiology, University College Cork, Ireland 
4Institut für Pharmazeutische Technologie, Goethe Universität, Frankfurt am Main, 
Germany 
 
Published in: European Journal of Pharmaceutics and Biopharmaceutics (2015), 96, 
207-216. 
  
 
 
92 
 
Graphical abstract 
 
Figure 3-1 Graphical abstract 
Abstract 
Novel formulations that overcome the solubility limitations of poorly water soluble 
drugs (PWSD) are becoming ever more critical to a drug development process 
inundated with these compounds. There is a clear need for developing bioenabling 
formulation approaches to improve oral bioavailability for PWSD, but also to 
establish a range of predictive in vitro and in silico biopharmaceutics based tools for 
guiding formulation design and forecasting in vivo effects. The dual aim of this study 
was to examine the potential for a novel lipid based formulation, termed a lipidic 
dispersion, to enhance fasted state oral bioavailability of fenofibrate, while also 
assessing the predictive ability of biorelevant in vitro and in silico testing. Formulation 
as a lipidic dispersion improved both dissolution and solubilisation of fenofibrate 
through a combination of altered solid state characteristics and incorporation of 
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solubilising lipidic excipients. These changes resulted in an increased rate of 
absorption and increased maximal plasma concentrations compared to a 
commercial, micronised product (Lipantil® Micro) in a pig model. Combination of 
biorelevant in vitro measurements with in silico physiologically based 
pharmacokinetic (PBPK) modelling resulted in an accurate prediction of formulation 
performance and forecasts a reduction in food effects on fenofibrate bioavailability 
through maximising its fasted state dissolution. 
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Introduction 
Designing novel formulations to enhance the oral bioavailability of poorly water 
soluble drugs has long been a key driver of the pharmaceutical industry. The poor 
intrinsic solubility of Biopharmaceutical Classification Scheme (BCS) class II 
compounds has stifled development of many emerging therapeutic compounds. 
With up to 75% of drug development candidates displaying poor aqueous solubility, 
the bioavailability limitations posed still form an unmet challenge for pharmaceutical 
drug development (Di et al., 2012). 
The absorption of these poorly water soluble drugs (PWSD) is limited by their poor 
solubility and resultant slow dissolution rate within gastrointestinal fluid (Butler and 
Dressman, 2010). In addition, these drugs can commonly display variable food effect 
bioavailability, with poor solubility being a strong predictor of positive food effects 
(Bergstrom et al., 2014, Lentz, 2008). Ingested lipids interact with bile salts and 
phospholipids in the post-prandial intestinal milieu to solubilise PWSD (Charman et 
al., 1997). While this can enhance absorption of PWSD, it can also lead to variable 
bioavailability during clinical use depending on the prandial state at the time of dose 
administration, potentially resulting in loss of efficacy (Custodio et al., 2008). 
Formulations that enhance bioavailability of these compounds, maximising it in the 
fasted state, will therefore result in reduced food effects (Sauron et al., 2006, 
Guichard et al., 2000). 
Formulation techniques that enhance bioavailability of PWSD in a predictable and 
reproducible manner are becoming increasingly critical. The design of these 
bioenabling formulation approaches can be described using the concept of the 
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“spring and parachute” approach (Guzman et al., 2007). Facilitation of dissolution is 
thought of as providing an initial “spring”, while inclusion of solubilising excipients or 
precipitation inhibitors can act as a “parachute”, retarding the transition back to a 
lower energy, crystalline form. Critically, the selection of formulation methods 
and/or excipients to maximise oral bioavailability is best guided by reliable and 
predictable in vitro biopharmaceutical screening. 
The advent of Developability Classification System (DCS), based on a revised BCS, has 
placed greater focus on understanding of the factors affecting drug and formulation 
performance in vivo. By sub-dividing BCS class II compounds into class IIa and IIb, 
based on more biorelevant screening, the DCS enables earlier prediction of drug 
limitations in development, guides formulation strategy and can be used to estimate 
formulation performance (Butler and Dressman, 2010). Complete oral absorption for 
dissolution rate limited (class IIa) drugs can generally be achieved by simply 
controlling particle size, surface area and wettability, while solubility limited 
candidates (class IIb) require more complex solubilisation techniques, such as 
nanonisation, solid dispersion, salt or co-crystal formation or inclusion of solubilising 
excipients, such as lipids and surfactants (Butler and Dressman, 2010, Williams et al., 
2013b). 
It is also imperative when designing bioenabling formulation strategies to establish 
reliable in vitro–in vivo correlations. While solubility, dissolution and permeability 
tests are often of merit for conventional formulations, more advanced biorelevant 
screening tools and computational modelling approaches are needed for reliably 
predicting in vivo performance (Bergstrom et al., 2014). In silico physiologically based 
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pharmacokinetic (PBPK) modelling builds on the available in vitro data and is being 
increasingly used to forecast formulation and food effects. Several programs are now 
commercially available for model generation and application to assess in vivo 
performance, including Gastroplus™, Simcyp® and PK-Sim® (Kostewicz et al., 2014a). 
Combination of in vitro solubility, dissolution and precipitation testing with in silico 
data modelling has been shown to be particularly effective at predicting in vivo 
performance of oral dosage forms (Fei et al., 2013, Juenemann et al., 2011, Stillhart 
et al., 2014b). 
Fenofibrate is an orally active, lipid regulating, BCS class II compound, and is a good 
model for the assessment of formulation strategies to enhance bioavailability and 
eliminate food effect (Fei et al., 2013, Juenemann et al., 2011). The Lipantil Micro® 
formulation, a micronised product, displays food dependent bioavailability, and 
therefore requires administration with food. A re-formulated product, Lipantil® 
Supra was developed using NanoCrystal® technology, to overcome this limitation and 
allows food independent administration and dose reduction (Sauron et al., 2006, 
Guichard et al., 2000, Junghanns and Muller, 2008). 
The aim of this study was to explore an alternative bioenabling formulation approach 
to overcome food dependent bioavailability using lipid based formulations. Lipid 
based formulations (LBFs) have been widely investigated for their ability in enhancing 
solubilisation within the GI tract, generating supersaturation and increasing drug 
absorption and have been shown to eliminate food effect in vivo (O'Driscoll and 
Griffin, 2008, Christiansen et al., 2014, Williams et al., 2013c). Solubilisation of PWSD 
within a lipid-based, liquid carrier allows delivery within a capsule which self 
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emulsifies on dispersion in GI fluids, maintaining drug solubilisation. Co-
administration of lipids as formulation excipients may promote formation of mixed 
micelles enhancing solubilisation and induce secretion of bile salts and phospholipids 
in vivo, mimicking the fed state environment (O'Reilly et al., 1994, Kossena et al., 
2007). 
This study has the dual objective of investigating the potential for a novel LBF, termed 
a lipidic dispersion, to enhance bioavailability of fenofibrate in fasted pigs, while 
assessing the ability of in vitro and in silico biopharmaceutical tools to predict in vivo 
formulation performance. The novel formulation is based on a modification of 
previous work and combines solid dispersion and lipid formulation techniques, 
addressing challenges associated with the delivery of dissolution rate and solubility 
limited drugs (Faisal et al., 2013). 
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Materials and methods 
Chemicals and materials 
Olive Oil ‘highly refined, low acidity’ (C18 triglycerides), fenofibric acid, Tween 85 
(polyoxyethylene-(20)–polysorbitan trioleate), sodium taurocholate (>95%) and 
sodium oleate (⩾82% fatty acids, as oleic acid) were purchased from Sigma–Aldrich 
(Ireland). Cremophor RH 40 (polyoxyl-40-hydrogenated castor oil) and Kollidon® 30 
(polyvinylpyrrolidine (PVP) K30) were received from BASF (Germany). Lipantil® Micro 
67mg hard capsules were obtained from Abbott Healthcare Products Ltd. (UK). 
Glycerol monooleate (GMO, Rylo MG19 Pharma®, 99.5% monoglyceride) was 
received from Danisco Specialities (Denmark). Fenofibrate was purchased from 
Kemprotec Ltd. (UK). Hard gelatin capsules (Size 0) were obtained from Capsugel 
(Coni-Snap®). Lecithin (Lipoid E PC S, >98% pure) was kindly donated by Lipoid GmbH 
(Ludwigshafen, Germany). All other chemicals and solvents were of analytical grade 
or HPLC grade respectively and were purchased from Sigma–Aldrich (Ireland). 
Preparation of fenofibrate loaded solid dispersion 
A solid dispersion of fenofibrate and PVP K30, in a 1:4 ratio, was prepared using a 
Büchi mini spray dryer B-290 (BÜCHI labortechnik AG, Switzerland). Fenofibrate and 
PVP-K30 were dissolved in dichloromethane (40mg PVP/ml) and dried in an inert 
nitrogen atmosphere. The operating parameters were as follows: inlet temperature: 
55°C, outlet temperature: 40°C, pump rate: 14% and aspiration rate: 100%. The solid 
dispersion was collected from the cyclone separator and stored in a desiccated 
environment at room temperature. Physical mixtures of the same ratios were also 
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prepared by mixing fenofibrate and PVP-K30 thoroughly in a mortar until a 
homogenous mixture was obtained. 
Preparation of lipidic dispersion 
An LBF composed of 40% long chain triglyceride (LCT) (Olive oil), 20% surfactant 
(Cremophor RH 40) and 40% co-surfactant (Tween 85) was prepared as previously 
described (Faisal et al., 2013). This self-emulsifying drug delivery system (SEDDS) was 
chosen on the basis of its high composition of LCT and the ability to form a stable, 
isotropically clear microemulsion on dilution with water. The SEDDS was prepared by 
weighing exact quantities of each excipient into a screw cap glass tube followed by 
vortexing to allow complete mixing and incubated overnight at 37 °C (Faisal et al., 
2013). Fenofibrate and PVP (1:4) were dissolved in dichloromethane (40mg PVP/mL). 
Subsequently, the LBF was added to the solution and mixed using a magnetic stirrer. 
The total weight ratio of constituents (fenofibrate: PVP: LBF) was 1:4:5. The solution 
was spray dried using parameters defined in the previous section. A blank 
formulation was prepared under similar conditions, but without the addition of drug, 
with a 4:5 ratio of PVP to LBF. Both drug loaded and blank lipidic dispersions resulted 
in the formation of a free-flowing white powder. These formulations were stored in 
a desiccated environment and fenofibrate content was assayed and found to be 
stable over a storage period of six months. Stability was indicated by similarity in 
fenofibrate content assay, as determined by HPLC, at initial and six-month time-
points. At the initial time-point 89.04% ± 5.56% of theoretical drug concentration was 
observed, compared to 91.94% ± 3.98% at the six-month time-point.  
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Physiochemical characterisation 
Thermal analysis 
Differential scanning calorimetry (DSC) analyses were carried out using a DSC Q1000 
(TA Instruments, Hertfordshire, UK). Sealed samples and reference pans were loaded 
into the sample chamber at ambient temperature, equilibrated to 25°C and held at 
this temperature for 5 min. Samples were heated at 3°C/min with an applied 
modulation of ±1°C every 60 sec from −40 to 200°C. The nitrogen gas flow rate was 
50ml/min. Analysis of the DSC thermograms was conducted with Universal Analysis 
2000 software (TA Instruments, Hertfordshire, UK). 
Powder X-ray diffraction 
Powder X-ray diffraction (PXRD) was carried out using a Stadi MP Diffractometer 
(Stoe GmbH, Germany). Samples were radiated using a copper anode (Cu Kα 
radiation, λ = 1.5406Å, 40kV, 40mA). The scanning angle ranged from 3.55° to 60° of 
2ϑ, with a scanning speed of 0.07°/sec. The diffraction patterns were analysed using 
Philips X’Pert High Score software (version 1.0a). 
Compendial dissolution 
Compendial dissolution studies were carried out in triplicate with an Erweka DT600 
dissolution test system (Erweka GmbH, Germany). Tests were performed in 900 ml 
0.05M sodium lauryl sulphate (SLS) at 37 ± 0.5°C using USP type II paddle method at 
75rpm. Samples equivalent to 67mg of fenofibrate were placed in the dissolution 
medium within gelatin capsules, using wire sinkers. Samples of 4ml were withdrawn 
at 5, 15, 30, 45, 60 and 90 min, immediately followed by the addition of an equal 
volume of fresh, pre-warmed medium. The withdrawn samples were filtered through 
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a 0.20μm PES membrane filter (Filtropur S 0.2, Sarstedt AG & Co., Nümbrecht, 
Germany), discarding the first 2ml. The resultant filtrate was visually assessed as 
being clear and free from particles. 100μL of sample was immediately diluted with 
900μL of acetonitrile and analysed using HPLC. 
Biorelevant solubility and dissolution 
FaSSIF-V2 and FeSSIF-V2 were prepared as outlined in the literature (Jantratid et al., 
2008). Enhanced FaSSIF-V2 and FeSSIF-V2, containing formulation excipients, were 
prepared by running a simulation of dissolution conditions outlined below with blank 
spray dried lipidic dispersion in biorelevant medium, in a quantity equivalent to that 
contained in biorelevant dissolution test samples. 
Solubility studies were carried out by the addition of excess fenofibrate to 
biorelevant media and using a standardised shake flask method with a shake time 24 
hr at 37°C (Juenemann et al., 2011). 2 ml samples were removed at 24 hr and added 
to 2ml centrifuge tubes. Samples were centrifuged at 16,500g for 13 min (Hermle 
z233M-2 fixed angle rotor centrifuge, HERMLE Labortechnik GmbH, Wehingen, 
Germany). The resultant supernatant was free from particles and was removed and 
centrifuged again under the same conditions. The resulting supernatant was 
analysed using HPLC after appropriate dilution with acetonitrile. 
Biorelevant dissolution was carried out under similar conditions to those described 
for compendial dissolution studies with the following modifications: 500ml of 
biorelevant media was used, with samples withdrawn at 5, 10, 15, 20, 30, 45, 60, 90 
and 120 min. 
 
 
102 
 
Oral bioavailability in pigs 
The study was carried out under licences issued by the Department of Health, Ireland, 
as directed by the Cruelty to Animals Act, Ireland and EU Statutory Instruments. Local 
University ethical committee approval was also obtained. The study was a partially 
randomised three-way crossover design, where the pigs were randomly allocated to 
one of the two oral formulations on the first leg, followed by a crossover for the 
second leg. The final leg of the study involved an intravenous study on all pigs. The 
data from this intravenous study have been previously used for the determination of 
fenofibrate clearance in pigs to allow absolute bioavailability to be determined in a 
separate study (Griffin et al., 2014). 
Four male landrace pigs (15–20kg, mean 17.5kg) were sourced locally and housed at 
the University’s Biological Services Unit. Pigs were fasted for 16 hr before 
experiments. On day 1, an indwelling intravenous catheter was inserted into the 
jugular vein, under general anaesthesia as previously described (Faisal et al., 2013). 
Following an overnight fast on day 3, oral formulations were administered in gelatin 
capsules (equivalent to 67mg fenofibrate) with the aid of a dosing gun, after which 
the pigs received 50mL of water via syringe. After dosing, pigs were returned to their 
pens. Blood samples (4mL) were collected at time zero (pre-dosing) and 0.5, 1, 2, 3, 
4, 6, 8, 12 and 24 hr post-dosing. Water was available ad libitum throughout the study 
period and the animals were fed 8 hr post-dose. 
For the intravenous treatment, animals were administered 25mg fenofibrate by slow 
infusion, over 2 min, via 3ml of a solution containing 8.33mg/ml fenofibrate in 80% 
w/w ethanol and 20% physiological saline into an ear vein. Blood sampling was 
 
 
103 
 
performed as outlined above, with an additional 3 blood samples taken at 0.0833, 
0.25 and 0.75 hr post-dose. All blood samples were collected in heparinised tubes 
(Sarstedt, Germany) and immediately centrifuged at 3,220g for 5 min at 4°C 
(Eppendorf 5810r swinging bucket rotor centrifuge, Eppendorf AG, Hamburg, 
Germany). Plasma was collected and stored at −80°C prior to analysis. A seven day 
washout period was observed between each leg of the study. All animals remained 
in good health throughout the study. 
Quantitative analysis of fenofibrate 
The concentrations of fenofibrate from solubility/dissolution tests were determined 
using a validated HPLC-UV method. The HPLC system comprised of an Agilent 
Technologies 1200 series HPLC system (Agilent Technologies, Santa Clara, Ca.) 
equipped with a Kinetex 5 μm XB-C18, 250 × 4.6 mm reversed phase column 
(Phenomenex Inc., Macclesfield, UK). A mobile phase consisting of 80% acetonitrile 
and 20% water was used at a flow rate of 1ml/min. An injection volume of 20μl was 
used. Fenofibrate was detected using UV light at 286nm, with retention time of 8 
min. This analysis displayed linearity (r2 ⩾ 0.99) over the range 25–5000ng/ml. The 
precision of the method at 25, 400 and 1500 ng/ml, expressed as the coefficient of 
variation (CoV), was 0.48%, 2.45% and 1.89% within days and 0.57%, 3.58% and 
2.23% between days respectively. 
The pharmacokinetic evaluation of fenofibrate was based on the quantification of 
fenofibric acid, the major active metabolite of fenofibrate, using a validated HPLC-
UV method, as previously described (Griffin et al., 2014). Briefly, 0.5ml of plasma was 
spiked with sulindac as an internal standard. Proteins were precipitated through the 
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addition of 0.5ml of 25% NaCl solution and 1 ml of 1% H3PO4 in methanol with 
thorough mixing. Samples were centrifuged at 11,500g for 9 min (Hermle z233M-2 
fixed angle rotor centrifuge, HERMLE Labortechnik GmbH, Wehingen, Germany). The 
clear supernatants were injected onto a Synergi, C18 reversed phase column (250 × 
4.6mm, 4μm) (Phenomenex Inc., Macclesfield, UK) using the Agilent system 
previously described in this section. Mobile phase consisted of 80% methanol: 20% 
water (adjusted to pH 2.5) at a flow rate of 1 ml/min, resulting in elution of fenofibric 
acid and fenofibrate at 6.5 and 10.5 min respectively. UV detection occurred at 
286nm. The analysis showed linearity over the range of 50–2000ng/ml with an LOQ 
of 80ng/ml and extraction recoveries ⩾95%. 
Pharmacokinetic data analysis 
Intravenous pharmacokinetic parameters were fitted to a two compartment model 
using the PKPlus™ module in Gastroplus™ (ver. 8.6, Simulations Plus Inc., Lancaster, 
Ca.). The AUC for fenofibric acid after oral administration was calculated for 8 hr and 
24 hr post-dosing using Prism (ver. 5, GraphPad Software Inc., La Jolla, Ca.). The peak 
plasma concentrations (Cmax) and the time for their occurrence (Tmax) were noted 
directly from the individual plasma concentration vs. time profiles. The Absolute 
Bioavailability (Fa) was calculated according to equation 3-1 below: 
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All pharmacokinetic parameters are reported as mean ± SD. 
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In silico predictive modelling 
In silico absorption modelling was conducted using GastroPlus™ (ver. 8.6, Simulations 
Plus, Lancaster, Ca.). The ADMET Predictor™ module was used to estimate 
fenofibrate physiochemical characteristics. Reference and biorelevant solubilities 
were changed to reflect those measured in vitro in aqueous, as well as biorelevant 
fed and fasted media. The z-factor for each formulation was established by fitting 
individual dissolution profiles in FaSSIF-V2 and FeSSIF-V2. Pharmacokinetic 
parameters and bioavailability were fit to a two-compartment model using the built-
in PKPlus™ module comparing mean i.v. profile to the quickest dissolving (lipidic 
dispersion) formulation and subsequently optimised using the software’s 
optimisation functionality to best fit i.v. and lipidic dispersion profiles. Simulations 
were based on the assumption that the entire absorbed dose was rapidly converted 
to fenofibric acid by gut and plasma esterases (Fei et al., 2013, Griffin et al., 2014). 
Simulations were set to 24 hr using the mini-pig physiological fasted ACAT™ model 
and incorporated a feeding step at 8 hr. Dose was set to 67mg and dose volume was 
50ml. All other values were kept at default values. Simulated profiles were compared 
to the mean plasma profile for each formulation. 
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Statistical analyses 
Dissolution curves obtained with each formulation were compared using the 
similarity factor, f2, described by Moore and Flanner, as defined by equation 3-2 
below (Moore and Flanner, 1996); 
𝑓2 = 50𝑙𝑜𝑔 {[1 +  
1
𝑛
∑ (𝑅𝑡 − 𝑇𝑡)
2𝑛
𝑡=1 ]
−0.5
𝑥 100}                 (3-2) 
where n is the number of sample time-points, Rt is the percentage of drug solubilised 
at time t in the reference vessel and Tt is the percentage of solubilised drug at time t 
in the test vessel. Curves were defined as similar when 50 ⩽ f2 ⩽ 100. 
In vitro solubility data were tested for significance (p < 0.05) using a two-tailed, 
independent sample t-test, assuming Gaussian distribution and equal variance. 
Paired t-tests were used to determine the statistical significance (p < 0.05) of 
calculated in vivo bioavailability and pharmacokinetic results, as each animal acted 
as its own control in this crossover study. 
Correlation between predicted and observed profiles was assessed using Pearson’s 
correlation test. Correlation between values was first assessed for linearity using a 
scatter plot, before calculating Pearson’s r. Gaussian distribution was assumed. 
Correlation was considered significant when p < 0.05. 
All statistical analyses were performed using GraphPad Prism version 5. 
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Results 
Lipid excipient effects on fenofibrate solubility in biorelevant conditions 
The measured solubility of fenofibrate in biorelevant media (FaSSIF-V2 and FeSSIF-
V2) was used as a predictor of in vivo solubility at the absorptive site. The effect of 
lipidic formulation excipients on solubilisation was assessed by their addition to these 
media (Enhanced FaSSIF-V2 and Enhanced FeSSIF-V2). Solubility in fasted state media 
was increased from 3.641 ± 0.623 μg/ml in FaSSIF-V2 to 58.173 ± 2.542 μg/ml in 
Enhanced FaSSIF-V2 (mean difference 41.6 ± 0.448 μg/ml, p < 0.0001). This was 
compared to an increase from 45.24 ± 0.462 μg/ml in FeSSIF-V2 to 88.829 ± 1.374 
μg/ml in Enhanced FeSSIF-V2 (mean difference 30.66 ± 1.668 μg/ml, p < 0.0001). As 
a result, the ratio of fed: fasted solubility was reduced from 16 without lipids to 2 
when lipids are present, demonstrating the ability of lipidic excipients to improve 
biorelevant solubility, while also attenuating a food effect for fenofibrate (fig. 3-2). 
 
Figure 3-2 Solubility of fenofibrate in fasted state simulated intestinal fluid-V2 (FaSSIF-V2), fed state simulated 
intestinal fluid-V2 (FeSSIF-V2) and similar media incorporating lipidic formulation excipients (Enhanced FaSSIF-
V2 and Enhanced FeSSIF-V2) (n = 3, mean ± SD)  
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Compendial dissolution 
A range of formulations was initially screened using FDA recommended dissolution 
conditions, with a view to forecasting in vivo performance. A lipidic dispersion, 
prepared as outlined in methods, was compared to the commercial Lipantil® Micro 
formulation and a PVP solid dispersion, devoid of lipid excipients. These formulations 
were compared to pure, unprocessed drug substance and physical mixtures of 
excipients. The pure drug substance demonstrated slow, incomplete dissolution and 
release from fenofibrate–PVP physical mixture was similarly slow to that of 
unprocessed drug. The release from the PVP solid dispersion was greatly enhanced 
relative to the physical PVP–drug mixture, confirming improved dissolution of 
fenofibrate following processing via PVP solid dispersion (Hugo et al., 2013). In the 
case of the lipidic dispersion, a comparable and near complete release profile was 
observed relative to the commercial micronised product. The dissolution profiles for 
the PVP solid dispersion, lipidic dispersion and Lipantil® Micro were similar, with 
>70% dissolution observed at 45 min, which would indicate that using a compendial 
dissolution set-up, there was no discernible difference detected due to lipid 
excipients on the dissolution profile (figure 3-3). 
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Figure 3-3 Dissolution profiles of 67 mg fenofibrate in 0.05 M SLS (n = 4, mean ± SD), (●) indicates Lipantil® 
Micro, (■) indicates Lipidic Dispersion, (▴) indicates solid dispersion, (▾) indicates pure fenofibrate drug 
substance, () indicates fenofibrate and PVP-K30 physical mixture. 
 
Physicochemical characterisation 
Solid-state characterisation of the formulations was subsequently evaluated using 
PXRD (figure 3-4) and DSC (figure 3-5). The PXRD diffractograms of pure fenofibrate 
and the physical mixture of fenofibrate and PVP were in accordance with Heinz et al. 
(Heinz et al., 2009), with characteristic peaks of crystalline fenofibrate observed at 
12° (2ϑ), 14.5° (2ϑ), 16.2° (2ϑ), 16.8° (2ϑ) and 22.4° (2ϑ). DSC investigation 
demonstrated a sharp melting endotherm at 77.63°C, verifying the crystallinity of 
fenofibrate. PXRD of Lipantil® Micro displays the characteristic peaks of crystalline 
fenofibrate, along with the additional peaks most likely corresponding to crystalline 
excipients present, such as lactose monohydrate, sodium lauryl sulphate and 
magnesium stearate. Although changes in heat flow are apparent, endotherms 
corresponding to the melting of crystalline fenofibrate are also evident for the 
physical mixture of excipients and Lipantil® Micro. 
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Figure 3-4 Powder X-ray diffraction patterns of fenofibrate, Lipantil® micro, PVP, fenofibrate–PVP physical 
mixture, fenofibrate–PVP solid dispersion and lipidic dispersion. 
 
 
 
Figure 3-5 Differential scanning calorimetry thermogram of fenofibrate, Lipantil® micro, PVP, fenofibrate–PVP 
physical mixture, fenofibrate–PVP solid dispersion and lipidic dispersion 
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Generation of a conventional solid dispersion with fenofibrate and PVP results in a 
loss of crystallinity, with characteristic peaks absent and elimination of the melting 
endotherm. The lipidic dispersion displays similar thermal behaviour to the solid 
dispersion, suggesting a loss in crystallinity relative to pure drug substance. However, 
characteristic peaks are apparent in PXRD and there appears to be some element of 
crystalline fenofibrate present. Direct quantitative comparison with the physical 
mixture of excipients is difficult due to differences in fenofibrate content in both 
samples. While the fenofibrate seems to retain some crystalline character, the similar 
thermal behaviour to that of the solid dispersion indicates that there is no additional 
energy input required to break up fenofibrate crystalline lattice in the lipidic 
dispersion, suggesting a solid-state change which should enhance dissolution 
performance in a comparable fashion to solid dispersion. 
Biorelevant dissolution under simulated fasting and fed state conditions 
To explore the likely impact of food on dissolution characteristics, dissolution studies 
were conducted using biorelevant fasted and fed state media (Juenemann et al., 
2011). Biorelevant dissolution testing of Lipantil® Micro demonstrates a marked 
increase in dissolution in the FeSSIF-V2 compared to the FaSSIF-V2 (figure 3-6A). In 
contrast to the compendial dissolution profile, drug release under simulated fasting 
conditions was low, with approximately 8% release after 2 hr. This increased 
substantially using FeSSIF-V2 with 52% release after 2 hr (f2 = 27.163). In the case of 
the lipidic dispersion, fenofibrate release under fasting condition was significantly 
higher than the micronised formulation, with 43% release at 2 hr. Interestingly, there 
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is no difference in dissolution of the lipidic dispersion in fasted or fed state media 
(figure 3-6B) with a similarity factor (f2) of 58.198. 
 
 
Figure 3-6 Biorelevant dissolution and solubility in simulated intestinal media, dotted line indicates fenofibrate 
solubility in FaSSIF-V2, dashed line indicates fenofibrate solubility in FeSSIF-V2, (■) indicates dissolution in 
FaSSIF-V2, (▾) indicates dissolution in FeSSIF-V2 (n = 3, mean ± SD). 
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Release in biorelevant media is compared to fenofibrate solubility in FaSSIF-V2 and 
FeSSIF-V2 in figure 3-6. The lipidic dispersion rapidly achieves concentrations greater 
than the measured solubility in FaSSIF-V2, through excipient mediated solubilisation. 
Oral bioavailability in pigs 
Figure 3-7 represents the plasma concentration profiles obtained following oral 
administration of 67mg of fenofibrate, as either a lipidic dispersion or Lipantil® Micro, 
to fasted pigs in a crossover study (mean ± SE, n = 4). Absolute bioavailability was 
determined relative to an intravenous control. The key pharmacokinetic parameters 
are summarised in table 3-1. A maximal plasma concentration of 4332 ± 1027ng/mL 
was observed at 1.75 ± 0.5 hr with the lipidic dispersion, while the absorption of 
fenofibrate from Lipantil® Micro was slower with Cmax 2691 ± 728ng/ml at Tmax 7.75 
± 4.92 hr. A prolonged absorption phase is evident for Lipantil® Micro, with 
absorption still apparent up to 12 hr post-dosing. An absolute bioavailability of 60.3 
± 8.2% was observed for the lipidic dispersion formulation and found to be not 
significantly different relative to absolute bioavailability of 66.1 ± 3.5% for Lipantil® 
Micro (mean difference = 3.482 ± 21.14%; p = 0.7634) (figure 3-8B). While there is no 
significant difference in the extent of oral bioavailability at 24 hr, graphical 
representation displays markedly different plasma concentration–time profiles. To 
provide further insights into the in vivo data, a partial AUC analysis was performed 
(Larsen et al., 2013). Profiles were compared up to the point where pigs were allowed 
access to food (0–8 hr). Partial AUC analysis demonstrates significantly greater 
bioavailability under the fasting period for the lipidic dispersion formulation (mean 
difference = 16.874 ± 7.333%; p = 0.0193) (figure 3-8A). 
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Figure 3-7 Plasma concentration of fenofibric acid vs. time profiles after oral administration of 67mg or i.v. 
administration of 25 mg fenofibrate to fasted pig (mean ± SE, n = 4), (●) indicates Lipantil® Micro, (■) indicates 
Lipidic Dispersion, (▴) indicates intravenous preparation. White area indicates fasting conditions, shaded area 
represents access to food. 
 
Table 3-1 Summary of pharmacokinetic parameters following intravenous administration of 25mg of fenofibrate 
and oral administration of 67mg of fenofibrate as lipidic dispersion or Lipantil® Micro to fasted pigs (mean ± SD, 
n = 4).  
* Bioavailability determined using Fa0→8hrs = (AUC(oral)0→8hrs/AUC(iv)0→24hrs)* (Dose(iv)/D(oral))  
**Bioavailability calculated using Fa0→24hrs = (AUC(oral)0→24hrs/AUC(iv)0→24hrs)* (Dose(iv)/D(oral)) 
Intravenous 
pharmacokinetic 
Parameters 
Oral pharmacokinetic parameters 
Vc (L/kg) 0.345 ± 
0.02504 
 Lipidic 
dispersion 
Lipantil® Micro 
Kel (hr-1) 0.221 ± 
0.064428 
Cmax (ng/mL) 4332.08 ± 
1026.98 
2691.35 ± 
728.01 
Kel (hr-1) 0.099 ± 
0.038687 
Tmax (hours) 1.75 ± 0.5 7.95 ± 4.73 
Kel (hr-1) 0.35125 ± 
0.241289 
Fa0→8hrs* 38.1% ± 13.4% 21.2% ± 10.3% 
AUC0→24hrs 
(ng.h/ml) 
18382 ± 4591 Fa0→24hrs** 60.3% ± 8.2% 66.1% ± 3.5% 
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Figure 3-8 Bioavailability of fenofibrate from Lipantil® Micro and lipidic dispersion in fasted pigs after 8 and 24 hr 
(n = 4, mean ± SD). 
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In silico predictive modelling 
In silico predictive modelling was used to generate in vitro- in vivo- in silico 
correlations and predict formulation performance. These results were generated by 
GastroPlus™ software provided by Simulations Plus, Inc., Lancaster, California, USA. 
Modelling of plasma fenofibric acid concentration for the lipidic dispersion 
formulation, incorporating in vitro solubility and dissolution measurements with 
PKPlus™ fitted pharmacokinetic estimates resulted in an absorption model which 
accurately predicts the observed data in the fasted state. A highly significant positive 
correlation was observed between predicted and observed plasma concentration 
(Pearson r = 0.9616, p < 0.0001). This model predicted bioavailability in the fasted 
state to be 63.315% with a Cmax of 4039.1ng/ml at 1.84 hr. Applying this model to the 
dissolution and solubility measurements for Lipantil® Micro formulation displays 
excellent correlation with the initial absorption phase, up to 8 hr (Pearson r = 0.9156, 
p < 0.005). However, the prolonged absorption observed in vivo is not modelled, with 
the result that Tmax and bioavailability are lower in the predicted profile (3.76 hr and 
44.8% respectively) than that seen in vivo. 
A comparable absorption model for the fed state was utilised to examine the 
potential impact of formulation on fed state bioavailability. For the lipidic dispersion 
formulation, the fed state model showed no change in overall bioavailability with 
only slight changes in Cmax (3665.7ng/ml) and Tmax (2.08 hr), values which are still 
within the 80–125% bioequivalence limit. Therefore, the in silico model predicts that 
oral bioavailability for the lipid dispersion is food independent. In contrast for the 
Lipantil® Micro, the in silico model predicted a significant increase in oral 
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bioavailability in the fed state (44.8% in fasted vs. 62.8% in fed state), which is as 
expected for this preparation in vivo (Sauron et al., 2006) (figure 3-9). 
 
Figure 3-9 Gastroplus™ in silico model of plasma fenofibric acid concentration vs. time profile compared to 
observed in vivo pig data, solid line indicates predicted fasted state profile, dashed line indicates predicted fed 
state profile, (○) indicates observed data (n = 4, mean ± SE, reproduced from Fig. 6).  
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Discussion 
Fenofibrate displays poor and variable oral bioavailability mediated by its poor 
solubility and slow dissolution, with optimal absorption seen when co-administered 
with food (Sauron et al., 2006). Numerous methods have been well characterised for 
their ability to enhance dissolution and bioavailability of PWSD, such as fenofibrate, 
including nanonisation, self-emulsifying drug delivery systems (SEDDS) and solid 
dispersion techniques (Williams et al., 2013b, Vogt et al., 2008). In particular, 
nanonisation of fenofibrate has proven quite successful, resulting in a commercial 
preparation which has allowed dose reduction and food state independent dosing 
through increased bioavailability (Sauron et al., 2006, Junghanns and Muller, 2008). 
This study investigates the use of solidified lipid based formulations as an alternative 
approach. Combination of a lipid based formulation with traditional solid dispersion 
technology aims to generate a novel “third-generation” solid dispersion (Vo et al., 
2013). Solubilisation by ingested lipids, their digestion products and endogenous bile 
salts increases the bioavailability in the post-prandial state. The formulation strategy 
employed in this study focuses on enhancing fenofibrate bioavailability utilising this 
mechanism of enhanced lipid excipient mediated solubilisation, along with 
processing to alter the solid-state characteristics of the drug. By producing a 
molecularly dispersed form of the drug in a hydrophilic PVP dispersion, drug 
dissolution is enhanced – providing an initial ‘spring’ or improved dissolution rate. 
Physiochemical characterisation of the lipidic dispersion has demonstrated changes 
in the solid state of fenofibrate relative to pure drug substance and Lipantil® Micro, 
resulting in enhanced dissolution of fenofibrate (figures 3-4 and 3-5). Furthermore, 
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inclusion of lipid excipients improves solubilisation within colloidal phases that exist 
in intestinal media, prolonging the ‘parachute’ or supersaturated state. Figure 3-2 
confirms the impact of lipid excipients at enhancing solubility of fenofibrate under 
biorelevant conditions (Williams et al., 2013b, Williams et al., 2013c). 
One of the primary aims of this study was to assess the ability of this formulation to 
enhance bioavailability of fenofibrate in fasted pigs. A significant increase in Cmax and 
shorter onset to Tmax for the lipidic dispersion show that fenofibrate is absorbed 
much more rapidly and extensively in the initial absorption phase compared to 
Lipantil® Micro (i.e. 0–8 hr). The prolonged absorption displayed with the Lipantil® 
Micro formulation means no difference was observed in the overall extent of 
bioavailability from either formulation over the 24 hr sampling period. This may be 
indicative of a pronounced food effect as the secondary peak is seen 2–3 hr after the 
pigs were provided access to food. It is clear that absorption is still occurring at least 
12 hr after the administration of Lipantil® Micro, while this is not seen for lipidic 
dispersion suggesting differences in the kinetics of absorption from the intestine for 
both preparations, which have been observed in studies where prolonged absorption 
or double peaking is evident (Metsugi et al., 2008). 
The study also demonstrated the advantages of biorelevant dissolution testing over 
conventional USP testing for providing more accurate prediction in vivo. Using 
dissolution conditions as defined in the USP, the lipidic dispersion and Lipantil® Micro 
displayed equivalent in vitro release profiles, whereas under biorelevant conditions, 
distinct differences between the formulations were observed. In this case, 
biorelevant dissolution testing has provided a qualitatively accurate prediction of in 
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vivo performance, with rapid and extensive dissolution in FaSSIF-V2 predicting the 
increased rate of bioavailability for the lipidic dispersion, whereas slow dissolution of 
Lipantil® Micro in vitro is reflected in its slower absorption in vivo. Enhanced 
solubilisation caused by incorporation of lipidic excipients results in rapid 
achievement of concentrations greater than thermodynamic solubility, which are 
maintained throughout the test. By overcoming the solubility limitation of 
fenofibrate in FaSSIF-V2, through inclusion of lipidic excipients, there is no 
enhancement in dissolution in the fed state compared to the fasted state, as is seen 
with Lipantil® Micro. It appears that dissolution in the fasted state medium has been 
maximised indicating potential of the lipidic dispersion to eliminate any food effects 
on dissolution and subsequent bioavailability of fenofibrate. 
The solubility of fenofibrate in the biorelevant media with added lipid excipients was 
used to predict the in vivo solubility at the site of absorption. However, this approach 
does not make allowances for the impact of digestion of lipid excipients on drug 
solubilisation in vivo. In the case of fenofibrate, previous studies have shown that in 
vitro digestion of lipid based formulations containing similar long chain lipids to the 
current lipidic dispersion, had a limited impact on drug solubility post-digestion. 
Furthermore, it appears that in the case of the non-ionisable compounds, such as 
fenofibrate, the risk of reduced in vivo absorption due to digestion-induced drug 
precipitation is low (Stillhart et al., 2014b, Griffin et al., 2014, Thomas et al., 2014). 
However, in the case of weak bases, in particular, there is potential for formulation 
digestion by intestinal lipases to result in a loss of solubilisation and cause 
precipitation (Christophersen et al., 2014, Stillhart et al., 2014a). These effects 
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appear to be drug and formulation specific and currently need to be assessed on a 
case by case basis (Williams et al., 2014). 
Incorporation of in vitro measurements with i.v. pharmacokinetics through in silico 
modelling can be used to accurately predict formulation performance through the 
generation of in vitro- in vivo- in silico correlations (Kostewicz et al., 2014a). The 
resultant model predicts a profile which accurately reflects in vivo performance for 
the lipidic dispersion. The rapid dissolution and increased solubilisation measured in 
vitro are predicted to maximise absorption in the fasted state, with the 
corresponding fed state model predicting no increase in dissolution, solubilisation or 
absorption. The prolonged absorption of Lipantil® Micro proved difficult to model 
with only a weak overall correlation, though this correlation is much stronger in the 
initial absorption phase. While this model requires further validation, initial 
estimates demonstrate that there is potential for the lipidic dispersion formulation 
to eliminate food effect by enhancing solubility and dissolution in the fasted state to 
levels comparable to the fed state, where optimal absorption of fenofibrate is 
observed. 
For Lipantil® Micro, it is clear from the in vivo profile that there is prolonged 
absorption and/or a secondary absorption phase occurring. Possible explanations 
suggested included either prolonged drug residence in the gastrointestinal tract or 
significant post-prandial effects, or potentially a combination of both these factors. 
To explore the validity of these hypotheses further the in silico model was modified 
by introducing (i) feeding at 8 hr post-dose; (ii) reduced gastrointestinal transit or (iii) 
a combination of reduced transit and feeding at 8 hr. Introducing a feeding stage 8 
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hr post-dose did not result in a change in the predicted profile. In the case of a 
reduced gastrointestinal transit, as can be seen from the profiles generated in figure 
3-10, prolonged transit results in slower absorption. Finally, coupling prolonged 
transit with feeding at 8 hr predicted a secondary peak in plasma profiles, which 
improved the correlation with the in vivo data (r = 0.8997, p ⩽ 0.001). To achieve this 
result the gastrointestinal transit time was increased to approximately 10 hr, but 
these values are speculative rather than predictive. The improved correlation 
obtained using in silico modelling therefore suggests that a combined effect of 
prolonged drug residence in the intestine coupled with a post-prandial intestinal 
conditions at 8 hr post-dose, may be used to explain the secondary absorption phase 
observed for the Lipantil® Micro formulations. However, further work is required to 
assess the accuracy and validity of these predicted profiles. 
 
Figure 3-10 Gastroplus™ in silico model of plasma fenofibric acid concentration vs. time profile compared to 
observed in vivo pig data, dotted line indicates physiological model in fasted state (reproduced from Fig. 3-9), 
solid line indicates predicted fasted state profile with delayed small intestinal transit, dashed line indicates 
predicted fasted state profile with delayed small intestinal transit and a feeding step at 8 hr (data also inset), (○) 
indicates observed data (n = 4, mean ± SE, reproduced from Fig. 3-7).  
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Conclusions 
The novel lipidic dispersion demonstrates improved biorelevant solubility and 
dissolution of fenofibrate relative to Lipantil® Micro, eliminating fed state 
enhancement of dissolution. The lipidic dispersion increased the rate of 
bioavailability of fenofibrate in fasted pigs, while the extent absorption was similar 
to Lipantil® Micro. Biorelevant dissolution testing provides a qualitatively accurate 
prediction of in vivo formulation performance. This approach appears to be 
appropriate for non-ionisable drugs, such as fenofibrate. Drug and formulation 
specific characterisation is still required to assess formulation performance. 
Combination of in vitro solubility and dissolution measurements with in vivo 
pharmacokinetic measurements to produce in silico generated simulated profiles can 
accurately predict in vivo profiles and has been used to predict a reduction in food 
effects on oral fenofibrate bioavailability. 
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Introduction 
Poorly water-soluble drugs continue to pose significant challenges for oral drug 
delivery. With the ever increasing prevalence of lipophilic, poorly soluble compounds 
in drug development pipelines, the identification of compounds with optimized 
pharmacodynamic properties, but poor ‘developability’ owing to sub-optimal 
absorption properties leads to formulation and delivery challenges in drug 
development, where significant delays or even failure to gain approval can occur 
(Butler and Dressman, 2010, Hauss, 2007). The successful delivery of these 
challenging compounds will often rely on the use of novel bioenabling formulations, 
designed to enhance their in vivo solubility and/or dissolution (Williams et al., 
2013b). Dissolution is considered the rate-determining step for absorption of poorly 
soluble and highly permeable compounds, and bioenabling formulations are 
frequently investigated for their potential to improve oral bioavailability through 
increases in the rate of absorption and in overall extent of bioavailability (Buckley et 
al., 2013). Development of novel bioenabling formulations relies heavily on the 
ability to screen performance pre-clinically, and requires suitable marker compounds 
and reliable in vitro and in vivo models to predict the likely effects in clinical use.  
Previous studies in the current thesis have focused on the utility of fenofibrate as a 
model compound in the assessment of bioenabling formulations. Based on these 
studies, a second model drug was desired to act as a marker of both bioenabling 
approaches and of food dependent bioavailability, particularly with a food effect 
which is less formulation dependent than that of fenofibrate, and which can act as a 
‘borderline’ case study with a low to moderate food effect. Celecoxib was identified 
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as such a candidate. As a pre-cursor to any studies assessing bioavailability altering 
approaches, it is desirable to first assess absolute bioavailability in vivo. The aim of 
the current study is, therefore, to assess the absolute bioavailability of celecoxib, and 
its potential to act as such a marker compound in biorelevant in vitro screening and 
in an in vivo fasted pig model for assessment of bioenabling approaches.  
Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) which exerts its 
pharmacological action by selective inhibition of the cyclooxygenase-2 (COX-2) 
isozyme. It is widely used in the treatment of osteo- and rheumatoid arthritis and 
ankylosing spondylitis (Shi and Klotz, 2008, Davies et al., 2000). Celecoxib is highly 
lipophilic and very poorly water soluble, with an approximate aqueous solubility of 
1μg/ml, but demonstrates good permeability and is classed as a BCS class II 
compound with dissolution/solubility limited oral absorption (Guzman et al., 2007, 
Paulson et al., 2001, Laine et al., 2016). As a result, the marketed Celebrex™ 
formulation was designed to maximise dissolution, with particle size identified as a 
critical quality attribute (CQA) during the regulatory process. The commercial 
preparation has a D90 below 25μm and contains sodium lauryl sulphate as a wetting 
agent, with the function of improving dissolution of the API in vivo (Laine et al., 2016, 
FDA, 1998). As a BCS class II compound, a significant positive food effect is anticipated 
for celecoxib. However, while a significant increase in Cmax (1.9 fold increase) is 
observed in the fed state, mediated by increases in post-prandial solubilisation, there 
is only a modest increase in overall bioavailability (approximately 1.1 to 1.3 fold), 
allowing Celebrex™ to be dosed independent of prandial state (Paulson et al., 2001, 
Pfizer Inc., 2000, Lyng et al., 2016). 
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Due to its poor solubility/dissolution celecoxib has been repeatedly used as a model 
compound for assessment of bioenabling approaches, including salt formation 
(Guzman et al., 2007), microcrystals (Nasr, 2013), lipid-based formulations (Song et 
al., 2014, Nguyen et al., 2013, Subramanian et al., 2004), nanoparticle formation 
(Morgen et al., 2012, Liu et al., 2010), cyclodextrin based formulations (Rawat and 
Jain, 2004) and a mesoporous silica based amorphous dispersion (Laine et al., 2016). 
The effect of food on celecoxib has also been assessed in both the pre-clinical animal 
models and in humans, with a moderate increase in bioavailability observed (Gong 
et al., 2012, Davies et al., 2000, Lyng et al., 2016, Paulson et al., 2001, Shono et al., 
2009).  
To date the majority of pre-clinical, in vivo studies of celecoxib bioavailability and 
assessment of bioenabling formulations, as with other compounds, have been 
performed in rats and/or dogs. While there is a well-established history of using these 
pre-clinical animal models, there is also significant limitations in their ability to 
predict human in vivo performance (Musther et al., 2014, Hatton et al., 2015, Sjogren 
et al., 2014). In this regard, the use of the pig model in pre-clinical assessment has 
expanded significantly in recent years (Colleton et al., 2016). The pig presents 
numerous advantages in the assessment of pre-clinical formulations, particularly 
with regard to the anatomical and physiological similarities in the gastrointestinal 
tract of pigs and humans (Hatton et al., 2015, Sjogren et al., 2014, Swindle and Smith, 
1998, Suenderhauf and Parrott, 2013). While there are many similarities in the 
gastrointestinal structure and physiology between pigs and humans, there are also 
significant differences, particularly with regard to metabolising enzymes (Henze et 
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al., 2018b). Overall, while “animal models remain a poor simulacrum of human 
physiology”, they are still widely utilised to anticipate human pharmacokinetics and 
to discriminate product performance (Hatton et al., 2015). Recognising the 
limitations of a “one size fits all” approach in the context of animal modelling, and 
the absence of one ideal species that mimics closely human GI physiology and 
function, the most reliable approach appears to be the utilisation of numerous 
different animal models to model the various aspects of human pharmacokinetics 
(Hatton et al., 2015). 
With this in mind, the aim of the current study was to determine the bioavailability 
and pharmacokinetics of celecoxib in fasted pigs in order to assess its utility as a 
model compound for the assessment of bioenabling formulations and to compare 
bioavailability in pigs to that previously determined in the dog model (Paulson et al., 
2001). Given the moderate food effect observed for the Celebrex™ formulation, 
celecoxib may also be appropriate as a marker compound for development of a food-
effect model in fasted pigs, acting as a ‘borderline’ case study assessing the sensitivity 
of such model. 
The aims of the current study were, therefore, to; 
 Characterise the biorelevant in vitro performance of celecoxib, with regard 
to solubility and dissolution, in order to predict likely in vivo performance  
 Develop a suitable intravenous (i.v.) formulation to allow for determination 
of absolute bioavailability 
 Assessment of celecoxib bioavailability and pharmacokinetics using 
Celebrex™ and the in-house developed i.v. formulation 
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These studies were performed as a partially randomised three-way crossover using 
male Landrace pigs where animals were dosed two oral preparations and an i.v. 
formulation in the fasted state with blood sampling performed over 24 hours. The 
third leg of the study involved an investigational formulation of celecoxib.  However 
due to confidentiality considerations with the industrial partner providing the 
investigational formulation, the oral pharmacokinetic data is unavailable for 
publishing. The data presented relate solely to the commercial Celebrex™ 
formulation and an in-house developed intravenous (i.v.) preparation.  
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Materials and methods 
Materials 
Celecoxib API was purchased from Kemprotec Ltd. (UK) and celecoxib reference 
standard was received from Institut für Pharmazeutische Technologie, Goethe 
Universität, Frankfurt am Main, Germany. 2, 5 – di methyl celecoxib, polyethylene 
glycol (MW400) acetonitrile, sodium chloride and ethyl acetate were purchased from 
Sigma-Aldrich (Ireland). Sterile 0.9% sodium chloride solution was purchased from B. 
Braun Medical Ltd. (Ireland). Celebrex™ capsules were obtained from Institut für 
Pharmazeutische Technologie, Goethe Universität. All other chemicals and solvents 
were of analytical grade or HPLC grade respectively and were purchased from Sigma-
Aldrich (Ireland). 
Celecoxib HPLC analysis 
Quantification of celecoxib was carried out using HPLC using a method developed 
based on the methods of Schonberger et al. and Tan et al. (Schonberger et al., 2002, 
Tan et al., 2009). The HPLC system consisted of an Agilent 1120 compact LC system 
equipped with auto-sampler and variable wavelength detector set at UV 254nm. The 
mobile phase was a mixture of acetonitrile and water (60% and 40% respectively) 
eluted at 1 ml/min through a Licrosphere C18 5µM RP-Select-B column (250 x 4.6 mm) 
equipped with a C18 RP 4 x 3mm guard cartridge (Phenomenex, Macclesfield, UK). 
Retention time of celecoxib was approximately 8.75 minutes. 
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Biorelevant solubility and dissolution 
FaSSIF-V2 and FeSSIF-V2 were prepared as outlined in the literature (Jantratid et al., 
2008).  
Solubility studies were carried out by the addition of excess celecoxib to biorelevant 
media and using a standardised shake flask method with a shake time 24 hr at 37°C 
(Juenemann et al., 2011). 2ml samples were removed at 24 hr and added to 2ml 
centrifuge tubes. Samples were centrifuged at 16,500g for 13 min (Hermle z233M-2 
fixed angle rotor centrifuge, HERMLE Labortechnik GmbH, Wehingen, Germany). The 
resultant supernatant was free from particles and was removed and centrifuged 
again under similar conditions. The resulting supernatant was analysed using HPLC 
after appropriate dilution with acetonitrile. 
Biorelevant dissolution studies were carried out in triplicate with an Erweka DT600 
dissolution test system (Erweka GmbH, Germany). Tests were performed in 500ml 
FaSSIF-V2 or FeSSIF-V2 at 37 ± 0.5°C using USP type II paddle method at 75rpm. 
Celebrex™ 100mg capsules were placed in the dissolution vessel with wire sinkers. 
Samples of 4ml were withdrawn at 5, 10, 15, 20, 30, 45, 60, 90 and 120 minutes, 
immediately followed by the addition of an equal volume of fresh, pre-warmed 
medium. The withdrawn samples were filtered through a 0.45μm regenerated 
cellulose filter (Whatman® Roby 25/0.45 RC-GF, GE Healthcare Life Sciences, 
Buckinghamshire, UK), discarding the first 2ml. The resultant filtrate was visually 
assessed as being clear and free from particles. The sample was immediately diluted 
with an appropriate volume of acetonitrile and analysed using the HPLC method 
outlined above. 
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Plasma Extraction 
Extraction of celecoxib from plasma was developed based on a method adapted from 
that of Schonberger et al. (Schonberger et al., 2002). 0.5mL was spiked with 50µL of 
2, 5-dimethyl celecoxib (10μg/ml) as an internal standard. Proteins were precipitated 
by adding 1ml of acetonitrile and 0.5ml of saturated sodium chloride. Samples were 
then centrifuged at 11,500g for 9 min (Hermle z233M-2 fixed angle rotor centrifuge, 
HERMLE Labortechnik GmbH, Wehingen, Germany) and supernatant was removed 
and added to a 15ml tube. 4ml of ethyl acetate was added and extraction was carried 
out with shaking for 10 minutes. The sample was centrifuged at 3220g for 4 minutes 
(Eppendorf 5810r swinging bucket rotor centrifuge, Eppendorf AG, Hamburg, 
Germany). Supernatant was transferred to a 5ml tube and evaporated to dryness 
under N2 at 50°C. A second similar extraction step was carried out and supernatant 
was added to corresponding 5ml tube from step 1. The residue was reconstituted 
with 200µL of mobile phase followed by vortexing for 1 minute.  
Samples were analysed using HPLC as per method described above with the addition 
of a cleaning step at the end of each run where a mobile phase consisting of 85% 
acetonitrile and 15% water was passed through the column for 5 minutes before re-
equilibrating the column with 60% acetonitrile and 40% water for a further 5 
minutes. The retention times of celecoxib and internal standard were approximately 
8.75 and 10.2 minutes respectively. 
Plasma standards were prepared by spiking 0.5mL of blank plasma with 50µL of 
appropriate concentration of celecoxib reference standard dissolved in acetonitrile. 
Plasma concentrations were determined by comparing celecoxib peak area to 
internal standard peak area. 
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Intravenous preparation 
An i.v. formulation was prepared based on a modification of a formulation used by 
Paulson et al. and Guzman et al. (Paulson et al., 2001, Guzman et al., 2007). Celecoxib 
solubility in varying concentrations of PEG-400 and ethanol mixed with normal saline 
was first determined.  
When a suitable solvent system was identified a formulation for i.v. administration 
was prepared by dissolving 0.5g of celecoxib in 10ml of solvent (60:20:20 PEG 
400/Ethanol/Saline). This preparation was then filtered using a 0.20µm PES 
membrane filter (Filtropur S 0.2, Sarstedt AG & Co., Nümbrecht, Germany) under 
aseptic conditions into a sterile vial and sealed. The final solvent system consisted of 
60% PEG 400, 20% ethanol and 20% physiological saline. The final formulation was 
assayed for celecoxib content by HPLC after appropriate dilution with acetonitrile to 
ensure no loss of drug on filtration. 
Oral bioavailability in pigs 
The study was carried out under licences issued by the Department of Health, Ireland 
as directed by the Cruelty to Animals Act, Ireland and EU Statutory Instruments. Local 
University ethical committee approval was also obtained. The study was a partially 
randomised three-way crossover design, where the pigs were randomly allocated to 
one of the two oral formulations on the first leg, followed by a crossover for the 
second leg. The final leg of the study involved an intravenous study on all pigs.  
Six male Landrace pigs (16.8–18.5kg, mean 17.5kg) were sourced locally and housed 
at the University’s Biological Services Unit. Pigs were fasted for 16 hours before 
experiments. On day 1, an indwelling intravenous catheter was inserted into the 
 
 
134 
 
jugular vein, under general anaesthesia as previously described (Griffin et al., 2014). 
Following an overnight fast on day 3, oral formulations were administered. 
Celebrex™ was delivered in its commercial capsule with the aid of a dosing gun after 
which the pigs received 50 mL of water via syringe. After dosing, pigs were returned 
to their pens. Blood samples (4mL) were collected at time zero (pre-dosing) and 0.5, 
1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12 and 24 hours post dosing. Water was 
available ad libitum throughout the study period and the animals were fed 8 hours 
post dose.   
For the intravenous treatment, animals were administered 100mg celecoxib by slow 
intravenous bolus injection of 2mls of a solution containing 50mg/ml fenofibrate in 
60% w/w PEG-400, 20% w/w ethanol and 20% w/w physiological saline into an ear 
vein.  Blood sampling was performed as outlined above, with additional blood 
samples taken at 0.25 and 0.75hr post dose.  All blood samples were collected in 
heparinised tubes (Sarstedt AG & Co, Germany) and immediately centrifuged at 
3220g for 5 minutes at 4°C (Eppendorf 5810r swinging bucket rotor centrifuge, 
Eppendorf AG, Hamburg, Germany).  Plasma was collected and stored at −80°C prior 
to analysis.  
A seven day washout period was observed between each leg of the study. One animal 
was lost to oral dosing due to loss of patency in the indwelling intravenous catheter 
over the course of the study. Another two animals were excluded from the 
intravenous leg of the study due to difficulties in cannulation of the ear vein for i.v. 
administration. 
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Pharmacokinetic Data Analysis 
Intravenous pharmacokinetic parameters were fitted to a one compartment model 
using the PKPlus module in Gastroplus™ (version 8.5, Simulations Plus, Lancaster, 
CA). The AUC for celecoxib was calculated using Prism (version 5, GraphPad Software 
Inc., La Jolla, Ca.). The peak plasma concentrations (Cmax) and the time for their 
occurrence (Tmax) were noted directly from the individual plasma concentration vs. 
time profiles. The Absolute Bioavailability (Fa) was calculated according to equation 
4-1 below:  
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.             (4-1) 
As i.v. data was only available for 3 animals the bioavailability was calculated by 
comparing the oral AUC for each animal to the mean i.v. AUC. 
All pharmacokinetic parameters are reported as mean ± SD, with the exception of 
Tmax, which is reported as median (range).  
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Results 
Validation of assay for quantification of celecoxib concentrations in plasma 
To ensure accurate and reproducible quantification of celecoxib from plasma both 
the assay and extraction procedure were validated. The limit of quantification for the 
in vitro assay was 20ng/ml and the method was linear in the range 20-2000 ng/ml. 
Calibration curves were considered linear when r2>0.99. Figure 4-1 contains a sample 
standard chromatogram, containing plasma spiked with both celecoxib and internal 
standard. Figure 4-1A contains the complete chromatogram, incorporating the wash 
step, while figure 4-1B contains an exploded view of the region of interest. Table 4-1 
contains analysis of intra- and inter-day assay variation form assay validation. In all 
cases variation was <5% confirming assay reproducibility. 
Concentration 
(ng/ml) 
Intra-day AUC Inter-day AUC 
  Mean 
Std. 
Dev. 
 % 
RSD 
Mean 
Std. 
Dev. 
% 
RSD 
2000 1007328 6971 0.69 1029572 31105 3.02 
1000 497703 2065 0.41 501178 5767 1.15 
500 199547 887 0.44 201419 966 0.48 
200 103024 829 0.80 103744 727 0.70 
100 51153 971 1.90 50698 281 0.55 
50 22903 388 1.69 22808 736 3.22 
20 11400 373 3.27 11322 349 3.08 
Table 4-1 Intra- and inter-day celecoxib assay validation (n=3) 
Table 4-2 displays data detailing recovery of both celecoxib and internal standard 
from each spiked plasma sample. In all cases recovery of celecoxib is >75%, while 
recovery of internal standard is >84%. The high recovery figures, coupled with low 
variation (standard deviation of 8% and 5% respectively) indicate a reliable and 
reproducible recovery. This was also demonstrated from the similarity in slope of the 
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between the lines of best fit for both calibration of in vitro standards (m = 509.12) 
and plasma standards (m = 472.26) with a difference of approximately 7%. The LOQ 
for plasma assay was 50ng/ml. 
 
 
Figure 4-1 Sample celecoxib standard chromatogram containing blank plasma spiked with celecoxib and internal 
standard. (A) complete chromatogram incorporating wash step. (B) Exploded view 
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Concentration 
(ng/ml) 
Celecoxib 
Recovery 
Internal 
Standard 
Recovery 
2000 0.943485311 0.961689 
1000 0.783124062 0.845516 
500 0.834282651 0.857017 
200 0.949426133 0.934266 
100 0.838927685 0.919651 
50 0.752158015 0.956941 
Average 0.850234 0.912513 
Std. Dev. 0.081289 0.049969 
Table 4-2 Recovery of celecoxib and internal standard from plasma standards 
Figure 4-2 displays data above standardised to recovery of internal standard for each 
sample by plotting the peak area ratio of celecoxib: internal standard as a function of 
concentration. This adjustment results in comparable calibration for both in vitro and 
plasma standards indicating that the peak area ratio of celecoxib: internal standard 
is an appropriate method to quantify plasma celecoxib concentrations from in vivo 
samples. 
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Figure 4-2 Celecoxib plasma extraction calibration (red line); comparison to in vitro standards (blue line); 
standardised for internal standard recovery 
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Biorelevant solubility and dissolution 
Solubility of celecoxib in biorelevant media was measured in order to assess the 
solubility at the site of absorption, allowing prediction of the likely limiting factor to 
oral absorption (Butler and Dressman, 2010, Augustijns et al., 2014). Celecoxib 
solubility was low in a fasted state representative medium (FaSSIF-V2) with an 
observed solubility of 8.638 ± 0.275 μg/ml, and increased to 99.076 ± 10.293 μg/ml 
in the fed state medium (FeSSIF-V2) (figure 4-3). The FeSSIF-V2/FaSSIF-V2 ratio 
demonstrates an 11.46 fold increase in solubility appears to be relatively comparable 
to previous studies examining the fed: fasted solubility ratio for celecoxib (Shono et 
al., 2009).  
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Figure 4-3 Biorelevant solubility of celecoxib in simulated intestinal media (mean ± SD, n=3) 
Subsequent to assessment of celecoxib biorelevant solubility, the dissolution of 
Celebrex™ in biorelevant media was evaluated in USP type II dissolution apparatus 
with 500ml of biorelevant media, in both FaSSIF-V2 and FeSSIF-V2 (figure 4-4). 
Dissolution from the Celebrex™ formulation appears to occur quite rapidly, reaching 
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plateau concentrations within 10 minutes for the fasted state medium and within 30 
minutes for the fed state medium. Moreover, the plateau concentrations reached 
reflect well the biorelevant solubility measurements observed for celecoxib in both 
the fasted and fed state media, with the kinetic solubility in FaSSIF-V2 only slightly 
greater than that previously determined (figures 4-3 and 4-4). However, it is worth 
noting that dissolution in both the fasted and fed state is incomplete with 
approximately 50% of the dose dissolved in the fed state, and only 6-7% of the dose 
dissolved in fasted state. These observations, coupled with the rapid dissolution, 
suggest solubility, rather than dissolution rate, hinders celecoxib absorption in vivo. 
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Figure 4-4 Biorelevant solubility of celecoxib and dissolution of Celebrex™ in simulated intestinal media (n = 3, 
mean ± SD) 
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Development of intravenous formulation of celecoxib  
In order to assess the absolute bioavailability and total extent of systemic absorption 
of celecoxib, an intravenous formulation for delivery of 100mg celecoxib was 
required. However, no clinically approved i.v. celecoxib formulation is available and 
this necessitated design of a suitable intravenous formulation. The intravenous 
vehicle used in the only other comparable studies of absolute bioavailability did not 
provide sufficient solubility to dissolve 100mg of celecoxib in an appropriate volume 
for administration (Guzman et al., 2007, Paulson et al., 2001). This necessitated use 
of a co-solvent parenteral vehicle. 
A formulation for intravenous administration was prepared based on equilibrium 
solubility in a three component solvent system consisting of PEG-400, ethanol and 
physiological (0.9%) saline using the following considerations; 
i) Ethanol concentration no greater than 20% based on previous in-house 
experience. 
ii) PEG-400 concentration no greater than 66% due to viscosity issues in 
administration. 
iii) Dose volume of no more than 3ml due to restrictions in administration in 
ear vein; ideal volume was considered 2ml. 
iv) Preference for 100mg dose to allow direct comparison between oral and 
i.v. formulation. 
Equilibrium solubility in a range of three-component solvent systems was 
determined and results are summarised in figure 4-5 below. Vehicle C was chosen 
based on having sufficient solubility for a 100mg dose in 2ml (50mg/ml; 
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approximately 62% loading). The celecoxib content of the i.v. formulation was 
assayed post filtration to ensure dose delivered was accurate. Analysis displayed that 
the mean 2ml dose was 94.31 ± 1.72mg. 
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Figure 4-5 Celecoxib equilibrium solubility in i.v. formulation media, Mean ± SD (n=3) 
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Oral pharmacokinetics in pigs 
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Figure 4-6 Mean celecoxib plasma concentration profile after oral administration of 100mg celecoxib as 
Celebrex™ Hard Capsules to fasted pigs (mean ± SEM, n=5)  
 
Figure 4-6 displays the mean plasma concentrations versus time profiles of after oral 
dosing of Celebrex™ to male landrace pigs in the fasted state. Absorption appears to 
be relatively rapid. With a median Tmax of 2.5 hours (range 2.5-5) and elimination is 
virtually complete at 12 hours, with negligible or non-quantifiable concentrations 
observed at 24 hours for all pigs. The maximal plasma concentrations (Cmax) and the 
time they occurred (Tmax) were observed directly from each individual profile and are 
summarised in table 4-3.  
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Intravenous pharmacokinetics and absolute bioavailability of celecoxib in pigs 
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Figure 4-7 Mean celecoxib plasma concentration profile on linear (A) and log transformed (B) scales after 
intravenous administration of 100mg celecoxib to fasted pigs (mean ± SEM, n = 3) 
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Figure 4-7 displays the mean plasma concentration in linear (A) and log transformed 
(B) plots for the pigs dosed with the intravenous formulation graphed against time.  
The log transformed i.v. data display excellent linearity (r2>0.9) indicating the in vivo 
data can be described using one compartment. The area under the curve (AUC) of 
the mean i.v. plasma profile was used to calculate the absolute bioavailability of 
celecoxib in the oral study leg using equation 4-1. Table 4-3 summarises these 
pharmacokinetic measurements from the oral and i.v. profiles.  
 
Intravenous Pharmacokinetic 
Parameters 
Oral Pharmacokinetic 
Parameters 
Vdss (L/kg) 0.7359 ± 0.095  Celebrex™ 
Kel (hr-1) 0.3878 ± 0.0697 Cmax (ng/ml) 3726.3 ± 2335.2 
Clearance 
(ml/min/kg) 
4.743 ± 0.974 
Tmax* 
(hours) 
2.5 (2.5-5) 
AUC0→24hrs  
(ng.h/ml) 
18536 ± 3105 
AUC0→24hrs 
(ng.h/ml) 
16539 ± 10274 
Fa0→24hrs 100% Fa0→24hrs 89.23% ± 55.43% 
Table 4-3 Pharmacokinetic parameters after intravenous administration of 100mg of celecoxib (mean ± SD, n=3) 
and oral administration of 100mg of celecoxib as Celebrex™ to fasted pigs (mean ± SD, n=5), *(median (range)) 
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Individual pig plasma concentrations 
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Figure 4-8 Individual celecoxib plasma concentration profile after oral administration of 100mg celecoxib as 
Celebrex™ Hard Capsules (blue squares) or as intravenous preparation (black triangles) to fasted pigs 
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Figure 4-8 displays the individual plasma concentration-time profiles for each pig in 
the current study, as summarised in figures 4-6 and 4-7. From animals involved in the 
current study, oral bioavailability data for Celebrex™ capsules is available for five 
pigs, while intravenous data is only available for three of these animals. For pigs 1 
and 3, the overall bioavailability of celecoxib from Celebrex™ appears to be 
substantially lower than that of the other pigs. Pig 4 also displays a significant lag 
time before appreciable levels of absorption are observed. Intravenous data appears 
to be more consistent for the three animals for which it is available. One point worth 
noting is the apparent secondary distribution phase observed with pig 5. This may be 
related to difficulties in cannulation of the ear vein observed in other animals and 
could potentially result from non-instantaneous perfusion from the site of 
administration. Observation of the individual profiles appears to confirm the 
observations of the mean profiles, with variable oral absorption but reduced 
variation in the intravenous dosing, indicating that the large variability may 
associated with pre-systemic, enteric processes.  
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Discussion 
Celecoxib, as a BCS class II compound, is anticipated to display either solubility and/or 
dissolution rate limited bioavailability in vivo. Early in vitro screening in the current 
study supports this hypothesis, with low celecoxib solubility and incomplete 
dissolution of Celebrex™ in biorelevant media (figures 4-3 and 4-4). The solubility and 
dissolution observed in fed state media vs. fasted state media further support the 
prediction of solubility-limited bioavailability, as the presence of solubilising species 
in the fed state medium considerably enhances the solubility and dissolution. These 
data suggest that celecoxib has potential as a model compound in the assessment of 
the ability of various bioenabling formulations to improve in vivo absorption, and 
indeed celecoxib has widely been utilised for this purpose previously (Laine et al., 
2016, Guzman et al., 2007, Nguyen et al., 2013, Subramanian et al., 2004, Rawat and 
Jain, 2004). As a BCS class II compound, it is also anticipated that celecoxib will 
demonstrate a significant positive food effect (Shono et al., 2009, Custodio et al., 
2008, Benet, 2013). This hypothesis is supported by the enhanced solubilisation and 
dissolution observed for celecoxib in vitro. Early in vitro screening, therefore, 
suggests that celecoxib may be a useful model for characterisation of bioenabling 
formulations and in assessment of in vivo models of food effect bioavailability.  
However, the extent of absorption of celecoxib in fasted state pigs seen here is higher 
and more variable than anticipated. A review of studies assessing celecoxib 
bioavailability in other species, namely dogs and humans, was conducted to provide 
further insights into and possible explanations for the current findings. The results of 
the studies assessed are summarised in table 4-4 and a detailed discussion of findings 
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of the current study, incorporating a comparison to these previously published 
results is provided in this discussion.  
The bioavailability of celecoxib from Celebrex™ in the current study is higher than 
expected (89% absolute bioavailability for Celebrex™), relative to that anticipated 
based on in vitro screening, or, indeed, relative to the only comparable single dose 
studies of absolute bioavailability (25 – 40% in dogs), as described in table 4-4 
(Paulson et al., 2001, Guzman et al., 2007). Near complete absorption suggests that 
bioavailability for the Celebrex™ formulation is not limited by solubility or dissolution 
rate in pigs. Bioenabling and dissolution enhancing formulations will, therefore, have 
limited efficacy in this case. Similarly, celecoxib does not appear to be a suitable 
candidate for assessment of food effect, as the large variability (CoV≈ 60%) will make 
it difficult to assess the moderate changes in bioavailability anticipated for a 
‘borderline’ food-effect drug, like celecoxib. A possible explanation for the extensive 
absorption is that Celebrex™ itself may, in fact, be formulated to achieve maximal 
bioavailability. Excipients in the Celebrex™ product include PVP and SLS and most 
likely reflect a wet granulation production process and can improve wettability, while 
the relatively low particle size of 25μm means that dissolution may be optimised in 
vivo (Laine et al., 2016, FDA, 1998, Pfizer Inc., 2000). This relatively refined 
formulation already shows near optimal absorption in pigs, and further formulation 
attempts aimed at enhancing dissolution may merely display enhanced in vitro 
dissolution, with poor correlation to in vivo analysis. 
A second factor to consider when analysing formulation performance is the high 
variation in the extent of bioavailability seen in this study. Celecoxib bioavailability 
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has previously been shown to be highly variable in multiple species. In fasted humans 
the coefficient of variation (CoV) in AUC has been shown to vary between 40-78%, 
while it reaches 40% in fasted dogs (table 4-4). High variability in oral absorption has 
also been observed in this study (CoV≈60% for Celebrex™), making it difficult to 
identify and quantify any true difference between formulations. 
The causes of such large variations in bioavailability not entirely clear, but differences 
in metabolism mediated by enzymatic polymorphism have been shown to have a 
significant effect on celecoxib pharmacokinetics and exposure. While significant 
interspecies metabolic differences for celecoxib exist, genetic variation has been 
shown to play a role in bioavailability in multiple species. In humans, CYP2C9 is the 
primary enzyme involved in celecoxib metabolism (Paulson et al., 1999, Gong et al., 
2012). Genetic variation in this enzyme reduces clearance and can more than double 
celecoxib exposure, with drug label warnings expressing caution in use of celecoxib 
in patients known to be poor 2C9 metabolisers owing to the risk of observing 
abnormally high plasma levels of celecoxib (Kirchheiner et al., 2003, Tang et al., 2001, 
Pfizer Inc., 2000). In such cases, using celecoxib at half the recommended lowest dose 
is advised. 
In dogs, while different enzymes are responsible for clearance (CYP2D family), 
genetic polymorphisms still result in altered metabolism and up to 2 fold differences 
in exposure when dosed Celebrex™.  While this goes some way toward explaining 
the variability in celecoxib exposure, even separation of dogs into different cohorts 
based on metabolism phenotype results in a CoV of 17-33% for animals dosed 
Celebrex™ (Paulson et al., 2001).  
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While, to our knowledge, the metabolism of celecoxib has not been assessed in the 
in vivo pig model or ex vivo in cultured porcine hepatocytes, such studies have been 
conducted with other Cyp2C9 substrates (Thörn et al., 2011). Of particular interest is 
the metabolism studies conducted with diclofenac, another NSAID which is 
principally metabolised by Cyp2C9 in humans (Brenner et al., 2003).  In vitro 
metabolism of diclofenac was virtually non-existent in pig liver microsomes relative 
to human microsomes, while quantification of mRNA has demonstrated low 
expression of CYP2C42 in pig liver, suggesting that the CYP2C family has low hepatic 
activity in pigs and that extrapolation of in vivo pharmacokinetics for its substrates is 
difficult (Thörn et al., 2011, Bogaards et al., 2000). The principle enzymes involved in 
celecoxib metabolism in pigs are unknown though it is possible that they may 
contribute to the high variability which makes detection of formulation absorption 
effects challenging. This theory is supported by comparing the variability in plasma 
concentrations observed in the oral, relative to the intravenous, leg of the current 
study. High variability (CoV≈60%) is observed in Celebrex™ oral bioavailability, while 
the variability in exposure is considerably lower in the i.v. study leg (CoV≈16%). This 
indicates that such large variability is principally associated with pre-systemic events, 
which may include absorption associated events such as dissolution and permeation, 
along with enteric and hepatic first pass metabolism.  
One potential limitation of this assessment is, however, the absence of intravenous 
data for pigs 1 and 3, which are the principle source of overall variability in the oral 
pharmacokinetics (figure 4-8). The individual profiles are presented here to highlight 
potential sources of the considerable variability in overall oral bioavailability. The 
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high variability observed in the oral plasma concentrations in the current study 
appears primarily attributable to these two individual pigs (pigs 1 and 3), which 
appear to display significantly lower overall bioavailability compared to other 
animals. These pigs received the Celebrex™ capsules in different study legs (pig 1 
received Celebrex™ in week 1, while pig 3 received Celebrex™ in week 2) and no 
anomalies were noted during dosing, suggesting administration is unlikely to be the 
primary source of variability in this case. It is worth noting that for both these pigs, 
difficulties in cannulation of the ear vein for i.v. administration, though how this 
would relate to overall bioavailability is unclear. The absence of i.v. data for pigs 1 
and 3 due to this inability to cannulate ear veins means limit our ability to 
conclusively relate these variable plasma concentrations to pre-systemic/ enteric 
effects, as there is no comparative i.v. data in animals which appear to display 
substantially lower plasma concentrations.   
While the extensive bioavailability and high variability contribute to limiting the 
suitability of celecoxib, and the Celebrex™ formulation in particular, as a model 
compound for the assessment of bioenabling formulations in pigs, discussion of 
whether this study accurately predicts the likely performance in humans is of merit. 
Inter-species variation in bioavailability, such as that seen here between pigs and 
dogs, is common. It is not always possible to determine which species most 
accurately reflects in vivo performance in humans. The dog model, however, has 
significant limitations in predicting celecoxib bioavailability in humans. In particular 
the shorter intestinal transit time (approximately half that of humans) may not 
provide adequate time for poorly soluble drugs to completely dissolve, which may 
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limit bioavailability (Sjogren et al., 2014). Dissolution plays a key role in determining 
the extent of celecoxib absorption in dogs, with significant increases in bioavailability 
when a solution is dosed and large fed state increases in bioavailability (Paulson et 
al., 2001). No similar significant food effect is seen in humans, suggesting extensive 
absorption already occurs in the fasted state (FDA, 1998, Shono et al., 2009). This 
indicates that solubility and dissolution may not play as critical a role in determining 
celecoxib exposure in humans as it does in dogs. The high levels of bioavailability in 
the fasted pig model may, therefore, more accurately reflect celecoxib bioavailability 
in humans. However, with no measure of absolute bioavailability in humans 
available, this cannot be stated with complete certainty. The results from the studies 
used in this discussion are summarised in table 4-4 below. 
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Table 4-4 Summary of published celecoxib food effect pharmacokinetic and bioavailability data (*concentrations originally reported as mcg/ml; converted to ng/ml for comparison) (EM; dogs 
phenotyped for extensive metabolism, PM; dogs phenotyped for poor metabolism, HFF; high fat fed, MFF; medium fat fed, LFF; low fat fed) 
Subjects Formulation Dose 
Food 
State 
n 
Cmax 
(ng/ml) 
Tmax 
(hours) 
AUC 
(ng.h/ml) 
Bioavailability 
(%) Comment Ref. 
     Mean CoV Mean CoV Mean CoV Mean CoV 
Human Celebrex™ 100mg 
Fasted 24 455 0.60 2.6 0.46 5127 0.78 - - High CoV, no 
significant food 
effect. 
(FDA, 1998) 
Fed 24 747 0.51 5 0.48 5419 0.71 - - 
Beagle 
dog 
(EM) 
Solution 
5mg/kg Fasted 
3 820 0.46 0.67 0.43 2630 0.38 63.7 0.27 
Significant 
differences in 
exposure depending 
on metabolism 
phenotype.  
Increase in 
bioavailability from 
solution compared 
to solid dosage 
forms.  
Higher variability 
with solid dosage 
forms.  
Neat chemical 
comparable to 
capsules in dogs. 
(Paulson et 
al., 2001)* 
Neat 
chemical 
6 230 0.53 1.5 0.32 950 0.85 21.7 0.60 
Capsule 6 280 0.17 1.3 0.18 970 0.25 24 0.17 
Beagle 
Dog 
(PM) 
Solution 
5mg/kg Fasted 
3 1320 0.03 0.5 0 10500 0.26 88.2 0.11 
Neat 
chemical 
6 580 0.63 3.3 1.26 4400 0.44 39.4 0.43 
Capsule 6 320 0.30 1.3 2.07 3000 0.24 27.2 0.33 
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Beagle 
dog 
(EM) 
Neat 
Chemical 
5mg/kg 
Fasted 3 230 0.30 1.5 0.34 1700 0.71 27.4 0.92 Significant food 
effects seen in dogs 
regardless of 
metabolism status.  
Bioavailability 
increases with 
increasing fat 
content and hence 
solubility.  
Difference in 
exposure seen with 
different metabolism 
phenotype. 
(Paulson et 
al., 2001)* 
LFF 3 670 0.59 3 0.28 4100 0.63 59.9 0.46 
MFF 3 580 0.41 5.3 0.22 4100 0.50 60.4 0.33 
HFF 3 660 0.28 4 0.51 5000 0.48 74.4 0.28 
Beagle 
Dog 
(PM) 
Neat 
Chemical 
5mg/kg 
Fasted 3 490 0.35 7.5 1.22 3900 0.17 42.2 0.20 
LFF 3 890 0.09 3.8 0.50 8100 0.14 87.5 0.18 
MFF 3 760 0.11 4.7 0.25 6300 0.08 67.9 0.06 
HFF 3 890 0.05 7.3 0.16 8800 0.09 93.7 0.02 
Human Celebrex™ 200mg 
Fasted 24 806 0.50 2.44 0.34 5994 0.39 - - 
High CoV, no 
significant food 
effect even with high 
fat meal and higher 
dose 
(Paulson et 
al., 2001) 
HFF 24 1042 0.34 3.42 0.37 7318 0.38 - - 
Dog Celebrex™ 5mg/kg Fasted 6 654 0.30 1.25 0.70 7663 0.41 40.1 0.38 Absolute 
bioavailability of 40% 
(Guzman et 
al., 2007) 
Pig Celebrex™ 100mg Fasted 5 3726 0.62 3.5 0.39 16539 0.62 89.23 0.62 
Absolute 
bioavailability of 
89.23% 
Large coefficient of 
variation 
This study 
 
 
Conclusion 
Biorelevant in vitro screening of celecoxib solubility and dissolution suggests that this 
BCS class II compound will display solubility limited oral absorption, poor 
bioavailability in the fasted state and a positive food-effect. This early screening 
initially suggests that celecoxib, would indeed be a good marker compound for 
assessment of bioenabling formulations and food-effect bioavailability. Oral dosing 
of the commercial Celebrex™ formulation in the fasted pig, however, displayed high, 
but variable oral bioavailability. The overall bioavailability of celecoxib in previous 
animal and human studies appears to be highly variable, while previous dog studies 
have not accurately predicted celecoxib pharmacokinetics in humans in terms of food 
effects. The pig model, while also variable, may more accurately reflect bioavailability 
of celecoxib in humans, though confirmatory studies to this end would be required. 
Overall, the results of the current study suggest that celecoxib would not be an 
appropriate model compound to screen the performance of bioenabling 
formulations or in the assessment of food-effect in the pig model.  
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Chapter 5 : The utility of a porcine model for predicting food 
dependent bioavailability: Case study with fenofibrate 
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Introduction 
The concomitant administration of oral dosage forms with food can have a significant 
impact on drug pharmacokinetics and bioavailability relative to the fasted state. With 
oral drug delivery continuing to be the method of choice for drug administration, 
understanding the effects food has on the biopharmaceutical aspects of drug delivery 
is key to the drug development process as well as the effective and rational use of 
medicines in the clinical setting (Fleisher et al., 1999, Abuhelwa et al., 2017).  
The intake of food has many and varied effects on drug absorption depending on 
drug and formulation characteristics, as well as the impact of physiological and 
physicochemical changes in the post-prandial GIT (Fleisher et al., 1999, Custodio et 
al., 2008, Gu et al., 2007, Abuhelwa et al., 2017, Lentz, 2008, Varum et al., 2013). This 
can either result from direct interaction of food components with the dosage form, 
or indirectly, with effects mediated by food-induced changes in gastrointestinal 
physiology or the physicochemical composition of gastrointestinal fluid. These 
physiological effects can include;  
1) Slower gastric emptying resulting in extended Tmax and a reduced Cmax 
2) Increase in gastrointestinal fluid volume, increasing the volume available for 
solubilization/dissolution 
3) Increased gastric pH, altering the solubility of ionisable compounds  
4) Increased secretion of biliary lipids (bile, cholesterol, phospholipids etc.) 
resulting in increased solubilisation for poorly soluble drugs 
5) Increased splanchnic blood flow, which can result in changes to drug 
metabolism 
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These effects can cause significant changes in drug absorption and bioavailability 
depending on the prandial state in which a drug is taken.  
The understanding of the effects food has on pharmacokinetics is consequently a 
critical factor in assessing the clinical potential of new medicines and designing a food 
effect resistant formulation early in drug development can both provide a 
commercial advantage and prevent costly reformulation later in the product 
lifecycle. Numerous challenges exist in the development of compounds which 
demonstrate a food effect, such as the potential for sub-therapeutic levels where a 
high-fat meal is required to increase absorption, unwanted side-effects where the 
bioavailability of a compound with a narrow therapeutic index is enhanced, or where 
a competitor holds a commercial advantage due to the absence of restrictions with 
regard to dosing with food (Lentz, 2008). Predicting the likelihood of a food effect 
and performing food effect bioavailability studies in early drug development is 
essential to provide a better understanding of the absorption process for a specific 
drug candidate, including what factors are critical to its absorption and anticipating 
the expected pharmacokinetic variability. Getting an early read on the anticipated 
food effect will also provide an opportunity to formulate away this effect and/or 
ensure that drug product labelling contains appropriate recommendations with 
regard to dose administration with food in the post-licensing environment (Mathias 
et al., 2015). 
Accordingly, the FDA have provided guidelines on how to design clinical trials to 
investigate food effects, recommending dosing in both fasted and fed states. The FDA 
guidance defines that a food-effect is established if the 90% confidence intervals for 
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the ratio of population geometric means, based on log-transformed data, for either 
AUC0→∞ or Cmax fall outside the 80-125% bioequivalence limits relative to the 
reference, i.e. the same formulation administered in the fasted stated (FDA, 2002). 
The fed state represents dosing post ingestion of a high fat, FDA standard breakfast, 
containing 800 – 1000 kcal with approximately 50% of total calories coming from fat, 
to maximise potential for demonstrating a food effect (FDA, 2002). While this 
regulatory guidance is essential when assessing the impact of food on absorption in 
the clinical setting, prediction of food effects is also important in drug development, 
where information is needed before initiation of the clinical program. 
The Biopharmaceutical Classification System (BCS) and Biopharmaceutical Drug 
Disposition Classification system (BDDCS) provide useful predictions of potential food 
effects based on drug physicochemical properties, as summarised in figure 5-1 (Wu 
and Benet, 2005, Amidon et al., 1995). The anticipated effects are predicted by the 
most likely limiting factor for bioavailability, namely solubility or dissolution for 
BCS/BDDCS class II compounds, permeability for class III compounds, or a 
combination thereof for BCS class IV compounds. An overall delay in Tmax and reduced 
Cmax for highly bioavailable compounds can be associated with a delayed gastric 
emptying (Custodio et al., 2008). While this tool does not capture all the potential 
effects of food and does not take formulation factors into account, it is the most 
widely utilised simple tool to predict food effect behaviour, and is estimated to be 
accurate in approximately 70% of cases (Benet, 2013). 
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Figure 5-1 Predicted effect of high fat meal on oral pharmacokinetics by BCS/BDDCS Class; adapted from 
Custodio et al. (2008) 
 
In order to provide a more accurate prediction of food effects a range of techniques 
have been developed including traditional in vitro dissolution apparatus in 
conjunction with biorelevant media which mimic the post-prandial  environment of 
the gastrointestinal tract (Kleberg et al., 2010, Nicolaides et al., 1999, Kalantzi et al., 
2006, Mathias et al., 2015, Baxevanis et al., 2016, Sunesen et al., 2005, Markopoulos 
et al., 2015). More advanced apparatus, such as dynamic gastrointestinal models 
have also been utilised to good effect, though the complexity and cost of these 
methods hinder their widespread utility (Brouwers et al., 2011, Lyng et al., 2016, 
Kostewicz et al., 2014b). The limitations of in vitro techniques in accurately reflecting 
the complexity of in vivo gastrointestinal environment physiology has led to the 
integration of these in vitro techniques with advanced in silico physiologically based 
pharmacokinetic (PBPK) models. These models vary significantly in design and in 
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complexity, but the overall aim is to combine molecule physicochemical and 
biopharmaceutical descriptors with data garnered from in vitro analysis, as well as in 
vivo factors such as gastrointestinal transit and luminal conditions, through the use 
of differential equations. These models have been widely utilised in recent years to 
analyse and predict in vivo food effects with varying degrees of success (Shono et al., 
2009, Otsuka et al., 2013, Jones et al., 2006, Fei et al., 2013, Pandey et al., 2014, 
Kostewicz et al., 2014a, Patel et al., 2014, Wagner et al., 2012, Shono et al., 2010). 
Despite the recent proliferation of in vitro and in silico techniques, the most 
commonly utilised pre-clinical approach to accurately anticipate food effect is the 
utilisation of in vivo bioavailability studies. To date, the most widely utilised animal 
model of food effect is the dog, despite the significant dietary and gastrointestinal 
anatomical and physiological differences relative to humans (Kararli, 1995, Lui et al., 
1986, Dressman, 1986, Sjogren et al., 2014). Lentz et al. (2007) have developed a 
protocol for conducting food effect studies in dogs comparing the Cmax and AUC in 
the fed and fasted state in dogs to that observed in humans. A range of nine 
compounds which displayed positive, negative and no food effects were investigated 
in this study and an optimal protocol involving pre-treating with pentagastrin and 
feeding of 50g of a homogenised FDA high fat, high caloric meal was identified. While 
this model was useful in identifying both positive and negative food effects, it was 
less useful in correctly identifying compounds which do not display any food effect 
(Lentz et al., 2007). This is an indication that dogs may be more sensitive to food 
effects than humans, a finding also identified elsewhere (Mathias et al., 2015). 
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In recent years, the pig has become increasingly popular in pre-clinical bioavailability 
studies owing to the perceived similarities in gastrointestinal anatomy and 
physiology between pigs and humans (Walters et al., 2011, Puccinelli et al., 2011, 
Suenderhauf and Parrott, 2013, Sjogren et al., 2014). Christiansen et al. (2015) have 
recently investigated the utility of the minipig as a model of food effect, using an 
approach similar to that of Lentz et al. (2007), utilising a homogenised FDA meal, as 
well as using a nutritional drink supplement, with both treatments applied both with 
and without pentagastrin. While their findings suggest that the use of pentagastrin 
is unnecessary in minipigs, and has an insignificant effect on absorption, overall the 
research demonstrates that the dog protocol cannot simply be transferred to 
minipigs, but requires further refinement (Christiansen et al., 2015). One of the 
challenges of the utility of the pig model is the apparent variability in gastric emptying 
which have been observedto , with values from as low as 1-2 hours to as high as 24 
hours reported in the literature for disintegrating tablets (Davis et al., 2001, Oberle 
and Das, 1994). Both Christiansen et al. (2015) and Henze et al. (2018a) co-
administered paracetamol (acetaminophen) with food, as a marker of gastric 
emptying rate, as it is rapidly absorbed upon entering the small intestine, but 
observed no difference in the fed and fasted groups, leading to the suggestion that 
the caloric content of the utilised meal was not high enough to delay gastric 
emptying. In light of the current research into the utility of the pig as a model of 
bioavailability, and specifically with regard to food effect, this study proposes to 
assess the utility of the landrace pig in such a scenario. 
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The aims of the current study were, firstly to assess the ability of a of the landrace 
pig in evaluating a proven positive food effect in humans using fenofibrate as a 
lipophilic marker BCS class II compound, and the FDA breakfast as a food source. The 
FDA breakfast is a common food source in such studies, consisting of high fat, high 
caloric meal designed to maximise the extent of food effect, particularly for poorly 
water soluble compounds. Secondly, standard pig feed was also investigated as an 
alternative food source, based on previous preliminary studies where significant 
quantities of residual food were observed post-mortem in ‘fasted’ pigs. A fed state 
incorporating pig pellet feed was, therefore, investigated in order to assess the 
potential impact of this residual food material. Thirdly, the effect of food on the 
pharmacokinetics of paracetamol is assessed, both as a marker of the gastric 
emptying rate in the fasted and fed states and as a comparator BCS class I compound. 
Significant increases are expected in both Cmax and bioavailability for the BCS class II 
compound fenofibrate in the fed state, while food is not expected to have any impact 
on the extent of paracetamol bioavailability as an immediate release BCS class I 
compound. Feeding is, however, anticipated to reduce the rate of absorption of the 
immediate release BCS class I compound, due to delayed gastric emptying, meaning 
paracetamol also acts as a useful indicator of gastric emptying. Finally, the effect of 
three different fasting regimens, as well as one fed state condition, on the 
gastrointestinal contents of pigs were evaluated in order to determine the ability of 
each regimen to ensure a complete fasted state and to elucidate the differences in 
gastrointestinal fluid characteristics in both the fasted and fed state. 
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Materials and methods 
Materials 
Paracetamol, 2-acetamidophenol and fenofibric acid were purchased from Sigma-
Aldrich (Ireland) Ltd. Fenofibrate was purchased from Kemprotec Ltd. (UK). Hard 
gelatin capsules (Size 0) were obtained from Capsugel (Coni-Snap®). Lipantil™ Micro 
67mg hard capsules and Paralief™ 500mg tablets were commercially sourced from 
local pharmacies. All food components used in preparing FDA recommended 
breakfast were purchased commercially. All other chemicals and solvents were of 
analytical grade or HPLC grade respectively and were purchased from Sigma–Aldrich 
(Ireland). 
Oral bioavailability in pigs 
The study was carried out under licences issued by the Health Products Regulatory 
Authority (HPRA), Ireland, as directed by the Cruelty to Animals Act, Ireland and EU 
Statutory Instruments (Licence number AE19130/P058). Local University ethical 
committee approval was also obtained. The study was a non-randomised, one 
sequence, three-way crossover design, where the pigs were dosed in the fasted state 
on week one, fed half a standard high-caloric, high-fat FDA breakfast (table 5-1) in 
week two and fed 175g pig weanling pellet feed in week three. The mass of FDA 
breakfast fed equated to approximately 18 – 20g/kg of body weight and was not 
adjusted for body weight. 
  
 166 
 
Table 5-1 Composition of high fat, high fat caloric meal fed to pigs in the current study 
Component Approximate 
weight (g) 
Approximate 
Total Calories 
(kcal) 
Approximate 
Calories from fat 
(kcal) 
One slice of bacon 30 70 53.9 
1 slice buttered 
toast 
45 100 27 
1 fried egg 60 92 64.4 
4oz (118ml) whole 
milk 
122.5 70 33.6 
2oz hashed brown 
potatoes 
57.5 112 45 
Total 315g 444 kcal 223.9 kcal 
 
Six male landrace pigs (15.7–17.3kg, mean 16.53kg) were sourced locally and housed 
individually at the University’s Biological Services Unit. Pigs were fed approximately 
175g of standard weanling pig pellet feed twice daily. The final feed was given 24 
hours prior to dosing. As part of the study design any remaining food was to be 
removed 16 hours before dosing, however no food remained at this point in any of 
the study legs.  
On day 1, an indwelling intravenous catheter was inserted into the jugular vein, 
under general anaesthesia as previously described (Faisal et al., 2013). Following an 
overnight fast on day 3, oral formulations of Lipantil® Micro 67mg hard gelatin 
capsules and Paralief™ 500mg tablets with the aid of a dosing gun, after which the 
pigs received 50mL of water via syringe. After dosing, pigs were returned to their 
pens. Blood samples (4mL) were collected at time zero (pre-dosing) and 0.5, 1, 1.5, 
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2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 24 hr post-dosing. Water was available ad libitum 
throughout the study period and the animals were fed with 175g of pig weanling 
pellet feed 8 hours post-dose. All blood samples were collected in heparinised tubes 
(Sarstedt, Germany) and immediately centrifuged at 3220g for 5 min at 4°C 
(Eppendorf 5810r swinging bucket rotor centrifuge, Eppendorf AG, Hamburg, 
Germany). Plasma was collected and stored at −80°C prior to analysis. 
A six-day washout period was observed between each leg of the study. All animals 
remained in good health throughout the study. However, problems arose with 
sampling via the indwelling cannula during the first week for three of the pigs, for 
one additional pig during week two of the trial and for one further additional pig 
during the third week. This means that three pigs completed the fasted leg of the 
study, two of which also completed the FDA meal leg, with a full crossover including 
the leg involving pig food only achieved in one individual pig. 
Pig fluid collection 
Upon completion of the pharmacokinetic study all animals were euthanized by 
intravenous injection of pentobarbital sodium followed by potassium chloride. The 
peritoneal cavity was exposed by midline incision and the stomach and small 
intestine were located and isolated. Occluding ligatures were applied proximal to the 
cardiac sphincter and distal to the pyloric sphincter and at the proximal and distal 
ends of the small intestine. Once both ends were secured, both the stomach and 
small intestine were removed from the peritoneal cavity. The luminal fluid was 
collected in sterile 50ml sample tubes and frozen. Thawed samples were 
subsequently homogenised using a T25 Ultra-Turrax® homogeniser (IKA®-Werke 
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GmbH & Co. KG, Germany) probe for 5 minutes at 200rpm. Samples were centrifuged 
at 3220g for 10 min at ambient temperature (Eppendorf 5810r swinging bucket rotor 
centrifuge, Eppendorf AG, Hamburg, Germany) to separate solid content from liquid 
content. Liquid supernatant was macroscopically observed to be free from solids and 
was removed and placed in 50ml sterile tubes. Solid content was measured using lab 
balances, while volume of liquid content was measured in a graduated cylinder. Fluid 
pH was measured using a calibrated Jenway 3510 pH meter. 
Differing dietary states were induced prior to euthanasia to assess the impact of 
varying fasting regimens on the remaining food in the gastrointestinal tract at time 
of dosing. This procedure was also carried out with pigs from previous studies 
conducted in this thesis (chapters two and four). The following feeding regimens 
were evaluated; 
A. 24 hour fast, once daily feeding (24 hour o.d.); Pigs fed approximately 500g 
of pellet feed once daily, with final feeding 24 hours prior to euthanasia (n=5; 
from study carried out in chapter four of this thesis) 
B. Fed state, twice daily feeding (4 hour b.d.); Pigs fed approximately 175g of 
pellet feed twice daily, final feeding consisted of 500g of pellet feed 
approximately 4 hours prior to euthanasia (n=3; current study) 
C. 16 hour fast, twice daily feeding (16 hour b.d.); Pigs fed approximately 175g 
of pellet feed twice daily, with final feeding 16 hours prior to euthanasia (n=3; 
current study) 
D. 24 hour fast, twice daily feeding (24 hour b.d.); Pigs fed approximately 175g 
of pellet feed twice daily, with final feeding 24 hours prior to dosing (n=6; 
from study carried out in chapter two of this thesis) 
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Quantitative analysis of fenofibrate 
The pharmacokinetic evaluation of fenofibrate was based on the quantification of 
fenofibric acid, the major active metabolite of fenofibrate, using a validated HPLC-
UV method, as previously described (Griffin et al., 2014). Briefly, 0.5ml plasma was 
spiked with 20μl of a sulindac 100μg/ml solution in methanol as an internal standard. 
Proteins were precipitated through addition of 0.5ml of 25% NaCl solution and 1ml 
of 1% H3PO4 in methanol with thorough mixing. Samples were centrifuged at 11,500g 
for 9 min (Hermle z233 M-2 fixed angle rotor centrifuge; HERMLE Labortechnik 
GmbH, Wehingen, Germany). The clear supernatants were injected onto a Synergi 
Fusion C18 reversed phase column (250 × 4.6mm, 4μm) (Phenomenex Inc., 
Macclesfield, UK) using an Agilent 1200 series HPLC system (Agilent Technologies, 
Santa Clara, CA, USA). The mobile phase consisted of 80% methanol: 20% water 
(adjusted to pH 2.5 with phosphoric acid) at a flow rate of 1ml/min, resulting in 
elution of fenofibric acid and fenofibrate at 6.5 and 10.5 min, respectively. UV 
detection was performed at 286nm. The analysis showed linearity over the range of 
50–2000ng/ml with an LOQ of 80ng/ml and extraction recoveries were ≥95%. 
Quantitative analysis of paracetamol 
The plasma concentrations of paracetamol were determined by a reversed-phase 
HPLC method. The HPLC system comprised an Agilent 1200 series compact HPLC 
equipped with a variable wavelength detector. A Synergi, C18 reversed phase column 
(250 × 4.6mm, 4μm) (Phenomenex Inc., Macclesfield, UK) column was used for the 
chromatographic separation. Mobile phase consisted of 0.1% w/v acetic acid: 
methanol (70:30 v/v) and was used at a flow rate of 1ml/min. The column 
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temperature was not controlled and the detection wavelength was set at 254nm. 
The retention time for paracetamol was approximately 6.5 minutes and for internal 
standard was 11 minutes. Due to the strong retention of fenofibric acid with this 
buffer/ column combination, a wash run was performed after every three sample 
runs. This was a 20 minute cleaning run with a gradient from 70% acetic acid and 30% 
methanol to 20% acetic acid and 80% methanol over five minutes. The system was 
held at this composition for five minutes before returning to the original gradient 
over five minutes and re-equilibrating the column at this gradient for five minutes.  
Paracetamol was extracted from the plasma samples by liquid-liquid extraction. 
100µl of plasma sample was transferred to a 1.5ml Eppendorf microcentrifuge tube. 
60mg sodium chloride, 10 µl internal standard (250 µg/ml, 2-acetamidophenol) were 
added to the tube. Sodium chloride was added to precipitate and denature protein 
before extraction. The tubes were mixed using a benchtop vortex. 1000µL of ethyl 
acetate was added to extract paracetamol. The tubes were shaken for 30 seconds 
using a vortex mixer followed by centrifugation at 11,500g for 9 min (Hermle z233M-
2 fixed angle rotor centrifuge, HERMLE Labortechnik GmbH, Wehingen, Germany) at 
ambient temperature. The supernatant was transferred to a round-bottom 
polypropylene vial and evaporated to dryness under a stream of nitrogen at 60°C. A 
second extraction step was carried out by adding 1000µL ethyl acetate to the 
precipitate containing tube, vortexing again for 30 seconds and centrifuging under 
similar conditions. The supernatant was transferred to the corresponding round-
bottom polypropylene vial from the previous step and evaporated to dryness under 
a stream of nitrogen at 60°C. The residue was dissolved in 100µl mobile phase and 
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20µl was injected into the column. The limit of quantification by this procedure was 
500ng/ml and the assay was linear between 500ng/ml and 15,000ng/ml. The 
extraction efficiency was greater than 89% across the concentration range. 
Pharmacokinetic data analysis 
The total exposure after oral administration was estimated by calculating AUC for 
fenofibric acid and for paracetamol using Prism (ver. 5, GraphPad Software Inc., La 
Jolla, Ca.). The peak plasma concentrations (Cmax) and the time for their occurrence 
(Tmax) were noted directly from the individual plasma concentration vs. time profiles. 
The Absolute Bioavailability (Fa) of fenofibrate was calculated according to equation 
5-1 below, using previously published intravenous data (O’Shea et al., 2015): 
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Fa ..
..
.             (5-1) 
All pharmacokinetic parameters are reported as mean ± SD, where possible, with the 
exception of Tmax, which is reported as median (range). Where the limited number of 
animals prohibited accurate estimation of the error associated with the mean due to 
loss of animals to the study, the pharmacokinetic parameters are presented as mean 
(range).  
Food effect was calculated using the fold difference (FD) in the AUC in fed vs the 
fasted state using equation 5-2: 
𝐹𝐷 = (
𝐴𝑈𝐶𝑓𝑒𝑑
𝐴𝑈𝐶𝑓𝑎𝑠𝑡𝑒𝑑
)                                    (5-2) 
Fold differences (FD) are presented, where possible, as mean FD ± standard error of 
the fold difference (SEFD) as calculated by equation 5-3: 
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𝑆𝐸𝐹𝐷 = 𝐹𝐷 × √
𝑆𝐸𝑓𝑒𝑑
2
𝐴𝑈𝐶𝑓𝑒𝑑
2 +
𝑆𝐸𝑓𝑎𝑠𝑡𝑒𝑑
2
𝐴𝑈𝐶𝑓𝑎𝑠𝑡𝑒𝑑
2           (5-3) 
Where FD is the mean fold difference in food effect, AUCfed and AUCfasted are the 
represent the mean AUC in the fed and fasted states and SEfed and SEfasted represent 
the standard errors corresponding to these values. In cases where insufficient sample 
size did not allow for calculation of a standard error, the FD is presented solely as the 
mean FD with no associated error. 
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Results 
Effect of food on oral pharmacokinetics of fenofibrate in pigs 
Figure 5-2 represents the plasma concentration profiles obtained following oral 
administration of 67mg fenofibrate as Lipantil® Micro to fasted pigs (n=3, mean ± 
range), pigs fed with half of a high-fat, high-caloric FDA standard breakfast, as 
described in table 5-1, 30 minutes prior to dosing (n=2, mean ± range) and pigs fed 
standard pig food (175g) 30 minutes prior to dosing (n=1). Absorption of fenofibrate 
in the fasted state begins rapidly, with detectable plasma concentrations of fenofibric 
acid observed as early as 30 minutes, relative to pigs fed the FDA meal, which displays 
an initial lag of 2.5 hours before quantifiable concentrations are observed. Dosing 
following pig food appears to significantly delay fenofibrate absorption. Drug levels 
in plasma were below the limit of quantification for 8 hours post dose, and the 
maximal observed concentration occurs at 24 hours. Given that highest observed 
concentration occurs at the final sampling time-point, accurate determination of 
AUC, Cmax or Tmax was not feasible in this case.  
 174 
 
0 5 10 15 20
0
500
1000
1500
2000
Fasted
FDA Breakfast
Pig Food
Time (hours)
F
e
n
o
fi
b
ri
c
 A
c
id
 P
la
s
m
a
 C
o
n
c
 (
n
g
/m
l)
 
Figure 5-2 Plasma concentration of fenofibric acid vs. time profiles after oral administration of 67 mg fenofibrate 
as Lipantil® Micro, (■) indicates fasted state (n=3, mean ± range), (▴) indicates fed half FDA standard breakfast 
(n=2, mean ± range), (●) indicates fed 175g weanling pellet feed (n=1). 
 
The key pharmacokinetic parameters for fenofibric acid are summarised in figure 5-
3 and table 5-2. Absolute bioavailability has been calculated from i.v. data previously 
published from a similar study (Griffin et al., 2014, O’Shea et al., 2015). The data from 
the standard pig feed leg of the study has been omitted from this summary due to 
the difficulty in calculating accurate pharmacokinetic data when the final sampling 
time-point corresponds to the observed Tmax. For the animals dosed 30 minutes 
following intake of a high fat breakfast there appears to be slight reductions in both 
Cmax and overall bioavailability. The mean observed Cmax in the fasted state of 
1489.29ng/ml reduced to 1143.72ng/ml in animals fed the FDA breakfast, while the 
overall bioavailability reduced from an average of 38.81% to 25.08% (table 5-2). Both 
these values are substantially lower than that reported in a similar study carried out 
with Lipantil® Micro in the fasted state, where a mean (±SD) Cmax of 2691.35 ± 
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728.01ng/ml and overall bioavailability of 66.1 ± 3.5% were observed (chapter three 
of this thesis). The Tmax, however, in both studies seem to correspond well, with 
prolonged absorption observed in the fasted state, and with two of the three animals 
demonstrating a Tmax which occurs after feeding at 8 hours in the current study. 
Partial AUC analysis, up to 8 hours post dose was also carried out in order to analyse 
if there was any difference in the rate of absorption, similar to the partial AUC 
analysis carried out in chapter three.  A similar trend was noted in comparing fasted 
to fed data at both 8 hours and 24 hours, where a slight reduction in mean AUC in 
the fed state (4857 ng.h/ml) was observed relative to the fasted state (6268 ng.h/ml), 
a similar ratio to that of overall bioavailability. Thus, while an initial lag is observed in 
the fed state, it does not appear to have had a significant impact on either the rate 
or extent of bioavailability, relative to the fasted state.  
The limited number of animals remaining at the end of this study prohibits the use 
of statistical tests of significance, however trends in both animals which have 
completed the current crossover follow that of the mean data. This observation runs 
contrary to the expected result, where fenofibrate bioavailability would be expected 
to increase in the fed state. This does, however, correspond to the lack of a 
consistently observed significant food effect for either atazanavir (expected positive 
food effect) or pravastatin (expected negative food effect) in a comparable food 
effect study carried out in minipigs (Christiansen et al., 2015). 
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Figure 5-3 Bioavailability at 24 hours (A) and Cmax (B) of fenofibrate from Lipantil® Micro 67mg in fasted (n=3, 
mean ± range) and FDA breakfast fed pigs (n=2, mean ± range) 
 
 
Table 5-2 Summary of pharmacokinetic parameters after intravenous administration of 25mg of fenofibrate to 
fasted pigs (mean ± SD, n = 4) and after oral administration of 67mg of fenofibrate as Lipantil® Micro to fasted 
pigs (n=3, mean (range)) and to pigs fed FDA breakfast (n = 2, mean (range))  
a Intravenous data reproduced from O’Shea et al. (2015) 
b Median (range) 
c No range – both Tmax occurred at 6 hours 
Intravenous 
pharmacokinetic 
Parametersa 
Oral pharmacokinetic parameters 
Vc (L/kg) 0.345 ± 
0.02504 
 Fasted FDA Breakfast 
Kel (hr-1) 0.221 ± 
0.064428 
Cmax (ng/mL) 1489.29  
(884.44 – 2012.53) 
1143.72 
(1094.42 – 1193.03) 
Kel (hr-1) 0.099 ± 
0.038687 
Tmax (hours)b 10 
(6 – 10) 
6c 
Kel (hr-1) 0.35125 ± 
0.241289 
Bioavailability 
(%) 
38.81 
(29.16 – 45.20) 
25.08 
(24.72 – 25.44) 
AUC0→24hrs 
(ng.h/ml) 
18382 ± 
4591 
AUC0→24hrs 
(ng.h/ml) 
19109 
(14356 – 22254) 
12350 
(12173 – 12527) 
  AUC0→8hrs 
(ng.h/ml) 
6268 
(4572 – 8162) 
4857 
(4416 – 5297) 
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Effect of food on oral pharmacokinetics of paracetamol in pigs 
In the current study, paracetamol was co-administered with fenofibrate in order to 
both act as a control compound, which is not expected to display a significant change 
in overall bioavailability when taken with food and to provide an estimate of gastric 
emptying and the impact of food on this dynamic physiological process. Paracetamol 
is rapidly absorbed on entry into the small intestine and has widely been used as a 
marker of gastric emptying, with Tmax corresponding to approximately 50% gastric 
emptying (Christiansen et al., 2015, Medhus et al., 2001). Figure 5-4 represents the 
plasma concentration-time profile for paracetamol in pigs dosed in the fasted state, 
as well as pigs fed with either the FDA breakfast or standard pig feed. As can be 
observed from the plasma profiles, absorption occurs quite rapidly, with no 
significant lag time observed for any of the feeding regimens. There appears to be a 
slight trend towards lower overall absorption in both the fed state regimens, though 
as with the fenofibrate leg of the current study, the limited numbers prohibit tests of 
statistical significance. 
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Figure 5-4 Plasma concentration of paracetamol vs. time profiles after oral administration of Paralief® 500mg 
tablets, (■) indicates fasted state (n=3, mean ± range), (▴) indicates fed half FDA standard breakfast (n=2, mean 
± range), (●) indicates fed 175g weanling pellet feed (n=1). 
 
Figure 5-5 and table 5-3 summarise the oral pharmacokinetics of paracetamol after 
oral administration of Paralief® 500mg tablets in the fasted and in both fed states. 
There appears to be a slight trend towards lower overall absorption of paracetamol 
in the fed studies. This appears to be more substantial with regard to Cmax rather than 
overall AUC. This is a trend often observed for immediate release preparations in the 
fed state, where a reduced Cmax is observed due to reduced absorption rate, 
indicating some promise in the ability of the pig food effect model to discriminate 
between fasted and fed performance for BCS class I compounds. However, this is not 
corroborated by a prolonged Tmax, with all values lying in the range of 2-3 hours for 
all pigs in all treatments. While longer than the typical gastric emptying rate of less 
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than 30 minutes in fasted humans, the gastric emptying rate observed in this study 
in landrace pigs appears to be quicker and less variable than that previously reported 
(Sjogren et al., 2014, Davis et al., 2001). Of particular interest is that the delayed 
absorption of fenofibrate observed when administered with pig food (figure 5-2) is 
not replicated in the absorption of paracetamol and Tmax has not been affected by 
feeding standard pig pellet feed, as had been observed for fenofibrate. 
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Figure 5-5 Bioavailability at 24 hours (A) and Cmax (B) of paracetamol from Paralief® 500mg tablets in fasted 
(n=3, mean ± range), FDA breakfast fed pigs (n=2, mean ± range) and following 175g weanling pellet feed (n=1) 
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Table 5-3 Summary of pharmacokinetic parameters after oral administration of paracetamol as Paralief® 500mg 
tablets to fasted pigs (n=3, mean (range)), and to pigs fed FDA breakfast (n = 2, mean (range)) or 175g weanling 
pellet feed (n=1) 
a median (range) 
Oral pharmacokinetic parameters 
 Fasted FDA Breakfast Pig Food 
Cmax (ng/mL) 11449 
(8281 – 14331) 
9646 
(6226 – 13066) 
7110 
Tmax (hours)a 3 
(2-3) 
2.5 
(2-3) 
3 
AUC0→24hrs 
(ng.h/ml) 
74248 
(68042 – 80353) 
65735 
(36343 – 95127) 
60375 
 
Effect of feeding regimen on gastric emptying  
In order to assess the effect of the varying fasting regimens, and to compare the 
characteristics of both fasted and fed state gastrointestinal contents post mortem 
sampling of the gastrointestinal contents was performed. Based on results of 
previous studies where a 16 hour fast was insufficient to ensure complete emptying 
of gastric contents, the ability of various fasting regimens to generate a truly ‘fasted 
state’ was assessed. Results of post-mortem assessment of pig gastrointestinal 
contents are summarised in table 5-4 and visualised in figure 5-6. Generating a fed 
state by providing daily food requirement as a single feed prior to euthanasia and 
sampling of contents led to a large increase in both solid and liquid content in both 
the stomach and small intestine (4 hour b.d.), which was accompanied with 
somewhat of a buffering effect on gastric pH. The rise of gastric pH, however, is 
perhaps not as substantial as would be predicted, given the volume of food present 
in the stomach. 
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It is the effect of different fasting regimens on the day prior to euthanasia, however, 
which are most notable. Despite being last fasted for almost 24 hours, feeding a large 
volume of pellet feed the day before analysis led to significant volumes of fluid and 
solid content in both the stomach and small intestine (24 hour o.d.). The analysis also 
revealed a high level of variability, with two of the five animals displaying virtually 
empty stomachs, while up to 199g of solid content was observed in one animal. There 
was also a noticeable trend for pH increases with increasing solid content most likely 
due to the buffering effect of remaining food material.  
In order to ensure a completely fasted state was achieved prior to dosing in future 
studies a range of other fasting regimens were investigated. Feeding regimens 
consisting of two smaller meals, rather than one large meal were trialled, involving 
feeding 175g of pellet feed twice daily. The reduced quantity of food fed 24 hours 
prior to sampling appears to be sufficient to induce a fasted state, with only very 
small levels of solid content observed in the stomach (max 3.09g) and small intestine 
(max 6.13g) (24 hour b.d.). When the final feed was given 16 hours prior to sampling 
there appears to be more inconsistency with regard to the presence of remaining 
food, with up to 60g of solid content observed in the stomach, and 94g in the small 
intestine, indicating that a 16 hour fast is insufficient to induce a complete fasted 
state (16 hour b.d.). However, no significant effects were determined between the 
feeding regimens as the current study was not sufficiently powered to observe a 
significant effect considering the variability in gastrointestinal contents.  
  
 
 
Table 5-4 Post-mortem assessment of pig gastrointestinal contents; all parameters reported as median (range) 
24 hour o.d. (n=5); 500g pellet feed once daily; last feed 24 hours prior to euthanasia 
4 hour b.d. (n=3) 175g pellet feed twice daily; fed 500g pellet feed 4 hours prior to euthanasia 
16 hour b.d. (n=3) 175g pellet feed twice daily; last feed 16 hours prior to euthanasia 
24 hour b.d. (n=6), 175g pellet feed twice daily; last feed 24 hours prior to euthanasia 
 
Stomach Small Intestine 
Feeding 
regimen 
Fluid Volume 
(ml) 
Solid Content 
(g) 
pH 
Fluid Volume 
(ml) 
Solid Content (g) pH 
24 hour o.d. 
56 
(30–220) 
22.47 
(2.58–199.26) 
2.25 
(2 – 4.79) 
99 
(34 – 156) 
72.39 
(13.66 – 102.9) 
7.26 
(7 – 7.52) 
4 hour b.d. 
221 
(85–269) 
357.91  
(191.83–446.55) 
3.44 
(3.14 – 
3.91) 
351 
(127 – 454) 
213.15 
(174.93 – 279.76) 
5.9 
(5.26 – 6.73) 
16 hour b.d. 
43 
(30–88) 
9.00 
(4.10–59.91) 
3.1 
(1.81 – 3.4) 
185 
(130 – 245) 
10.56 
(10.26 – 93.88) 
6.31 
(6.29 – 6.75) 
24 hour b.d. 
29.5  
(23–55) 
1.76  
(0.96–3.09) 
2.205 
(2.05 – 3.4) 
93 
(41 – 168) 
4.005 
(1.31 – 6.13) 
7.68 
(7.41 – 7.81) 
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Figure 5-6 Scatter dot plot of post-mortem assessment of pig gastrointestinal contents; line at median  
24 hour o.d. (n=5); 500g pellet feed once daily; last feed 24 hours prior to euthanasia 
4 hour b.d. (n=3) 175g pellet feed twice daily; fed 500g pellet feed 4 hours prior to euthanasia 
16 hour b.d. (n=3) 175g pellet feed twice daily; last feed 16 hours prior to euthanasia 
24 hour b.d. (n=6), 175g pellet feed twice daily; last feed 24 hours prior to euthanasia 
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Discussion 
Effect of food on fenofibrate bioavailability in pigs 
The primary aim of the current work was to evaluate the utility of the pig model to 
predict food effects on oral bioavailability in vivo. To date, the most commonly used 
preclinical food effect model has been the dog, and Lentz et al. (2006) have 
developed a food effect model in beagle dogs based on feeding a 50g aliquot of a 
homogenised FDA high-fat meal which provided a close qualitative agreement to 
human data. However, given that canine gastric pH is considered to be, on average, 
higher and more variable than humans, dogs must be pre-treated with pentagastrin 
to simulate the lower gastric pH conditions of humans. In their study, Lentz et al. 
demonstrated that both the type and quantity of food are critical, with a specialised 
high-fat dog meal proving ineffective in inducing a positive food effect and 100g high-
fat FDA meal over-predicting the human food effect. This model has been further 
used and adapted, proving useful in assessing food effect in vivo, with greater success 
in qualitative rather than quantitative predictions and a general trend towards over-
prediction of human food effects in dog models (Mathias et al., 2015, Zane et al., 
2014).  
With the growing popularity of the pig as a pre-clinical animal model, Christiansen et 
al. subsequently adapted this food-effect protocol for use in Göttingen minipigs 
(Christiansen et al., 2015). In their study, Christiansen et al. investigated the effects 
of both pentagastrin pre-treatment and the type and amount of food on in vivo food 
effects in Göttingen minipigs. However, no significant food effects were observed for 
compounds exhibiting either a positive (atazanavir) or negative (pravastatin) food 
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effect in their study. It is in the context of the analysis of this study that the current 
protocol was designed and investigated.  
In this previous study, the effects of feeding a homogenised FDA breakfast at two 
different volumes, 5g/kg bodyweight and 10g/kg bodyweight, as well as the potential 
for replacing the food with Fresubin® liquid energy drink. A key outcome from this 
study was to suggest that in order to improve the function of a pig model of food 
effect there was both a need for higher caloric and more viscous meals, while also 
persisting with the FDA breakfast as a food source due to its tendency to predict a 
positive food effect for atazanavir (Christiansen et al., 2015). Therefore, in the 
current study the design for assessment of positive food effect in pigs it was decided 
to use the FDA meal in increased quantities in landrace pigs. The current study uses 
a fixed volume of food, at half the volume used in human food effect studies, as 
described in table 5-1. This results in an approximate doubling of food relative to 
previous studies in minipigs (mean 19g food /kg bodyweight; range 18.2 – 20.1g) with 
the intention of maximising the potential for observing positive food effects. The 
effect of pig food on bioavailability was also assessed, and while the rate of 
absorption of fenofibrate appeared to be reduced somewhat, detailed analysis of the 
data was not feasible in this case, as the highest observed plasma concentration 
occurred at the Tlast, meaning determination of AUC, Cmax or Tmax was not possible. 
Interestingly a similar observation has been made in a food effect study in mini-pigs 
using atazanavir as a model compound for positive food effect, with the final (24hr) 
time-point corresponding to Tmax for at least one animal in each of a range dosing 
regimens (Christiansen et al., 2015). 
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Fenofibrate displays a formulation dependent, positive food effect in humans, with 
approximately 35% - 50% increase in bioavailability from Lipantil® Micro in humans 
in the fed state, dependent on composition of a meal, and in particular the fat 
content, with even greater increases in Cmax (Guivarc'h et al., 2004, Guichard and 
Sauron, 1993, Ling et al., 2013). The current studies main aim was to assess whether 
this can be emulated in a pig food effect model. As can be seen from the results, in 
figures 5-2 and 5-3 and table 5-2, there was no significant difference in food effect 
between the fasted and FDA breakfast fed legs of the current study, and in fact with 
a trend towards a negative food effect in the fed state. It appears that FDA breakfast 
fed pigs do not demonstrate solubility and dissolution enhancing effects that 
promote absorption of fenofibrate. Further characterisation is required to assess the 
physiological and physicochemical environment in the fed state pig, and in particular 
the effects of different meal composition on the post-prandial pig gastrointestinal 
environment. Specifically, the effect of varying quantities of an FDA high fat breakfast 
on the gastrointestinal environment will provide an insight into the lack of a food 
effect observed both here and previously (Christiansen et al., 2015). It seems 
plausible, based on the lack of an observed food effect on the extent of fenofibrate 
absorption and on gastric emptying, that the current meal caloric content and 
volume is too small to induce a response.  
A comparison of the food effect between humans and in pigs, as described by the 
fold differences in bioavailability in the fed and fasted state, is presented in figure 5-
7. There is a poor correlation between fenofibrate food effects in humans and pigs. 
The results in the current study further demonstrate the limitations of a pig model of 
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food effect, as despite the increased food volume relative to previous studies, no 
significant food effects were demonstrated. 
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Figure 5-7 Lipantil® Micro food effect expressed as fold difference in AUCfed/AUCfasted  
Human low fat fed extracted from (Guivarc'h et al., 2004) 
Human high fat fed extracted from (Guichard and Sauron, 1993) 
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Effect of food on paracetamol absorption and gastric emptying 
A secondary objective of the current study was assessment of gastric emptying in fed 
and fasted pigs, using paracetamol as a marker. Henze et al. (2018a) and Christiansen 
et al. (2015) have previously used this approach to address the general disagreement 
in the literature regarding the gastric emptying rate in pigs, and the effect of food on 
gastric emptying. While in their studies, Göttingen minipigs rather than Landrace pigs 
were used, a similar trend to the current study, where no significant changes in 
paracetamol Tmax was observed between fasted and fed states. Gastric emptying is 
anticipated to slow post-prandially, with larger effects seen with increasing caloric 
density and increasing volume of ingested food (Abuhelwa et al., 2016b, Hunt and 
Stubbs, 1975). In the current study, there is no significant differences in the gastric 
emptying rates in pigs fed the FDA breakfast, nor with the pellet feed, as assessed by 
paracetamol Tmax. The gastric transit observed in fasted pigs (2-3 hours) in the current 
study is longer than that observed in humans in the fasted state of less than 0.5 hours 
(Sjogren et al., 2014, Abuhelwa et al., 2016b). Though the current sample size is small, 
there is less variation in gastric emptying than has previously been reported in pigs 
(Christiansen et al., 2015, Suenderhauf et al., 2014, Suenderhauf and Parrott, 2013, 
Oberle and Das, 1994, Davis et al., 2001, Henze et al., 2018a).  
This longer gastric transit in pigs relative to that in humans may contribute to the 
delayed Tmax observed for fenofibrate (6 – 10 hours) in this and previous studies, 
compared to clinical, human data (Guivarc'h et al., 2004, O’Shea et al., 2015). 
However, this does not fully account for the delayed and reduced absorption of 
fenofibrate when administered with pellet feed. Despite similar gastric emptying 
rates being observed for paracetamol in pellet fed pigs relative to fasted and FDA 
 189 
 
breakfast fed groups, there is substantial changes in fenofibrate absorption, with 
appreciable levels of absorption only observed at 24 hours, which corresponds to Tlast 
of the current study. Thus, it appears that drug and/or formulation dependent 
inhibition of gastrointestinal absorptive and/or transit processes are observed in 
pellet fed pigs. The rate and extent of fenofibrate absorption in pellet fed pigs is 
significantly different to that observed in pigs fed the FDA breakfast, while absorption 
of paracetamol in these two groups appears to be quite consistent. This emphasizes 
the importance of having completely fasted pigs in fasted state studies, and also 
demonstrates the limitations of implementing a food effect study utilising standard 
pig feed as formulation dependent variation can occur. A similar limitation was 
observed when utilising a dog specific high fat diet, and supports the continued use 
of an FDA breakfast, or similar, in pre-clinical food effect models (Lentz et al., 2007, 
Christiansen et al., 2015). 
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Effect of feeding regimen on gastrointestinal contents 
An area of particular concern and a significant limitation of pig models of absorption, 
particularly with regard to fasted state bioavailability studies, which has become 
apparent in recent years is the current inability to ensure a true fasted state prior to 
study commencement (Christiansen et al., 2015, Suenderhauf et al., 2014). Recently 
a potential limitation of the utility of the pig, and specifically the minipig, in 
assessment of bioavailability has been identified as that of incomplete food emptying 
depending on the fasting protocol utilised (Suenderhauf et al., 2014). This has been 
suggested to be one potential cause for the longer gastric transit time observed, 
relative to humans. In their study, Suenderhauf et al. (2014) observed that despite a 
12 hour fast, pigs fed a pellet diet the day before dosing retained a significant amount 
of food in the stomach. This is a potential limitation where a fasted study protocol is 
required, and was overcome by feeding a liquid meal the day before dosing or by pre-
treating with i.m. metoclopramide, a pro-kinetic agent, though such a 
pharmacological intervention may limit the applicability of a model designed to 
investigate the effect of food on absorption, where altered gastric transit is a 
significant variable of interest (Suenderhauf et al., 2014). 
A similar concern arose rather serendipitously during the conduct of the studies 
outlined in the current thesis, when during a post-mortem examination of a ‘fasted’ 
pig, the stomach was found to contain a substantial volume of solid material. This led 
to the design of the current study to assess the effects of different fasting regimens 
on stomach contents. As with the previous analysis carried out by Suenderhauf et al. 
(2013), it was observed that even a fast of up to 20 hours was insufficient to ensure 
complete emptying of gastric contents when a large feed volume is given (24 hour 
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o.d.; figure 5-6). It appears that the emptying is inherently variable and complete 
emptying cannot be assured. Anecdotal observations of feeding habits pointed to a 
tendency for animals to gorge on the available feed volume before becoming 
sedentary and docile post-prandially. This led to the suggestion to restrict the feed 
to a smaller volume twice daily, with the aim to keep pigs more mobile, promoting 
gastric motility, and potentially stimulating the gastroileal reflex and promoting 
gastrointestinal transit. In this regimen the final feed was given 24 hours prior to 
dosing. When adopting this feeding regimen, all animals analysed post mortem had 
insignificant levels of solid content in either the stomach or small intestine, with a 
trend towards reduced stomach fluid content and similar intestinal fluid content. 
There also appeared to be a trend toward increased stomach acidity, with a 
corresponding increase in small intestinal pH (24 hour b.d.; figure 5-6). All this data 
correlates well with the expected result when moving from a ‘fed’ to a ‘fasted’ state, 
suggesting the modified feeding regimen was adequate to ensure a completely 
fasted state. 
The twice-daily feeding regimen was further investigated, to assess whether it was 
the multiple daily feedings or the reduced food provided on the day prior to dosing 
that ensured a completely fasted state. In this regimen, a second feed on the day 
prior to analysis was provided 16 hours prior to euthanasia. Of the three pigs 
analysed, one demonstrated appreciable levels of solid material in both the stomach 
and small intestine (16 hour b.d.; figure 5-6), suggesting that fasting cannot be 
ensured when feeding the evening prior to dosing. 
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Finally, pigs were analysed in a fed state to compare the stomach contents to that in 
the original feeding regimen in order to assess how closely the original ‘fasted’ state 
resembled a true fed state (4 hour b.d., figure 5-6). Unsurprisingly, there is a far 
greater volume of both solid and liquid intestinal contents in the fed pigs. However, 
it is noteworthy that the upper limits of the ‘fasted’ regimen are comparable to the 
lower limits of the fed regimen, suggesting that, in at least some instances, what was 
thought to be fasted pig may at least have been in a semi-prandial state. The 
variability in gastric contents, in particular, has the potential to cause variable 
gastrointestinal transit and absorption. Thus, it appears necessary to carefully design, 
not only the fed state aspect of a food effect study in pigs, but due consideration 
must also be given to ensure adequate fasting. 
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Conclusion 
In conclusion, the current study demonstrates continued limitations in the 
assessment of food effect in the pig model. Despite attempting to address some of 
the issues previously encountered in similar studies, the current protocol is not 
effective at inducing a food effect for fenofibrate. It appears that the current meal 
volume and caloric content is insufficient to cause an increase in solubilisation. This 
is further supported by the lack of a delayed gastric transit in fed pigs, as 
demonstrated by the similar Tmax and Cmax values for paracetamol in the fasted and 
fed state. Further optimisation of this model is necessary in order to use pigs to 
predict food effects in humans. Specifically, the effects of varying fed regimens with 
regard to the meal composition and quantity, the characterisation of pig 
gastrointestinal physiology, in particular gastric transit, and the physicochemical 
properties of intestinal contents with varying quantities of food are priorities. These 
measures will be useful in providing a mechanistic understanding for the lack of an 
observed food effect in the current and similar studies. 
The current study does, however, provide useful insights into definition of effective 
fasting protocols. This study has demonstrated that the presence of food leads to 
unpredictable responses in drug absorption in pigs, therefore it is critical to ensure 
that all fasted studies in pigs are appropriately defined. The data presented here 
demonstrate that that feeding smaller volumes twice daily and providing a final feed 
24 hours prior to dosing is an effective approach to ensure a fasted state. The 
implementation of such a fasting regimen is crucial to the performance of future pig 
models of bioavailability and food-effect. 
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Chapter 6 : General discussion 
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Overview and Summary 
It is widely recognised that R&D productivity in terms of bringing new licensed 
medicines to market has consistently decreased, with the number of new medicines 
approved per $1 billion R&D invested decreasing by 50% every nine years since the 
1950s (Scannell et al., 2012). One of the key challenges in the development of new 
oral medicines is that most emerging drug molecules display poor solubility, leading 
to poor oral bioavailability. The poor intrinsic solubility of Biopharmaceutical 
Classification Scheme (BCS) class II compounds has stifled development of many 
emerging therapeutic compounds. With up to 75% of drug development candidates 
displaying poor aqueous solubility, the bioavailability limitations posed still form an 
unmet challenge for pharmaceutical drug development (Di et al., 2012). The 
absorption of these poorly water soluble drugs (PWSD) is limited by their poor 
solubility and resultant slow dissolution rate within gastrointestinal fluid (Butler and 
Dressman, 2010). With the ever increasing prevalence of lipophilic, poorly soluble 
compounds in drug development pipelines, the identification of compounds with 
optimized pharmacodynamic properties, but poor ‘developability’ owing to sub-
optimal absorption properties leads to formulation and delivery challenges in drug 
development, where significant delays or even failure to gain approval can occur 
(Butler and Dressman, 2010, Hauss, 2007). The need to develop novel bioenabling 
formulation technology tailored to the properties of the drug molecule is, therefore, 
critical.  
A key issue is that there has traditionally been a lot of ‘trial and error’ involved in 
formulation screening, with a series of formulations assessed in preclinical models, 
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with a view to identifying the optimal candidate for Phase 1 clinical trials.  This 
conventional formulation development approach consists of initial in vitro screening, 
followed by pre-clinical bioavailability studies and subsequent clinical evaluation in 
humans. Traditionally, this process has proven both iterative and laborious, as in vitro 
and pre-clinical screening remained largely empiric, rather than mechanistically 
driven. This has led to significant wastage in drug development, where initial 
screening has been a poor indicator of clinical performance and this has been a 
contributory factor to the growing cost of drug development. This approach leads to 
excessive in vivo bioavailability testing in animals, and possibly a range of animals, 
generally as a result of gaps in the knowledge regarding which choice of animal model 
is most appropriate for the drug and formulation under investigation and poor 
understanding of their biopharmaceutical properties. There is consequently a need 
to increase R&D productivity by expediting development of new drug molecules to 
facilitate earlier access to patients. A key tenet of this process is improving the ability 
to select formulation approaches with the highest potential for success, and screen 
out those unlikely to succeed earlier in the drug development process, ensuring a 
‘quick win, fast fail’ for developers (Paul et al., 2010).  
In light of these development bottlenecks, a key theme in modern drug and 
formulation development is to move from a “test and confirm” to a “learn and 
confirm” paradigm, where predictions will be made in the ‘learn phase’ on how to 
maximise medical value for a new drug in advance of in vivo studies. In this scenario, 
in vivo studies become ‘confirmatory’ rather than ‘exploratory’ (Selen et al., 2014).  
Adopting a ‘learn and confirm’ approach for development of bioenabling 
formulations could prove beneficial both with regard to improving the screening 
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capability of early in vitro tests and in validating the predictive capacity of pre-clinical 
models in respect of clinical biopharmaceutics. Improving the predictive capabilities 
of in vitro screening tools consists of two main approaches; firstly improving the 
biorelevance of the test itself, through the utilisation of approaches such as 
simulated intestinal media, by adapting equipment to more accurately physiological 
processes, such as passage through the GIT or hydrodynamic processes, or by adding 
a dynamic aspect to the screening tool, such as introducing an absorption sink, 
inducing lipolysis or by utilising a transfer model approach; or secondly by integrating 
in vitro screening results into predictive models utilising in silico approaches. The 
range of in silico approaches is many and varied and can either be empiric or 
mechanistic in approach. The choice of approach will be dictated both by availability 
of data and expertise and also by the desired level of mechanistic understanding. 
Considering the limitations of current R&D approaches outlined above, and 
recognizing that most new drugs are poorly soluble, the drive to accelerate the 
development and approval of break-through therapy drugs urgently requires an 
accelerated development paradigm, consisting of three key elements:  
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1. Design of innovative, bioenabling formulations for poorly soluble drugs, with 
choice guided through knowledge harnessed in formulation screening 
2. Generation of predictive in vitro and in silico tools capable of rapidly and 
accurately screening formulations and predicting their ability to deliver drug 
in vivo 
3. Improve the predictive capacity of pre-clinical in vivo testing by prudent 
choice of animal model and understanding of the key biopharmaceutical 
properties of model choice 
In light of the factors described here, the specific objectives of this thesis are, 
therefore, to assess novel bioenabling formulations and new in vitro and in silico tools 
to predict their in vivo performance in pigs as a means to improve efficiency in 
formulation development. The current thesis aims to shed new insights on the 
processes involved in drug product development.  
Specifically, we have assessed the utility of the pig as a pre-clinical animal model with 
regard to the assessment of bioenabling approaches, using dissolution enhancing 
formulations and by concomitantly administering dosage forms with food, placing 
specific emphasis on eliminating food mediated changes in bioavailability. The ability 
of biorelevant screening approaches, in conjunction with in silico approaches of 
varying levels of complexity to predict in vivo performance and the potential of the 
pig to act as a model for food effect bioavailability were also assessed. The 
approaches involved in assessing these aims have been described in detail in the 
preceding chapters, and an overall, general discussion of the findings and how they 
relate to the wider literature is provided here. 
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Bioenabling approaches in drug development 
With the increasing proportion of drug candidates with relatively poor 
biopharmaceutical properties, the drive to design novel “bioenabling formulations”, 
to enhance oral absorption has increasingly gained attention. As a result, 
biopharmaceutical assessment is shifting focus from drug candidate‐assessment to 
formulation assessment (Buckley et al., 2013). While numerous formulation 
technology platforms have been developed with the aim of improving the 
bioavailability of poorly soluble drugs, the simplified hypothesis behind each design 
is the ability to make a BCS class II compound behave like a BCS class I compound 
(Kawabata et al., 2011). This is achieved through maximising dissolution and 
solubilisation of drug in the GIT through the use of a range of different formulations 
including lipid based formulations, amorphous solid dispersions and mesoporous 
carriers, approaches considered in this thesis (Williams et al., 2013b, Bergström et 
al., 2016). However, despite this increased interest, significant improvements in 
bioavailability in vivo through the use of bioenabling formulations remains 
challenging, as demonstrated by the relatively low number of successful commercial 
examples. While there has been a wide range of formulations proposed and 
evaluated in vitro, the lack of direct in vitro to in vivo correlations means that the 
significant increases in dissolution/ solubilisation enhancement in vitro rarely 
translate to comparable increases in in vivo bioavailability (Buckley et al., 2013).  
Accordingly, a primary aim of the current thesis was to investigate the bioenabling 
potential of a variety of novel formulations in a large animal model, in this case, the 
pig. Thus, two novel fenofibrate containing formulation platforms have successfully 
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been assessed in fasted pigs. Fenoﬁbrate was chosen as a novel compound as its 
absorption and bioavailability have been well characterised and is typical of a BCS 
class II compound, with conventional formulations of fenoﬁbrate displaying low and 
variable bioavailability in the fasted state due to low solubility and resultant slow 
dissolution (Miller and Spence, 1998). Fenoﬁbrate bioavailability increases 
signiﬁcantly with increased solubilisation and/or dissolution, as demonstrated by the 
considerable increases in absorption when delivered either in the fed state or in 
dissolution enhancing formulations (Sauron et al., 2006, Ling et al., 2013). Thus, it is 
seen as a reliable model for assessment of the formulation approaches chosen. In 
order to facilitate comparison, both a crude reference formulation of fenofibrate and 
a commercial micronised formulation were also delivered.  A comparison of the 
pharmacokinetic parameters of all administered formulations are summarised in 
figure 6-1 below, while figure 6-2 provides a snapshot of the plasma concentrations 
from all the trials conducted. 
As can be seen from the data presented here, both mesoporous silica based 
formulations and the lipidic dispersion formulation improved both the rate and 
extent of bioavailability of fenofibrate, relative to the crude formulation, to a similar 
or greater extent compared to the commercial Lipantil® Micro formulation. Thus, the 
potential for two novel bioenabling formulations to enhance the oral bioavailability 
of poorly water soluble drugs, using fenofibrate as a model compound, has been 
demonstrated. 
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Figure 6-1 Summary pharmacokinetics of fenofibric acid following oral delivery of 67mg fenofibrate from 
reference formulation (n = 6), Lipantil® Micro (n = 4), lipidic dispersion (n = 4), FF-SLC: HPMCAS (4:1) capsules (n 
=6) and FF-SLC: HPMCAS (4:1) suspension (n=6). (a) Displays bioavailability, (mean ± SD) (b) displays Cmax (mean 
± SD), and (c) displays Tmax (median, range). 
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Figure 6-2 Plasma concentration of fenofibric acid vs. time profiles after oral administration of 67 mg to fasted 
pig, all data mean ± SE,  Reference formulation (n=6),  Lipantil Micro (n=4),  Lipidic Dispersion (n=4),  FF-
SLC : HPMCAS (4: 1) capsules (n=6) and  FF-SLC : HPMCAS (4: 1) suspension (n=6) 
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Mesoporous silica and precipitation inhibitors 
Mesoporous silicas have been the focus of a significant amount of research in recent 
years with regard to enhancing absorption and bioavailability of poorly water soluble 
drugs (Maleki et al., 2017, Riikonen et al., 2018). Traditionally, mesoporous materials 
have been loaded with poorly soluble drugs that exist as molecularly adsorbed with 
the aim of improving drug dissolution and, hence, bioavailability through the 
generation of supersaturation (McCarthy et al., 2016). Numerous in vivo studies in 
both rodent and large animal models have demonstrated significant improvements 
in bioavailability (Van Speybroeck et al., 2010a, Van Speybroeck et al., 2011, Kiekens 
et al., 2012, Bukara et al., 2016a). While recently, a study utilising fenofibrate loaded 
mesoporous silica was the first to demonstrate proof of this concept in man, further 
emphasizing the potential of mesoporous silica formulations (Bukara et al., 2016b). 
However, a potential problem with generation of supersaturation in mesoporous 
silica based formulations is the potential to cause precipitation, and for this reason 
recent focus has turned to the co-administration of precipitation inhibitors with 
these silica formulations (Dressman et al., 2016, McCarthy et al., 2016). To date, a 
number of pre-clinical studies using such formulations have been carried out in 
rodents (Laine et al., 2016, Van Speybroeck et al., 2010b). To our knowledge, the 
bioavailability study outlined in chapter two, with results summarised in figures 6-1 
and 6-2, is the first large animal study to utilise such an approach. In this study both 
the rate and extent of bioavailability were signiﬁcantly increased by delivery of the 
fenoﬁbrate-loaded silica with HPMCAS, relative to the crude fenofibrate formulation, 
with bioavailability comparing favourably to previously assessed formulations in 
fasted pigs.  
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Lipidic dispersion: a solid lipid based formulation 
Similarly, lipid based formulations (LBF), and in particular self-emulsifying drug 
delivery systems (SEDDs), have long been investigated for their potential to improve 
bioavailability of PWSD, with numerous commercial examples. Fenofibrate also has 
a long history as a model compound for the assessment of LBF, with numerous 
preclinical studies demonstrating improvement in fenofibrate bioavailability from 
such formulations (Griffin et al., 2014, Thomas et al., 2014) and prototype fenofibrate 
containing LBF have also been demonstrated to enhance bioavailability in fasted 
humans (Fei et al., 2013). While traditionally LBF have consisted of liquid or semi-
solid formulations, significant research has been focussed on methods to generate 
solidified LBF, owing to industrial preference for solid forms, mainly due to cost and 
capsule compatibility issues (Riikonen et al., 2018, Jannin et al., 2008, Tan et al., 
2013). The bioavailability study carried out as part of chapter three investigates the 
use of solidified LBF through combination of a SEDDs with traditional solid dispersion 
technology aims to generate a novel “third-generation” solid dispersion (Vo et al., 
2013). The combination of lipid mediated solubilisation, along with altered solid-
state characteristics of the drug enhanced dissolution, both in vitro and in vivo with 
resultant improvement in the rate of drug absorption. This improvement in 
dissolution was also predicted to eliminate food-mediated alterations in 
bioavailability. 
In summary, two novel approaches enabling approaches have been assessed in the 
fasted pig model and have demonstrated positive results with regard to improving 
bioavailability. This lends further support to the growing case for clinical assessment 
of both solidified LBF and mesoporous silica formulations. 
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The pig as a pre-clinical animal model 
Large animal models represent a costly yet valuable tool in the evaluation of the 
gastrointestinal absorption of oral dosage forms. With increasing focus on the 
predictive capacity of animal models and on the scientific justifications and ethical 
implications of animal testing, there has been renewed interest in the use of the pig 
model (Forster et al., 2010, Bode et al., 2010, Colleton et al., 2016). In recent years, 
the pig has become increasingly popular in pre-clinical bioavailability studies owing 
to the perceived similarities in gastrointestinal anatomy and physiology between pigs 
and humans (Walters et al., 2011, Puccinelli et al., 2011, Suenderhauf and Parrott, 
2013, Sjogren et al., 2014, Swindle, 2016, Swindle and Smith, 1998, Davis et al., 2001). 
Pigs, like humans, are omnivorous (Patterson et al., 2008), they have similar digestive 
system (Davis et al., 2001, Kararli, 1995) and they are a suitable model for evaluation 
of many biopharmaceutical aspects of drug absorption, distribution, metabolism and 
elimination (van der Laan et al., 2010). While there are numerous drug delivery 
technologies designed to enhance oral bioavailability, it is increasingly clear that each 
formulation platform cannot be universally applied to all poorly water-soluble drugs 
and the selection of the correct formulation technology is often complex. As a result, 
it is crucial that the pre-clinical development program provides an accurate 
performance assessment and a key question that needs to be addressed in pre-
clinical evaluation is whether the chosen animal model will reliably predict the in vivo 
performance of a selected drug and/or formulation technology. With the increasing 
focus on the pig in pre-clinical development programs, this thesis poses three general 
questions; 
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1. Does bioavailability in the pig accurately reflect bioavailability in humans? 
2. Does the pig model discriminate in screening of bioenabling formulations? 
3. Can a pig food effect model successfully predict human food effect? 
The pig as a predictor of human bioavailability 
Henze et al. (2018b) have recently investigated the correlation between pig and 
human bioavailability by conducting a systematic review of studies involving 
compounds for which absolute bioavailability was available. This analysis included 
data from various pig breeds, namely Landrace, Yucatan and Gottingen minipig, and 
found a moderate positive correlation (r=0.4985, p = 0.0253) for the 20 compounds 
identified, a correlation similar to that of the canine model. There are, however, 
cases where the bioavailability of specific compounds varies significantly between 
humans and pigs, particularly in cases where specific metabolising enzymes appear 
to lack homologues between species. The authors identified metoprolol and 
diclofenac as particular cases where differences in rates and extent of metabolism in 
pigs may differ to that in humans, particularly with regard to the effect of first pass 
metabolism (Henze et al., 2018b). Assessment of the absolute oral bioavailability of 
celecoxib in pigs in chapter four further supports this hypothesis, where the extent 
of oral bioavailability was quite variable, while such high variability was not reflected 
in intravenous administration. This has been observed in previous studies comparing 
oral and parenteral drug delivery in pigs, such as that carried out by Holm et al. 
(2013). In their study buccal administration of metoprolol was examined and large 
increases in absorption and reduction in variability were observed relative to oral 
delivery, indicating that differences in first pass metabolism may play a significant 
role in differences in oral bioavailability between pigs and humans (Holm et al., 
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2013a). Similarly, parenteral administration of celecoxib in this study (via the 
intravenous route in this case) reduced the variability in exposure relative to the oral 
route. Overall, while there appears to be a moderate correlation between pig and 
human bioavailability, prudent selection of model compounds may improve the 
predictive capacity. Particular consideration should be given to the enzymes 
responsible for drug metabolism, and the occurrence of their homologues in pigs. 
The data presented in chapter four lend further support to this hypothesis and 
emphasize the desire for improved characterisation of the cytochrome P450 
isozymes present in pigs. The primary aim of chapter four of this thesis was originally 
the assessment of the absolute oral bioavailability of celecoxib pigs in order to assess 
its utility as a model compound for the assessment of bioenabling formulations, 
along with its potential to act as a “borderline” case in a food-effect model. Overall, 
the results of the study suggest that celecoxib would not be an appropriate model 
compound for such studies, however analysis of the extent and variability of 
celecoxib bioavailability in pigs has provided useful insights into the pig as a 
predictive model of human bioavailability. 
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The pig in the assessment of bioenabling approaches 
In formulation development it is crucial to assess the bioavailability of orally 
delivered drugs, and in particular how this can be influenced by the use of different 
formulations in order to support the development work. These pre-clinical in vivo 
studies are often used in combination with in vitro and in silico approaches to gain 
insights into the biopharmaceutical processes underpinning formulation 
performance prior to clinical studies. Optimizing the predictive capacity from in vitro 
analysis, through in vivo performance in preclinical animal studies, incorporating in 
silico tools, can therefore help to expedite the development process. An important 
consideration in this approach is the ability of the chosen animal model to 
discriminate between formulations based on in vivo performance. 
In this regard, the pig has been widely used in the assessment of bioenabling 
approaches in early drug development, particularly with fenofibrate as a model 
compound. The bioenabling approaches used in these settings have included lipid-
based formulations (Griffin et al., 2014, Thomas et al., 2014), mesoporous silica and 
nanosized formulations (McCarthy et al., 2017), and micronised formulations 
(Thomas et al., 2014) and has proven effective in discriminating between formulation 
performance.  
The current thesis has investigated three novel fenofibrate containing bioenabling 
formulations; a mesoporous silica based suspension with a precipitation inhibitor 
(chapter two: FF-SLC: HPMCAS (4:1) suspension), a mesoporous silica based capsule 
formulation with a precipitation inhibitor (chapter two: FF-SLC: HPMCAS (4:1) 
capsule) and a spray dried lipid based formulation (chapter three; lipidic dispersion), 
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along with a commercial micronised formulation (chapter three; Lipantil® Micro) and 
a crude reference formulation. The observed bioavailability, along with the dose 
normalised Cmax, for these formulations as well as those of previously investigated 
formulations from similar studies in published literature (Griffin et al., 2014, 
McCarthy et al., 2017) are compared in figure 6-3 in order to assess the ability of the 
pig model to discriminate between formulation performance. The figure has been 
divided based on the formulation platform utilised where crude reference is shaded 
black, commercial preparations based on size reduction (micronisation and 
nanonisation) are shaded grey, lipid based formulations are shaded blue and 
mesoporous silica formulations are shaded red. 
As presented in figure 6-3, all the investigated formulations demonstrate improved 
bioavailability relative to the reference fenofibrate (19.92%). While a relatively broad 
range of increases in bioavailability were observed across the range of formulations 
(54.55% for SBA-15 – 86.69% for FF-SLC: HPMCAS (4:1) capsule), there is no clear 
distinguishing feature between the formulations. Two commercial preparations are 
included in the analysis, the micronised Lipantil® Micro capsule formulation and the 
nanocrystal formulation Lipantil® Supra. Bioavailability from the Lipantil® Supra 
capsule in pigs (71%) is comparable to that observed in humans (69%) (McCarthy et 
al., 2017, Zhu et al., 2010), however absorption from the micronised capsule appears 
to be higher than anticipated. While no studies of absolute bioavailability for 
micronised capsule formulations have been conducted in humans, an increase in 
bioavailability of approximately 30% - 50% can be expected in nanosized relative to 
micronised formulations (Guichard and Sauron, 1993, Guivarc'h et al., 2004). Overall, 
while there are obvious increases in fenofibrate bioavailability, it has proven difficult 
 210 
 
to discriminate between performances of the different types of enabling 
formulation. While the pig has shown ability in demonstrating proof of concept for 
enabling formulations, it remains to be determined if a quantitative assessment can 
be achieved. One clear trend which has emerged, however, is the relative increase in 
rate of absorption from lipid solutions relative to solid dosage forms, demonstrated 
here by the relatively higher Cmax observed for lipid solutions (e.g. Type IIIA & IV LBFs) 
compares to the other formulations. This is likely due to the fact that the drug is 
presented in a pre-solubilised form, therefore avoiding the drug dissolution step that 
is necessary when a drug is presents in a solid crystalline form. 
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Figure 6-3 Summary pharmacokinetics of fenofibric acid following oral delivery of fenofibrate from:  
 Reference formulation (67mg, n = 6) – chapter 
two 
 Lipantil® Micro (67mg, n = 4) – chapter three 
 Lipantil® Supra (67mg, n = 4) - (McCarthy et 
al., 2017) 
 Lipidic dispersion (67mg, n = 4) – chapter 
three 
 Type IIIA MC SEDDS (96mg, n=5) - (Griffin et 
al., 2014) 
 Type IIIA LC SEDDS (96mg, n=6) - (Griffin et al., 
2014) 
 Type IIIB/IV SEDDS (96mg, n=5) - (Griffin et al., 
2014) 
 FF-SLC: HPMCAS (4:1) capsules (67mg, n =6) – 
chapter two 
 FF-SLC: HPMCAS (4:1) suspension (67mg, n=6) – 
chapter two 
 SBA-15 (67mg, n = 4) - (McCarthy et al., 2017)
(a) Displays Bioavailability (mean ± SD), (b) displays Dose normalised Cmax (mean ± SD). 
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The pig as a model to assess food effect 
Along with the ability to screen novel formulations, the bioenhancing capability of 
administering fenofibrate with food in pigs was also assessed. One of the aims of the 
current thesis was to design a formulation which could over-come food mediated 
alterations in bioavailability (chapter three) and subsequently assess its ability in vivo. 
As part of this process an effective food effect model in pigs was required, and the 
design and implementation of such a model was the primary aim of chapter five. The 
design of the porcine food effect model was ultimately based on a previously 
published dog model (Lentz et al., 2007), taking into consideration a previously 
unsuccessful attempt to adapt this model to pigs (Christiansen et al., 2015). Despite 
consideration to the limitations of previous studies, both with regard to the content 
of the meal utilised (Christiansen et al., 2015, Henze et al., 2018a) and to the optimal 
fasting period prior to study commencement (Suenderhauf et al., 2014), it was not 
possible to induce an increase in fenofibrate bioavailability in the fed state. Thus, 
while the lipidic dispersion formulation described in chapter three is postulated to 
eliminate food effect, we have not been successful, thus far, in generating a porcine 
food effect model to further investigate this hypothesis. This point is further 
discussed, with possible explanations and solutions suggested, in the proceeding 
section when assessing the accuracy of in silico models of porcine bioavailability. 
One area of particular concern when in pig models of bioavailability is that of variable 
gastric emptying. Previous experience has demonstrated that insufficient fasting 
periods prior to absorption studies can lead to incomplete emptying of gastric 
contents, meaning a true ‘fasted’ state may not be obtained. This is a potential 
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explanation for the differences in bioavailability for Lipantil® Micro in the fasted 
state, as observed in chapter three (66.1% ± 3.5%) and chapter five (38.8% ±8.5%) 
and as presented graphically in figure 6-4. While some of this variation can be 
attributed to the inherent variability of in vivo studies of absorption, it also may 
reflect the observation that the previous fasting regimen was insufficient to ensure 
complete emptying of stomach contents. Hence pigs were not dosed in a ‘truly’ 
fasted state. The fasting protocol implemented in chapter five, consisting of a small 
(175g; circa 10.5g/kg) meal 24 hours prior to dosing (24 hour b.d.), ensured adequate 
fasting, with no significant residual contents observed in the GIT post-mortem. 
However, the previously implemented feeding regimen in chapter three, consisting 
of a larger (500g meal) 24 hours prior (24 hour o.d.) to dosing, did not successfully 
lead to complete gastric emptying, with residual gastric contents observed post-
mortem, indicating these animals are not in a truly fasted state. The retention of 
significant quantities of food in the GIT, even after a 24 hour fast, is a possible 
explanation for the increased bioavailability seen in the earlier study, suggesting that 
to ensure bioavailability studies in pigs are truly reflective of the fasted state, the 
updated fasting protocol should be implemented. This data also suggests that it is 
indeed possible to demonstrate a food related increase in bioavailability in pigs, 
however further studies are required for model characterisation and refinement.  
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Figure 6-4 (A) Plasma concentration of fenofibric acid vs. time profiles after oral administration of 67mg to fasted 
pig, all data mean ± SE, 24 hour o.d. (n=4), 24 hour b.d. (n=3)  
(B) Fenofibrate bioavailability in fasted pigs, all data mean ± SE, fasting regimen A (n=4), fasting regimen B (n=3) 
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The predictivity of porcine in silico models of bioavailability 
One of the aims of the current thesis was to streamline the formulation process by 
means of assessing the predictive capacity of early in vitro screening and identifying 
the relationship between in vitro screening tools and in vivo performance in pigs, 
through the use of in silico approaches including IVIVC and PBPK modelling. A key 
consideration when assessing in vitro- in vivo relationships is the biorelevance of the 
in vitro screening method being utilised (Kostewicz et al., 2014a, Kostewicz et al., 
2014b). In this regard, chapter three addressed the use of biorelevant dissolution 
media, demonstrating its superiority over compendial or FDA recommended media 
in discriminating between performances of varying formulations. Thus, utilisation of 
such biorelevant dissolution tests is an appropriate starting point for in vitro 
assessment for bioenabling formulations, particularly with regard to elucidating in 
vitro-in vivo relationships. 
The simplest methods of predicting in vivo results using in vitro input is by means of 
an in vitro- in vivo correlation (IVIVC), which directly links in vitro and in vivo 
parameters, and numerous groups have demonstrated such relationships in the pig 
model. Kesisoglou et al. demonstrated the use of a simple level C IVIVC in a 
retrospective analysis of the in vivo performance of extended release matrix and 
multi-particulate preparations of a BCS class III development candidate (MK-0941) 
with different targeted release rates (8hr, 12hr and 16 hr) in Yucatan minipigs. A good 
correlation between the in vitro release and bioavailability was reported (Kesisoglou 
et al., 2014). Similarly, Keohane et al. demonstrated an in vitro- in vivo relationship 
for coated microspheres containing Ciclosporin A. The resultant IVIVR demonstrated 
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a strong linear correlation between in vitro release and in vivo absorption (Keohane 
et al., 2016). McCarthy et al., meanwhile, demonstrated the possibility of obtaining 
a level A IVIVC using such an approach, by optimising the biorelevance of the 
dissolution test for fenofibrate, as a model poorly water soluble compound. 
McCarthy and co-workers demonstrated that computational in silico methods could 
be used to deconvolute the oral absorption process from the pharmacokinetic 
profile, correlate this with in vitro release and model in vivo pharmacokinetics by re-
convolution (McCarthy et al., 2017). Govender et al. have recently proposed a similar 
approach to describe the absorption of amoxicillin from a delayed release, dual-biotic 
system (Govender et al., 2016). 
In chapter two, the relationship of in vivo performance to simple in vitro screening 
tools has been further explored. By utilising a straightforward dissolution test, with 
optimised biorelevance through the use of media simulating the composition of the 
intraluminal intestinal fluid it was possible to consolidate both the in vitro and in vivo 
findings reported in the study, demonstrating an IVIVR between dissolution 
efficiency and bioavailability. This implies that increases in in vitro dissolution of 
fenoﬁbrate from silica formulations are translated into enhancement of in vivo 
dissolution and therefore oral bioavailability. However, a couple of limitations remain 
with the current approach, most notably the use of simulated intestinal fluid which 
mimics human intestinal conditions (FaSSIF-V2) and the low number of different 
formulations utilised (three) limits the applicability of the model and its quantitative 
potential.  
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The potential for utilisation of simple linear relationships between in vitro and in vivo 
performance is relatively limited for immediate release, bioenabling formulations, 
where factors other than those assessed in vitro (dissolution in this case), including 
absorption and gastrointestinal transit, play a role in controlling the rate and extent 
of bioavailability. In these scenarios, one the most useful ways of assessing the 
implication of altered in vitro performance is through the integration of in vitro data 
with computational in silico PBPK models (Kostewicz et al., 2014b, Kostewicz et al., 
2014a). The distinguishing feature of PBPK models, relative to empirical 
computational models, is the application of prior physiological knowledge in the 
mechanistic mapping of model compartments and in the processes that determine 
absorption (Suenderhauf and Parrott, 2013, Dressman et al., 2011).  
The growing use of the pig as a preclinical species of choice has led to significant 
developments in porcine PBPK models. The most significant development in PBPK 
modelling in pigs was the minipig PBPK model developed using the advanced 
compartmental absorption (ACAT) model and which was subsequently incorporated 
into the GastroPlus™ simulation program (Suenderhauf and Parrott, 2013). By using 
a series of mass-balance equations that describe the specific physiology of the 
minipig, a porcine PBPK model was generated to simulate oral PK. The proposed 
model was initially validated with griseofulvin and moxifloxacin, with encouraging 
results (Suenderhauf and Parrott, 2013). However, the authors also identified areas 
where this model can further be refined, particularly in the areas of absorption 
related parameters and bile salt profiles within the minipig intestine. Further 
physiological characterisation along with pharmacokinetic analysis of well-chosen 
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reference compounds, and adjustment of the model to reflect in vivo PK, was 
suggested to contribute to model refinement (Suenderhauf and Parrott, 2013). 
Subsequent work using paracetamol as a marker of GI motility and gastric emptying, 
was used to update the model, which was subsequently validated on a number of PK 
studies in minipigs using omeprazole, caffeine, midazolam and warfarin. The 
prolonged gastric emptying in the re-parameterised PBPK model accurately 
predicted pharmacokinetics of this validation dataset in minipigs (Suenderhauf et al., 
2014). 
In chapter three, this GastroPlus™ minipig ACAT PBPK model has been used to 
simulate bioavailability of fenofibrate from a commercial micronized formulation and 
novel lipid based formulation in fasted landrace pigs. The model successfully 
simulated fasted bioavailability for both formulations by incorporating the 
intravenous pharmacokinetic data, along with biorelevant in vitro solubility and 
dissolution measures into the mechanistic model. The model was subsequently used 
to extrapolate this data to the fed state, where the elimination of a food dependent 
increase in fenofibrate bioavailability utilising the novel formulation was predicted.  
The generation of food effect data in chapter five allowed the opportunity to assess 
the ability of the previously published predictive PBPK model (from chapter three) of 
fenofibrate bioavailability from Lipantil® Micro in the fasted and fed state. The 
predicted fed and fasted state profiles, as well as previously reported data for fasted 
state administration of Lipantil® Micro from chapter three, and fed and fasted data 
from chapter five is reproduced in figure 6-5. The pharmacokinetic data from these 
predicted and observed profiles are summarised in figure 6-6. As can be seen from 
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figure 6-5A and 6-6A and 6-6B, the PBPK model seems to predict reasonably well the 
extent of bioavailability in the fasted state, however the rate of absorption is not 
accurately predicted, with a substantially longer Tmax observed compared to 
predicted profile. The most likely cause for this observation is the longer gastric 
transit observed in the fasted pigs in vivo relative to that used in the PBPK model. The 
standard GastroPlus pig physiology implements a gastric emptying rate similar to 
human at 0.5 hours. Reducing the rate of gastric emptying will prolong Tmax and will 
also likely reduce Cmax slightly, improving the correlation observed in the current 
study. A similar finding was observed in the study of Suenderhauf et al. (2014), where 
the initial estimates of gastric emptying in a similar, previously published PBPK model 
were shorter than that observed by means of paracetamol pharmacokinetics. In their 
study, Suenderhauf et al. re-parameterised this PBPK model using their deconvoluted 
lag time and gastric emptying rate, before validating the new model with a dataset 
of four compounds (Suenderhauf et al., 2014). In light of the current work, future 
PBPK modelling carried out using landrace pigs as a model species should consider 
the effects of long and variable gastric residence when assessing model fit and 
performance. 
With regard to the fed state data, the predicted profile substantially over-estimates 
the extent of absorption compared to the observed plasma profile. This further 
supports the hypothesis that the pig model, as it is currently utilised, is not predictive 
of human food effect. It appears that FDA breakfast fed pigs do not demonstrate 
solubility and dissolution enhancing effects that promote absorption of fenofibrate 
(figure 6-5C and 6-5D). Further characterisation is required to assess the physiological 
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and physicochemical environment in the fed state pig and in particular the effects of 
different meal composition on the post-prandial pig gastrointestinal environment. 
Specifically, the effect of varying quantities of an FDA high fat breakfast on the 
gastrointestinal environment will provide an insight into the lack of a food effect 
observed both here and previously (Christiansen et al., 2015). It seems plausible, 
based on the lack of an observed food effect on the extent of fenofibrate absorption 
and on gastric emptying, that the current meal caloric content and volume is too 
small to induce a response.  
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Figure 6-5 Gastroplus™ in silico model of plasma fenofibric acid concentration vs. time profile compared to 
observed in vivo pig data in the fasted state (A) and fed state (B)  
Gastroplus™ Model predicted profiles and fasted data (red) (n = 4, mean ± SE) reproduced from chapter 3  
Fasted state data from chapter 5 (blue) (n=3, mean ± range) 
Fed state data from chapter 5 (n = 2, mean ± range) 
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Figure 6-6 Observed vs GastroPlus predicted fenofibric acid pharmacokinetic parameters for Lipantil® Micro in 
landrace pigs; (A) Fasted Cmax, (B) Fasted AUC, (C) Fed Cmax, (D) Fed AUC; fasted state data (black) and GastroPlus 
model data reproduced from chapter 3 
 
The PBPK modelling approach has since also been utilised elsewhere, with Kesisoglou 
et al. using the GastroPlus™ minipig model, in conjunction with modelling of dog and 
human data, in the formulation development of a modified release preparation of 
gaboxadol (Kesisoglou et al., 2015). The authors successfully incorporated in vitro 
dissolution data and preclinical pharmacokinetic data within the PBPK models to 
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guide formulation development. Subsequently, it was possible to use this minipig 
PBPK model to develop an IVIVC in order to project formulation performance 
(Kesisoglou et al., 2015). Using regional permeability data measured in dogs and 
clinical pharmacokinetics from human studies, the minipig ACAT model was 
optimised using an immediate release dry filled capsule as a reference. Using this 
optimised model, the in vivo dissolution was deconvoluted from the simulated 
plasma profile for two modified release formulations. This in vivo dissolution profile 
was subsequently plotted against the in vitro release profile resulting in a linear IVIVC 
(Kesisoglou et al., 2015). 
The use of PBPK modelling during drug and formulation development is an emerging 
field for the prediction of preclinical and clinical PK using physiochemical and in vitro 
measurements. However, thus far the use of PBPK modelling has been largely 
confined to the retrospective, mechanistic analysis of preclinical data. While some 
work has focused on the extrapolation of these models to alternative formulations 
or dosing scenarios (e.g. in fed versus fasted state), and extrapolating between 
different preclinical species, there is still a lack of prospective models used in 
formulation design. There remains a need for systematic studies utilising PBPK 
models as part of a ‘learn and confirm’ paradigm before the full benefit of this 
approach is realised. 
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Overall conclusion and future perspectives 
This thesis has, firstly, demonstrated the ability of two novel bioenabling approaches; 
fenofibrate loaded mesoporous silica in combination with HPMCAS, and a lipidic 
dispersion to improve oral drug bioavailability. To build on this work, further studies 
are now needed to address the feasibility of delivering such formulations in human 
subjects, particularly considering recent success of the first human proof of concept 
study involving oral delivery of mesoporous silica (Bukara et al., 2016b). In order to 
elucidate fully the utility of these promising approaches, clinical validation will be 
required.  
Secondly, the utility of in vitro and in silico tools to predict in vivo performance in 
fasted pigs has been investigated. In particular, the utility of biorelevant dissolution 
testing to provide both a simple, qualitative indicator of in vivo performance through 
the use of dissolution efficiency calculation, and the integration of biorelevant 
dissolution and solubility data into a quantitative PBPK model have been 
investigated. While the PBPK model developed was useful in predicting and 
modelling bioavailability in the fasted state, extrapolation to the fed state proved 
difficult. Building on this approach will require both validation of PBPK models with 
a wider array of compounds, representing different biopharmaceutical classes, as 
well as further characterisation of the gastrointestinal physiology of pigs, particularly 
with regard to physicochemical composition of luminal contents, gastrointestinal 
transit and the absorptive processes, and successful incorporation of these 
measurements into PBPK models. 
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Thirdly, the understanding of the pig as a model for both the in vivo performance of 
solid oral dosage forms and the pre-clinical performance of bioenabling approaches 
has been examined. The ability of the pig to act as a model of human bioavailability 
for both fenofibrate and celecoxib, as well as its ability to act as an in vivo screening 
tool for bioenabling approaches for poorly water soluble drugs has been assessed. In 
particular, the need for prudent consideration of the model compounds to be 
assessed in the pig model, principally with regard to the effect of metabolising 
enzymes and the need for further characterisation of the metabolic pathways 
involved in first pass metabolism in pigs has been identified. 
Finally, limitations of the pig model for assessment of food effect using current 
approaches have been identified, and alterations to be made for future 
characterisation, particularly with regard to meal volume and caloric content, have 
been made. In order to elucidate the physiological and biopharmaceutical aspects 
determining drug absorption in fed state pigs, future work should also focus on 
characterisation of both the gastrointestinal fluid in the fed and fasted state, as well 
as assessing the effects of future fed state protocols on gastrointestinal transit. 
Concomitantly, the issue of effective fasting protocols for bioavailability studies in 
pigs has also been addressed. By demonstrating that the presence of food leads to 
unpredictable responses in drug absorption in pigs, the criticality of appropriate 
fasting regimens in pigs has been shown, and regimen which will ensure pigs are in a 
true fasted state has been proposed.  
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